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Abstract 
2The type-II-cytokine IFN-γ (interferon gamma) is not only a pivotal player in innate immune 
responses but also assumes functions in controlling tumor cell growth by orchestrating cellular 
responses against neoplastic cells. It predominantly triggers cellular responses through the 
Janus Kinase (Jak)/ Signal Transducer and Activator of Transcription 1 (STAT1) pathway leading 
to STAT1 binding to the promoter region of target genes. As key regulators of mRNA and 
protein expression levels, microRNAs (small non-coding RNAs) take part in fine-tuning complex 
biological processes such as cell proliferation, neoplastic transformation, apoptosis, immune 
surveillance and differentiation. 1MiR-29, one of the most interesting miRNA families in humans 
to date, consists of three mature members miR-29a, miR-29b and miR-29c, which are encoded 
in two genetic clusters. In this PhD thesis, the miR-29 primary cluster pri-29a~b-1 was shown 
to be IFN-γ-induced and STAT1-dependently up-regulated in melanoma cell lines. 2Furthermore, 
expression levels of mature miR-29a and miR-29b were elevated in cell lines and in primary 
melanoma patient samples while the pri-29b-2~c cluster was almost undetectable in cell lines. 
Moreover, tumor-suppressing properties of miR-29 family members have been detected: 
inhibition of melanoma cell proliferation could be induced by miR-29a, which down-regulated 
CDK6 (cyclin-dependent kinase 6), an important player in cell cycle G1/S transition. Also, 
knockdown of CDK6 resulted in reduced proliferation of melanoma cells, suggesting that miR-
29-mediated growth inhibitory effects may be brought about by CDK6-downregulation. 
These findings identify the pri-29a~b-1 cluster as a novel IFN-γ-regulated gene. Furthermore, a 
potential novel signaling pathway was identified: IFN-γ  Jaks  P-STAT1  miR-29  CDK6, 
which opens up new connections between miRNAs, interferon signaling and malignant 
melanoma, possibly clearing the way to novel concepts for new treatment options in the future. 
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Zusammenfassung 
Das Typ-II-Zytokin IFN-γ ist nicht nur ein zentraler Akteur in der angeborenen Immunantwort, 
sondern besitzt auch wichtige Funktionen in der Wachstumskontrolle von Tumorzellen, indem es 
zelluläre Antworten gegen neoplastische Zellen vermittelt. Es wirkt hauptsächlich über den 
Janus Kinase (Jak)/ Signal Transducer and Activator of Transcription 1 (STAT1) Signalweg, 
welcher zur Bindung von STAT1 in der Promoterregion von Targetgenen führt. MikroRNAs 
(kleine, nicht-codierende RNAs) sind bedeutsame Regulatoren von mRNA- und 
Proteinexpressionsspiegeln und tragen zur Feinjustierung komplexer biologischer Prozesse bei, 
wie z.B. Zellproliferation, neoplastische Transformation, Apoptose, Immunkontrolle und 
Differenzierung. miR-29, momentan eine der interessantesten der bisher bekannten miRNA-
Familien, besteht im Menschen aus den drei „reifen“ Familienmitgliedern, miR-29a, miR-29b und 
miR-29c, welche in zwei genetischen Clustern codiert sind. In dieser Doktorarbeit wurde 
gezeigt, dass das miR-29 Primärtranskript pri-29a~b-1 in Melanomzellen IFN-γ-induziert und 
STAT1-abhängig hochreguliert ist. Desweiteren waren die Expressionsspiegel der reifen miRNAs 
miR-29a und miR-29b in Zelllinien und primären Melanompatientenproben erhöht, während das 
pri-29b-2~b Transkript in Zelllinien fast nicht detektierbar war. Darüber hinaus wurden Tumor-
supprimierende Eigenschaften von miR-29-Familienmitgliedern ausfindig gemacht: eine 
Inhibierung der Proliferation von Melanomzellen konnte durch miR-29a induziert werden, welche 
CDK6 (cyclin-dependent kinase 6) herunterregulierte, einen wichtigen Akteur im G1/S-Übergang 
des Zellzyklus. Auch „Knock-down“ von CDK6 führte zu verminderter Proliferation von 
Melanomzellen, was darauf hindeutet, dass die durch miR-29a vermittelte Wachstumsinhibition 
durch Verminderung der CDK6-Expression bewerkstelligt werden könnte.  
Diese Ergebnisse beschreiben das pri-29a~b-1-Cluster als neues, IFN-γ-reguliertes Gen. 
Außerdem wurde ein neuer Signalweg entdeckt, IFN-γ  Jaks  P-STAT1  miR-29  CDK6, 
welcher neue Verbindungen zwischen miRNAs, Interferon Signaling und malignen Melanomen 
aufzeigt und möglicherweise den Weg für neuartige Behandlungskonzepte ebnet. 
Introduction 
1 
1 Introduction 
This PhD project addresses the fundamental question of if and how miRNA expression can be 
regulated by the cytokine IFN-γ and STAT1 transcription factors and furthermore considers their 
potential relevance for melanoma development. Accordingly, the introduction focuses on three 
major topics: miRNAs, Interferon/Jak/STAT signaling and melanoma. The first part of the 
introduction provides an overview on miRNAs, their biogenesis, regulation, mode of action and 
role in cancer as well as the miR-29 family, which became of special interest while the project 
was in progress. The second part introduces the canonical Jak-STAT signaling pathway and its 
main players. The last part of the introduction presents a brief overview on melanoma, an 
aggressive type of skin cancer, which was the main biological system investigated in this PhD 
project. 
1.1 MicroRNAs 
In the past decade, small non-coding microRNAs (miRNAs) have been identified as important 
novel players in post-transcriptional gene regulation and ever since, their expression patterns 
and cellular functions have been investigated in cancer and other diseases (Winter et al. 2009; 
Krol et al. 2010b). MicroRNAs (miRNAs) are a class of small non-coding RNA molecules (~22 
nucleotides), whose main function is the negative regulation of gene expression at a post-
transcriptional level. They are conserved in plants and animals (Ambros 2003), but not present 
in bacteria (Tjaden et al. 2006). In human cells, miRNAs are expressed in all cell types and are 
involved in the control of fundamental cellular processes such as differentiation, apoptosis, 
proliferation, cell death and others (Esau et al. 2004; Hwang and Mendell 2006; Jovanovic and 
Hengartner 2006). MiRNAs were initially discovered in 1993, when Victor Ambros, Rosalind Lee 
and Rhonda Feinbaum were studying the larval development in the nematode C. elegans and 
discovered the miRNA lin-4, which they showed to inhibit the lin-14 mRNA (Lee et al. 1993). 
However at that stage, lin-4 was only described as a short RNA product from the lin-4 gene. 
The term ‘miRNA’ was only introduced following their characterization as a separate class of 
biologically relevant molecules around the year 2000 (Pasquinelli et al. 2000; Lagos-Quintana et 
al. 2001; Lau et al. 2001; Lee and Ambros 2001). The rapidly growing interest in various 
aspects of miRNA biology is reflected by the constantly increasing number of publications since 
their first discovery. For the current version 19 of miRBase, entries for newly identified miRNAs 
have risen to 26,264 representing 193 different species (Kozomara and Griffiths-Jones 2011). 
Over the past decade, many diseases including almost all types of cancer have been connected 
to aberrant expression of miRNAs (Esquela-Kerscher and Slack 2006; Chang and Mendell 2007; 
Iorio and Croce 2012b). 1Like protein-coding genes, miRNAs can either act as tumor 
Introduction 
2 
suppressors when down-regulating potentially oncogenic targets or they can exert oncogenic 
functions when tumor-suppressive target mRNAs are down-regulated (Carleton et al. 2007). 
Apart from their role in regulation of mRNA expression and involvement in cancer, miRNAs were 
postulated to confer robustness to biological processes by compensating for alterations of 
cellular transcription levels (Ebert and Sharp 2012). 
Biogenesis of miRNAs 
The canonical miRNA biogenesis pathway (Winter et al. 2009; Krol et al. 2010a; Treiber et al. 
2012) is a multi-step process and an overview is shown in Fig. 1. miRNAs are transcribed in the 
nucleus mainly by RNA-polymerases II, but the involvement of RNA-polymerases III has also 
been reported for some cases (Faller and Guo 2008). The polymerases create a primary 
transcript, which is several thousand nucleotides long and contains a 5’-methylguanosine-cap as 
well as a 3’-poly(A)-tail like mRNAs. This primary (pri-) miRNA is then processed into a 70-80 
nucleotide-long precursor form (pre-miRNA) by the RNase III enzyme Drosha and the dsRNA-
binding protein DGCR8 (DiGeorge syndrome critical region 8). This pre-miRNA exerts a typical 
hairpin structure with a 2 nucleotide 3’-overhang derived from Drosha-processing (Graves and 
Zeng 2012). Its nuclear export is subsequently mediated by Exportin 5 which, supported by 
Ran-GTP, delivers the pre-miRNA to the cytoplasm (Davis-Dusenbery and Hata 2011). The 
following step, i.e. cleaving of the precursor molecule into its bioactive, mature form, is 
performed by the RNase enzyme Dicer, one of the most important proteins within the miRNA 
biogenesis pathway (Ma et al. 2011b). Together with its interacting partners TRBP (TAR RNA-
binding protein), PACT (protein activator of PKR) and Ago2 (Argonaute 2) (Koscianska et al. 
2011), it is often referred to as RISC (RNA-induced silencing complex) loading complex (RLC) 
(Winter et al. 2009). The Dicer-derived mature miRNA duplex is 21-23 nucleotides long. It is 
quickly separated by helicase into two single strands whose further distribution depends on 
thermodynamic stability and which are subsequently named differently: The ‘major’ strand (also 
known as ‘guide’ strand) is generally incorporated in the RISC and is found in a higher 
concentration in the cell in comparison to the ‘minor’ strand (also known as ‘passenger’ strand 
or miRNA star (*) sequences). However, recently evidence was provided that also star (*) 
sequences, which are now labeled as ‘-3p’ in contrast to the ‘-5p’-suffix for the ‘major’ strands, 
are not always degraded but can exhibit biological functions and thus target an own set of 
mRNAs (Fig. 1) (Czech and Hannon 2011). The RISC, sometimes referred to as ‘miRISC’ when 
loaded with a miRNA, is in charge of directing the incorporated, single-stranded miRNA to its 
target mRNA (Winter et al. 2009). The miRNA subsequently represses expression of mRNAs and 
their encoded proteins in the cytosol, mostly by binding to their 3’-UTR but binding to the 5’-
UTR (Orom et al. 2008) or the coding region (Fang and Rajewsky 2011) has also been reported. 
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Fig. 1 Schematic overview: genomic organization and biogenesis of human miRNAs 
((Winter et al. 2009; Meister 2011), adapted). (A) miRNAs can be encoded in polycistronic clusters or as 
monocistronic genes. Most miRNA genes are encoded within introns of protein coding genes; some 
miRNAs, which are processed by the splicosome, form entire introns. (B) Pri-miRNAs are transcribed in 
the nucleus mainly by RNA-polymerase II. After first processing of the primary transcript to the pre-
miRNA by Drosha and DGCR8, the precursor molecule is exported to the cytoplasm by Exportin 5. 
Cleavage by Dicer leads to the ~22 nucleotide long mature miRNA duplex. The major strand gets 
incorporated into the RISC complex, where it can act on target mRNAs while the other strand is degraded 
or targets an own set of mRNAs. Ago2 - Argonaute protein 2; DGCR8 - DiGeorge syndrome critical region; 
RISC – RNA-induced silencing complex; TRBP – TAR RNA binding protein.  
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The seed region determins, which mRNA can potentially be targeted by a given miRNA. It 
comprises nucleotides 2-7, which generally exhibit a perfect complementarity to the 
corresponding binding site of the mRNA-3’-UTR (Fabian et al. 2010). The seed sequence also 
influences target gene recognition and the efficiency of the subsequent repressing procedure. 
Interaction with the 6 nucleotides of positions 2-7, (‘6-mer’) results in the weakest possible 
binding to the target UTR and consequently leads to a weak repression. The repression is 
enhanced, if an adenosine is present at position 1 (‘7-mer-A1’-site, Fig. 2) and even more so, if 
nucleotides 2-8 exibit a perfect match (‘7mer-m8’-site) or if eight nucleotides perfectly pair with 
the target mRNA as shown in Fig. 2 (Bartel 2009; Schnall-Levin et al. 2011). However, so-called 
atypical sites with mismatches can also occur (Bartel 2009). 
 
 
 
Fig. 2: Canonical miRNA target sites 
Different possibilities of target gene recognition and binding by miRNAs as described in the text. The 
binding efficiency increases together with the efficiency of target gene repression from the 7mer-A1 
pairing to the 8mer site. Adapted from (Bartel 2009). 
 
Mode of action 
MiRNAs and target mRNAs interact while the mature miRNA strand is incorporated in the RISC 
complex. The two main mechanisms which had been described initially for miRNA-mediated 
gene silencing were mRNA degradation and inhibition of translation of the respective mRNA 
(Filipowicz et al. 2008). It was furthermore claimed that the detailed mode of action depends on 
the complementarity between miRNA and target mRNA sequence with full complementarity 
leading to mRNA degradation while incomplete complementarity induces prevention of 
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translation (Lim et al. 2005; Brodersen and Voinnet 2009). In principle, protein translation can 
be inhibited at multiple steps, for example during initiation, assembly of the ribosomal subunits 
as well as during elongation and termination of translation (Chekulaeva and Filipowicz 2009). 
Additional modes of action have been proposed in recent years. Very recently, Morozova et al. 
published an overview of miRNA-mediated mechanisms based on literature analysis and on a 
mathematical model, suggesting that the various reported mechanisms coexist in the cell, as 
shown in Fig. 3 (Morozova et al. 2012). These mechanisms include: cap inhibition, 60 S joining 
inhibition, inhibition of elongation, ribosome drop-off, co-translational protein degradation, 
sequestration in P-bodies (processing bodies), mRNA decay, mRNA cleavage and transcriptional 
inhibition. Most of them have been confirmed experimentally, however, some remain 
controversial (Morozova et al. 2012; Zinovyev et al. 2012). 
 
 
 
 
Fig. 3: Possible miRNA modes of action on protein translation 
From (Zinovyev et al. 2012). Translation can be inhibited at several steps: (1) initiation of translation can 
be prohibited by preventing the assembly of the initiation complex (for example by action on eIF4 or 
40S), (2) searching for the start codon can be prevented, (3) ribosome assembly can be affected, (4) the 
translation process can be inhibited. Other mechanisms include for example transport to P-bodies, 
ribosome drop-off, co-translational protein degradation and others (not shown here). 
40S, 60S: ribosomal subunits; 80S: assembled ribosome, RISC: RNA-induced silencing complex; eIF4 - 
eukaryotic translation initiation factor 4; PABPC1 - Polyadenylate-binding protein 1; cap – mRNA cap 
structure.  
 
In terms of target gene repression, in silico, in vitro and in vivo studies show that a single 
miRNA can down-regulate hundreds of genes (Krek et al. 2005; Lim et al. 2005). On the other 
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hand, one gene can be targeted by several miRNAs (Wu et al. 2010). According to recent 
publications, miRNA functions are not solely limited to actions in the cytoplasm, but can also 
perform tasks in the nucleus (Huang and Li 2012). 
Genomic organization and regulation of miRNA expression 
miRNAs can be organized in genetic clusters with several members being encoded close to each 
other or within a certain distance between genomic locations of single miRNAs (Fig. 1). Cluster 
members are often generated within a transcriptional unit from a common primary transcript, 
but can also be regulated separately. For miRNA families, precursor sequences of the different 
members are positioned in different genomic locations, but all members share the same 
conserved seed region. miRNA family members have the same name which is followed by a 
letter to differentiate between family members from different genomic locations: for example 
hsa-miR-23a is encoded on chromosome 19 whereas its ‘sister’ miRNA hsa-miR-23b is 
transcribed from chromosome 9. 
MiRNAs exhibit a relatively low rate of evolutionary changes and thus can be used as 
phylogenetic markers (Wheeler et al. 2009). Their genes can be located in intergenic regions or 
within introns or exons of protein-coding genes (Kim and Nam 2006) and entire pri-miRNAs can 
also be spliced like normal mRNAs (miRtrons) (Kim 2005) (Fig. 1). In contrast to the 
transcriptional start sites (TSSs) of protein-coding genes, identification of miRNA TSSs and 
assignment of promoter regions remains difficult and conventional methods for TSS 
identification are often not suitable, mainly due to the quick processing and rapid turnover times 
of primary miRNA transcripts (Krol et al. 2010a). Thus, only a few precise miRNA promoters 
have been experimentally characterised so far (Chien et al. 2011). 
Transcriptional regulation is thought to be the main mechanism for regulation of miRNA 
expression (Bartel 2004), but other controlling processes including epigenetic silencing (Bueno 
et al. 2008) and different processing and turnover times have also been described (Krol et al. 
2010b). Depending on the surrounding cellular context or tissue, differential expression of 
proteins of the miRNA processing machinery will affect miRNA amounts (Lu et al. 2005b). 
Furthermore, expression levels of certain miRNAs can be drastically altered if the primary 
transcript is encoded at genomically instable sites, which are often deleted or multiplied in 
cancer (Calin et al. 2004). Binding of transcription factors to the promoter region of a gene 
normally leads to activation of targets, however, transcription can also be repressed. Identifying 
the transcription factors, which regulate miRNAs or their respective host genes (in the case of 
intragenic miRNAs) is crucial for understanding regulation and different miRNA expression 
patterns in a healthy versus a diseased cellular context. 
As miRNAs are predicted to control approximately 50 % of human genes (Friedman et al. 2009) 
and are often de-regulated in cancer and other diseases, deciphering cellular networks of their 
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own regulation is of obvious importance. Different mechanisms are implicated in the regulation 
of miRNAs, which can act at several cellular stages as was recently reviewed by Krol and 
colleagues (Krol et al. 2010b). For example the protein machinery involved in miRNA processing 
can be influenced by other proteins: Drosha and Dicer efficiencies are largely dependent on 
their binding partners DGCR8 and TRBP, respectively (Han et al. 2009; Melo et al. 2009). 
Furthermore, miRNA stability can be influenced by modifications at the 3’-end, as exemplified by 
the RNA-binding protein LIN-28 which can repress the maturation of the let-7 miRNA 
(Viswanathan et al. 2009). Furthermore, RNA-binding proteins partake in the regulation of 
miRNAs by direct interaction with the RISC-complex (Galgano et al. 2008) and miRNAs can also 
be epigenetically silenced (Bueno et al. 2008; Yan et al. 2011). 
Like mRNAs, most miRNAs are transcribed by RNA-polymerase II. Likewise, transcription factors 
can regulate miRNA expression in the same way as they control expression levels of protein-
coding genes. Among others, miRNA-regulation by c-myc (O'Donnell et al. 2005), p53 (Jin et al. 
2011) and HIF (hypoxia-inducible factor) (Kulshreshtha et al. 2007) has been demonstrated. 
Hence, transcription factors provide the opportunity to fine-tune miRNA expression levels also in 
a tissue-specific manner. Additionally, transcription factor-miRNA interactions can be part of a 
regulatory network including feedback loops: Transcription factors can guard the expression of 
a certain miRNA and vice versa, a transcription factor can be negatively regulated by a miRNA 
either via direct interaction or via a secondary regulator. The feedback loop involving miR-133b 
and the transcription factor PitX3 (Pituitary homeobox 3) in neurons is a well-described example 
with miR-133b-mediated repression of PitX3 and PitX3-dependent transcriptional regulation of 
miR-133b (Kim et al. 2007). More loops involving miRNA-transcription factor-interaction will be 
discussed below. A major focus of this PhD thesis was the investigation of transcriptional 
regulation of miRNA expression and therefore a brief introduction of eukaryotic transcription is 
provided in chapter 2.3. 
miRNAs in cancer 
miRNAs have been implicated in the regulation of processes that promote cancer growth or 
conversely, in processes that might prevent cancers from developing. Since their discovery, 
deregulation of miRNA expression has been connected to a plethora of malignancies and other 
diseases. Like protein-coding genes, miRNAs can be classified as being either ‘oncogenic’ or 
‘tumor-suppressive’. A very recent review lists the ‘key microRNAs involved in cancer’, whose 
oncogenic or tumor-suppressive functions have been extensively studied in several cancer types 
(Lujambio and Lowe 2012). Table 1 shows an overview of the most prominent cancer 
microRNAs. 
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Table 1: Selection of most prominent cancer microRNAs 
(green) Tumor suppressor miRNAs and (red) oncogenic miRNAs, ↑ ≙ up-regulated; ↓ ≙ down-regulated. 
Adapted from (Garzon et al. 2009a; Iorio and Croce 2012a). 
 
miRNA Expression in 
patients 
Selection of confirmed 
targets 
Experimental data 
miR-15a/16-1 ↓ in CLL Bcl-2, WT-1 Induce apoptosis and decrease tumorigenicity 
Let-7 (a-d) ↓ in lung and 
breast cancer 
Ras, c-myc, HMGA2 Induce apoptosis 
miR-29 ↓in CLL, AML, lung 
and breast cancers, 
cholangiocarcinoma 
and others 
TCL-1, MCL-1, CDK6, 
DNMT3s 
Induce apoptosis and decrease tumorigenicity 
miR-34a-c ↓in pancreatic, 
colon and breast 
cancers 
CDK4, CDK6, cyclinE2, 
E2F3 
Induce apoptosis 
miR-155 ↑ in CLL, DLBCL, 
AML, BL, lung and 
breast cancers 
c-maf Induces lymphoproliferation, pre-B 
lymphoma/leukemia in mice 
miR-17~92 
cluster 
↑ in lymphomas, 
breast, lung, colon, 
stomach and 
pancreatic cancers 
E2F1, Bim, PTEN Cooperates with c.myc to induce lymphoma in 
mice, transgenic miR-17-92 develop 
lymphoproliferative disorders 
miR-21 ↑ in breast, colon, 
pancreas, lung, 
prostate, liver and 
stomach cancer, 
AML, CLL and 
glioblastoma 
PTEN, PDCD4, TPM1 Stimulates invasion and metastasis in different 
tumour types 
miR-372/373 ↑ in testicular 
tumors 
LATS2 Promote tumorigenesis in cooperation with RAS 
 
One of the first ‘oncomirs’ described was miR-21, which exhibits elevated levels in many human 
cancers and which down-regulates tumor suppressor genes such as those encoding PTEN 
(phosphatase and tensin homolog) and RECK (reversion-inducing-cysteine-rich protein with 
kazal motifs) (Meng et al. 2007a; Gabriely et al. 2008; Pan et al. 2010). Another well-known 
example is oncogenic miR-155, which was shown to repress genes responsible for repair of DNA 
damage (Costinean et al. 2006; Tili et al. 2011). On the other hand, the most prominent 
representatives of miRNAs exhibiting predominantly tumor-suppressive properties include miR-
34, miR-15~16, members of the let-7 family as well as the miR-29 family (Calin et al. 2002; 
Garzon et al. 2009b; Hermeking 2009; Buechner et al. 2011; Zhang et al. 2011b). The miR-29 
family or its single members, which will be described in more detail below, have been shown to 
be down-regulated in glioblastoma (Cortez et al. 2010), lung cancer (Yanaihara et al. 2006), 
prostate cancer (Porkka et al. 2007), colon cancer (Cummins et al. 2006), chronic lymphocytic 
leukemia (Calin et al. 2005) and many other malignancies. Apart from those miRNAs which can 
clearly be attributed to a distinct class, miRNAs with ‘dual’ functions as oncogenic or tumor-
suppressive, depending on the cellular context, have been reported. Examples are miR-125b, 
the miR-181 family and miR-220 (Fabbri et al. 2007b; Visone et al. 2007; Nam et al. 2008). 
Reliable and detailed knowledge of these miRNA functions is crucial to pave their way to the 
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clinic: The allocation to the ‘oncomir’ or ‘tumor-suppressive’ group should be determined before 
levels of miRNAs are manipulated in clinical treatments. 
miRNAs as biomarkers and therapeutical agents 
1Since it has been demonstrated that miRNAs often have tissue- and disease-specific expression 
patterns, the possibility to use miRNAs as biomarkers for early diagnosis of malignancies and 
other diseases has been studied extensively in recent years. They exhibit an extreme high 
stability in formalin-fixed tissues, plasma and serum samples (Mitchell et al. 2008) and are 
present in most solid tissues (Lu et al. 2005a; Liang et al. 2007). Apart from blood, where they 
are currently being examined and evaluated as ’secreted or circulating’ miRNAs, the small RNA 
molecules have been detected in many body fluids such as tears, breast milk, urine, bronchial 
lavage and others (Weber et al. 2010). Thus, as soon as there are robust and standardized 
methods for extraction, quantification and analysis of these secreted miRNAs, they are likely to 
become promising biomarkers, offering a non-invasive approach for the diagnosis of diseases, 
which alter miRNA expression profiles. The respective studies, which have been initiated for 
many different cancer types mostly rely on a panel of different miRNAs instead of single 
molecules (Chen et al. 2012). 
As described above, a cancer cell can emerge following the over-expression of classic 
oncogenes and so-called ‘oncomirs’ (such as the miR-17-92 family, miR-21, -155, miR-34a etc.), 
which down-regulate tumor-suppressors that normally control cell proliferation (Krutovskikh and 
Herceg 2010). On the other hand, miRNAs that function as tumor-suppressors by targeting 
cellular oncoproteins (such as let-7 family members, miR-15a, -16, -29, etc.) are frequently 
down-regulated in cancer tissues (Henry et al. 2011). Therapeutics opting to replace the 
diminished tumor-suppressor miRNAs are currently being investigated and seem promising, as 
miRNAs exhibit high stability as well as high specificity for their target mRNAs (Henry et al. 
2011; Kasinski and Slack 2011). 1Furthermore, miRNAs and their target genes represent 
interesting pharmaceutical targets as part of a general or personalized therapy in the future. 
However, several problems need to be adressed, such as efficient delivery and potential side-
effects. The miRNA treatment with the biggest potential for clinical application is currently a LNA 
(locked nucleic acid)-inhibitor of liver-specific miR-122 termed ‘Miraversen’, which is in clinical 
trials as an application against hepatitis C virus (HCV) infections, which can lead to the 
development of hepatocellular carcinoma (HCC). Remarkably, miR-122 inhibition was shown to 
reduce HCV viremia in monkeys (Lanford et al. 2010; Hildebrandt-Eriksen et al. 2012). 
1Otherwise, clinical applications are still rare and before miRNAs will routinely be incorporated in 
clinical therapeutic interventions, more detailed information on their precise biological functions 
within different cellular contexts will need to be collected. 
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The miR-29 family 
1The miR-29 family is among the earliest ones discovered (Lagos-Quintana et al. 2001) and is 
highly conserved among species (Kozomara and Griffiths-Jones 2011). An overview on the 
genomic organization and the mature sequences of the miR-29 family is shown in Fig. 4. 1In 
humans, it is encoded by two clusters, miR-29a~29b-1 (chromosome 7q32.3) and miR-29b-
2~29c (chr 1q32.2). miR-29a and miR-29b-1 (GenBank accession number EU154353 as well as 
miR-29c and miR-29b-2 (EU 154351 and EU154352) are co-transcribed by RNA-polymerase II 
as a polycistronic primary transcript from the minus strand (Chang et al. 2008; Mott et al. 
2010), only encoded 649bp and 504bp apart from each other, respectively. 1With identical seed 
sequences, miR-29 family members share most of their predicted targets. 1MiR-29b-1/b-2 have 
the same mature sequence and miR-29a and 29c mature sequences only differ by one 
nucleotide (Fig. 4). 
 
 
 
Fig. 4: miR-29 family: genomic organization and mature sequences. 
(A) 2The miR-29 family is transcribed from the respective antisense strand from two genetic clusters of 
chromosomes 7 (pri-29a~b-1) and 1 (pri-29b-2~c). (B) The three mature forms miR-29a/29b/29c share 
the same seed region (blue box). 2Differences between the mature sequences are underlined; the one 
nucleotide difference between miR-29a and miR-29c is shown in italics. 
 
1All miR-29 family members are ubiquitously expressed in healthy tissues (www.microrna.org, 
(Betel et al. 2008)). 1Both clusters, miR-29a~29b-1 and miR-29b-2~29c, are intergenic with no 
protein-coding genes in close proximity. 1Only a non-coding RNA (LOC646329), which has not 
been further characterized yet, shares part of the sequence with miR-29a~29b-1 
(www.genome.ucsc.edu) (Kent et al. 2002). The human miR-29 family represents a very 
important miRNA family whose members are increasingly recognized as tumor suppressors in a 
variety of malignancies. 1Since their sequence was added to miRBase in 2001 (Lagos-Quintana 
hsa-miR-29a: 5’-U AGCACCA UC UGAAAUCGGUUA-3’
hsa-miR-29b: 5’-U AGCACCA UU UGAAAUCAGUGUU-3’
hsa-miR-29c: 5’-U AGCACCA UU UGAAAUCGGUUA-3’
649 bp
29b-129a
Chr7 q32.3
29b-229c
504 bp
Chr1 q32.2
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et al. 2001), the number of publications on one or more members of the human miR-29 family 
rose quickly to more than 100. In recent overview articles on miRNAs in cancer, the miR-29 
family resided among the topmost cancer-associated miRNAs (Spizzo et al. 2009; Lujambio and 
Lowe 2012). Members of the miR-29 family have been shown to be implicated in many 
divergent cellular processes like extracellular matrix homeostasis (Villarreal et al. 2011), 
collagen expression (van Rooij et al. 2008), insulin signaling (Pandey et al. 2010), aging (Ugalde 
et al. 2011) and others. The number of confirmed targets for one or more family members is 
constantly rising, including many different protein classes ranging from transcription factors 
(Steiner et al. 2011; Ugalde et al. 2011), viral proteins (Ahluwalia et al. 2008) to growth factors 
(Hand et al. 2012), structural cell components (van Rooij et al. 2008) and others. 1Noteworthy, 
miR-29 members have also been connected to diseases other than cancer, for example 
myocardial infarction (van Rooij et al. 2008), diabetes (Pandey et al. 2010) and atherosclerosis 
(Chen et al. 2011). The implication of the miR-29 family in diseases like myocardial infarction 
and renal injury has recently been reviewed as well as its tumor-suppressing functions and its 
role in the immune system (Kriegel et al. 2012; Liston et al. 2012; Schmitt et al. 2012a). 
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1.2 Signal Transduction 
Signal transduction in cellular communication 
A task which the human body solves with a fascinating accuracy is the allocation of an efficient 
communication system for intercellular correspondence. Already in the early steps of embryonal 
development, the few cells which will grow up to organs and constitute the complex organism 
later on, exchange information to ensure proper division, differentiation and positioning. After 
formation of organs and the organism as such, cell communication remains crucial for everyday 
survival. Signal transduction in general represents a fundamental basis for the regulation and 
maintenance of the body functions. It provides the basic elements for the communication of 
cells with each other, enables them to take up extracellular information in form of signals and 
process them to the inside of the cell where subsequent tasks like gene regulation can be 
fulfilled (Eckardstein 2009). 
The impact of signal transduction in cancer and other diseases is obvious - false regulation of 
the extracellular signal or entire signal transduction pathways leads to wrong transmission of 
the information from the extracellular environment to the inside and thus can cause imbalances 
in the homeostasis of the cell. Therefore, it is important to decipher the functions of single 
components, which take part in signal transduction processes in order to understand those 
malfunctions and to develop therapeutical treatment options. One of the most evolutionary 
conserved and simultaneously very prominent signal cascade in eukaryotic cells is the Jak-STAT 
signaling pathway, which will be of major interest for this PhD project. 
Interferons as inducers of the Jak-STAT pathway 
Cytokines are key glycoproteins involved in cellular signaling, which regulate, amongst other 
fundamental processes, growth and differentiation of cells. They are subdivided into five main 
groups, i.e. interleukins, interferons, tumor necrosis factors, colony-stimulating factors and 
chemokines (Eckardstein 2009). The respective cytokine receptors can also be divided into five 
groups according to structural features of their extracellular domains. These are type-I- and 
type-II-cytokine receptors, TNF (tumor necrosis factor) receptors, receptors of the Ig 
(immunoglobulin) superfamily and seven-transmembrane receptors (Eckardstein 2009).  
Interferons comprise a cytokine family with important functions in immune responses and they 
signal via type-II-cytokine receptors. They were originally described as agents that ‘interfere 
with viral replication’ by Isaacs and Lindenmann in 1957 and are classified into two groups type 
I (‘viral interferons’: IFN-α with subtypes, IFN-β, IFN-ω and IFN-τ) and type II (‘immune 
interferon’: only IFN-γ) interferons (Borden et al. 2007). Apart from their specific anti-viral 
activities, common actions of interferons are the regulation of cell growth, differentiation and 
apoptosis as well as the activation of immune cells (Samuel 2001; Santos and Costa-Pereira 
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2011). Because of their above mentioned properties in infection and other cellular processes, 
interferons have first been introduced as therapeutical agents already in 1986 (Pestka 2007). 
Today, IFN-α is still used for treatment against melanoma, (hairy cell) leukemia, chronic 
hepatitis B and C and other diseases, whereas multiple sclerosis patients receive IFN-β 
treatment and IFN-γ is given in chronic granulomatous disease and malignant osteopetrosis 
(Pestka 2007). The probably best known example for the use of interferons as medication is a 
pegylated interferon α 2 which is used in combination with ribavirin for treatment of hepatitis C 
and has been FDA (food and drug administration)-approved in 2002. However, interferon-
treated patients regularly suffer from severe side effects such as flu-like symptoms (headache, 
fever, fatigue etc.), depression and others (Dusheiko 1997). 
IFN-γ has long been recognized for its crucial role in defense against viral and bacterial 
infections as well as in tumor control (Dunn et al. 2006; Schreiber et al. 2011). It can be 
produced by APCs (antigen-presenting cells, such as dendritic cells, monocytes and 
macrophages) and NK (natural killer)-cells and primarily signals through the Jak/STAT pathway 
via binding to the IFNGR1 (IFN-γ-receptor 1, associates Jak1) and IFNGR2 (associates Jak2). 
Examples for IFN-γ-regulated genes are STAT1, IRF-1 and SOCS1 (Fig. 6). IFN-α and IFN-β 
signal via IFNAR1/2 (IFN-α-receptor 1) (Fig. 6). 
The Jak-STAT signaling pathway 
Conserved among eukaryotes, STAT pathways are also present in slime molds, worms, flies and 
vertebrates, but not in fungi and plants (Darnell 1997; Aaronson and Horvath 2002). The Jak-
STAT pathway was discovered 20 years ago (Stark and Darnell 2012) and can be activated by 
cytokines, but also by growth factors and hormones (Subramaniam et al. 2001; Eckardstein 
2009). Main components of the pathway are the respective receptor, Janus kinases and STAT 
transcription factors. STAT transcription factors can also become activated independently of the 
Jak-STAT pathway, for example by receptors with intrinsic tyrosine kinase activity such as the 
EGF (epidermal growth factor) and PDGF (platelet-derived growth factor) receptor (Levy and 
Darnell 2002). This PhD project focuses on the induction of the Jak-STAT pathway by 
interferons, following the path: IFN-γ  IFNGR1/2  Jak1/2  P-STAT1  STAT1 target 
genes. 
Main players of the Jak-STAT pathway: Janus kinases and the STAT family of 
transcription factors 
The Janus kinase family consists of the four cytoplasmic, receptor-associated tyrosine kinases 
Jak1, Jak2, Jak3 and Tyk2. Jak1, Jak2 and Tyk2 show ubiquitous expression, whereas Jak3 is 
only expressed in hematopoietic cells (Cornejo et al. 2009). Janus kinases are named after the 
two-faced roman god Janus, which stands for the past and the future. Similar to the two faces 
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of the god Janus, Jaks have two kinase domains, i.e. a functional kinase domain and a so-called 
pseudokinase domain, which is catalytically inactive (Saharinen and Silvennoinen 2002).  
In total seven STAT genes (STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B and STAT6) have 
been identified in mammals. The common feature of the mammalian STAT protein family are 
their conserved domains (Levy and Darnell 2002; Reich and Liu 2006), some of which are 
shown in Fig. 5 for STAT1. The sizes of STAT proteins range from 750 to 850 amino acids 
(Kisseleva et al. 2002). 
 
 
Fig. 5: STAT1 crystal structure and DNA binding motif 
Crystal structure of the STAT1 dimer bound to DNA with the following protein domains; green: coiled-coil 
domain; red: DNA-binding domain; orange: linker domain; cyan: SH2-domain. The phosphotyrosine 
residue Tyr701, which is critical for activation is indicated by the red arrow, the DNA backbone is grey. 
(taken from (Chen et al. 1998))  
 
The N-terminal and the coiled-coil domain are important for protein-protein-interaction, as for 
example the interplay of STAT1 with PIAS (protein inhibitor of activated STAT) (Shuai 2000). 
The DNA binding domain provides the possibility for dimerized STATs to interact with promoter 
regions of their respective target genes. Another important region, which is crucial for the 
dimerization of STAT proteins is the SH2 protein domain (Src homology 2). This motif is 
structurally conserved, present in many signaling molecules and generally recognizes 
phosphotyrosine residues. Importantly, phosphorylation of a single tyrosine residue (pY 701, 
Fig. 5) only within the C-terminus is required for STAT-activation (Santos and Costa-Pereira 
2011). Briefly, STATs can dimerize by interaction between the SH2 domain of each STAT protein 
with the phosphotyrosine of the other STAT monomer. In contrast to the other domains, the 
sequence of the C-terminal transactivation domain is quite variable and therefore mostly 
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responsible for the formation of the seven different STAT proteins. STAT1 represents a central 
player of interferon signaling and consists of the two isoforms alpha (p91) and beta (p84), 
which are produced by alternative splicing of the STAT1 gene with p91 being the designated 
canonical form (UniprotConsortium 2011). The importance of STAT1 proteins as transducers of 
interferon signaling is emphasized by studies, which observed effects after impairment of STAT1 
function: STAT1 knockout mice exhibited an increased susceptibility to viral and bacterial 
infections (Meraz et al. 1996; Schroder et al. 2004). Diminished immune reaction to 
mycobacterial attacks were observed in humans with STAT1 germline mutations (Dupuis et al. 
2001; Boisson-Dupuis et al. 2012). Apart from dimerization with other STAT factors, STAT1 can 
also associate with other proteins and transcription factors, as for example with p48 (also 
known as IRF-9 within the ISGF3 complex (Fig. 6) (Boisson-Dupuis et al. 2012). STATs can 
function in cooperation with other transcription factors such as c-Jun and SP-1 (Shuai 2000; 
Ginsberg et al. 2007). Another well-described interaction of STATs is the association with the 
co-activators p300 and CBP (CREB-binding protein), which improve the interaction with the 
basal transcription factors (Wojciak et al. 2009). 
The Jak-STAT pathway: Events following IFN-γ stimulation 
Binding of IFN-γ to its receptor leads to oligomerization of two IFNGR1/IFNGR2 complexes, 
which are pre-assembled with Jaks (Samuel 2001; Saha et al. 2010). Subsequently, Jak1 and 
Jak2 get trans-phosphorylated and activated. Subsequently, they phosphorylate the tyrosine 
residues Y440 of the IFN-γ-receptor chains, which thereby create docking sites for the SH2 
domains of STAT1. The attracted STAT1 is then phosphorylated at the tyrosine residue Y701 
(Fig. 5). Additionally to tyrosine Y701, also the STAT1 serine residue S727 can be 
phosphorylated, which is required for maximal transcriptional activity (Sun et al. 2005). In 
addition to Tyr701 and Ser727 phosphorylation, acetylation, methylation and sumoylation as 
additional posttranslational modifications have been reported for STAT1 (Boisson-Dupuis et al. 
2012). After activation, the resulting STAT1-STAT1 homodimers dissociate from the receptor 
and translocate to the nucleus. Nuclear import is supported by importins (Jerke et al. 2009), 
mediated by nuclear localization signal (NLS) (Fagerlund et al. 2002). There the STAT1-STAT1 
homodimer binds to GAS-elements in promoter regions of target genes, which carry the 
consensus sequence TTCN(2-4)GAA (Decker et al. 1997). However, also unphosphorylated STAT1 
is able to drive gene expression (Cheon et al. 2011). 
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Fig. 6: Signal transduction processes following IFN-γ and IFN-α/β stimulation 
(A) IFN-γ stimulation of the IFN-γ receptor induces a conformational change in the receptor chains, 
resulting in phosphorylation of Jak1/Jak2 and subsequent phosphorylation of the tyrosine residues Y440 
in the IFNGR1 chains. These form docking sites for latent STAT1 proteins, which get recruited to the 
cytosolic receptor chains, become phosphorylated, dimerize and translocate to the nucleus. There they 
bind to regulatory promoter elements, i.e. GAS elements (gamma activated sequences). Known STAT1 
target genes are for example STAT1, IRF-1 and SOCS1. (B) IFN-α/β signaling is accomplished via the 
IFNAR, which leads to the production of STAT1-STAT2-IRF-9 trimers. They bind to ISREs (IFN stimulated 
response elements) in promoter regions of target genes and initiate their transcription. Alternatively, 
STAT1-STAT1 dimers can also be formed upon IFN-α/β stimulation of the IFNAR, as indicated by the 
arrow. 
 
For IFN-α and IFN-β, signal transduction follows a similar way via IFNAR1/2, which are 
associated with Tyk2/Jak1, respectively, the subsequent formation of STAT1/STAT1 dimers or 
STAT1/STAT2/IRF-9 heterotrimers, which are also known as ISGF3 (interferon-stimulated 
gamma factor 3) complexes. Following IFN-α/β stimulation, they bind to ISRE (IFN stimulated 
response elements) in promoter regions of the respective genes, represented by the consensus 
sequence AGTTTN3TTTCC (Kessler et al. 1988).  
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Negative regulation of the Jak-STAT pathway 
Several negative regulators can partake in the inactivation of the Jak-STAT pathway, such as 
SOCS (suppressor of cytokine signaling) and PIAS (protein inhibitor of activated STAT) proteins. 
SOCS proteins are rapidly up-regulated with enhanced STAT activation, thus providing a typical 
loop of feedback inhibition. They bind to phosphorylated Janus kinases and the respective 
receptors to block the pathway; for example binding of phosphotyrosines in a receptor chain by 
SOCS proteins prevents the subsequent binding of STAT factors (Rawlings et al. 2004). PIAS 
proteins are constitutively expressed E3-SUMO protein ligases which directly interact with 
phosphorylated STAT dimers and inhibit the DNA recognition process (Wormald and Hilton 
2004). Another group of negative regulators are PTPs (protein tyrosine phosphatases), as for 
example the tyrosine phosphatase SHP-1 (Src homology region 2 domain-containing 
phosphatase-1), which can dephosphorylate Jaks or their receptors (Rawlings et al. 2004). 
Several phosphatases such as SHP-2 which can act as negative regulators of STAT proteins 
have been described (Shuai and Liu 2003; Xu and Qu 2008). 
Concerning negative regulation of the Jak-STAT-pathway following IFN-γ-stimulation in 
particular, several specific mechanisms have been reported. For example, the IFN-γ/IFNGR 
complex can be internalized and subjected to degradation in the endosomal pathway, making it 
unavailable for further transduction of the signal, possibly to hamper overstimulation (Claudinon 
et al. 2007; Trinchieri 2010). However, receptors are not always degraded but can be recycled 
and send back to the surface (Claudinon et al. 2007). STAT1 can be sumoylated by PIAS1, 
leading to inhibition of its activity (Ungureanu et al. 2005). Additionally, SOCS1 provides specific 
feedback inhibition of IFN-γ-signaling, which itself induces SOCS1 (Fig. 6). 
Connecting the Jak-STAT pathway to miRNAs 
STAT factors have been first described to regulate transcription of miRNA genes a few years 
ago (Löffler et al. 2007; Meng et al. 2007b) and the importance of miRNA-STAT factor 
interactions has very recently been summarized in a review (Kohanbash and Okada 2012). 
However, only few connections have been described in detail. One of the first relationships 
between cytokine-induced Jak/STAT signaling and miRNAs has been established by Löffler et 
al., who showed that IL-6 increased the expression of oncogenic miR-21 via STAT3 activation in 
myeloma cells (Löffler et al. 2007), which has been subsequently confirmed by other groups in 
different cell lines (Iliopoulos et al. 2010; Yang et al. 2010; Kohanbash and Okada 2012). Also, 
miR-181b, miR-17-92 and miR-199a-5p have been shown to be STAT3-induced (Brock et al. 
2009; Iliopoulos et al. 2010; Haghikia et al. 2011). A positive feedback loop between STAT1 and 
miR-155 has recently been discovered in epithelial cells, where STAT1 induced up-regulation of 
miR-155, which in turn negatively regulated SOCS1 (Kutty et al. 2010). 
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1.3 Regulation of gene expression and eukaroytic transcription  
Several different ways to control the regulation of gene expression are known to date including 
transcriptional and posttranscriptional regulation, epigenetic mechanisms including structural or 
chemical modifications of DNA, posttranscriptional regulation by miRNAs and regulation of 
translation. The regulation by miRNAs has been briefly explained above (2.1 MicroRNAs – mode 
of action) and the transcriptional regulation of gene expression as well as additional epigenetic 
mechanisms will be addressed below. 
 
 
 
Fig. 7: Epigenetic changes in mammalian cells: DNA methylation and different chromatin 
structures 
taken from (Ohgane et al. 2008) 
(upper part) Methylation of CpG islands within the DNA leads to silencing of corresponding genes 
(methylation of CpG islands is indicated by black circles (left) in contrast to white circles (right), which 
represent hypo-methylated CpG islands). (lower part) Chromatin structure (condensed – in closed 
conformation, transcriptionally inactive in contrast to relaxed – in more open conformation, at 
transcriptionally active sites) is accommodated by histone modifications, i.e. acetylation and methylation. 
H3 – histone 3; K – lysine residus.  
 
To fit into the nucleus and to prevent the DNA from damage, it is generally tightly packed 
around histone proteins into nucleosomes (Fig. 7). For the initiation of transcription, the 
compact chromatin (‘heterochromatin’) has to be re-arranged to a more open comformation 
(‘euchromatin’) in order to provide enough space for the polymerase. This is accomplished by 
several well-described modifications at specific histones, which become enzymatically modified 
and include methylation and acetylation. In contrast to DNA-methylation, which occurs at CpG 
islands and epigenetically silences genes, the methylation status of distinct histone residues can 
be correlated with the chromatin status: for example H3K4me3 (tri-methylation of histone H3 at 
lysine 4) is often found close to the transcription start site (TSS) of active promoters 
(Benevolenskaya 2007), whereas H3K9me3 (tri-methylation of lysine 9 within histone 3) is a 
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marker for inactive genes (Rosenfeld et al. 2009) (Fig. 7). Also acetylation of lysines, as 
mediated by histone acetyltransferases (HATs) influences chromatin structure; as for 
methylation, acetylation of histones is associated with a less condensed chromatin structure 
whereas hypo-acetylated chromatin is tightly packed (Fig. 7). Only in the open conformation, 
chromatin is accessible for the RNA-polymerase and the transcription process can be initiated.  
As the first step in gene expression, eukaryotic transcription enables cells to elicit a response 
following exposure to extracellular signals via diverse signaling processes (Lee and Young 2000; 
Maston et al. 2006). To start the transcription process, assembly of the initiation machinery 
including the positioning of the RNA polymerase at the respective DNA sequence is required. For 
protein-coding genes and the majority of miRNA genes, transcription is performed by RNA-
polymerase II and can be subdivided into initiation, elongation and termination, with the 
majority of regulation happening at the initiation step. Initiation of transcription takes place at 
the promoter region of DNA, which is located upstream of the transcription start site. The so-
called ‘core promoter’ region mostly contains the minimum number of elements which are 
necessary for transcription like a TATA box, an initiator element (INR), a downstream promoter 
element (DPE) and a TFIIB (transcription factor 2B) recognition element. Furthermore, the TSS 
and a binding site for the RNA-polymerase are located here. Besides this region, other 
regulatory elements such as silencers and enhancers, which provide recognition sequences for 
the specific transcription factors are part of the genomic regulatory region. In contrast to the 
‘core promoter’ elements, they can be localized up to many thousands of base pairs away from 
the transcription start site. The transcription process starts with the assembly of the ‘pre-
initiation’ complex. Briefly, TBP (TATA-binding protein), a subunit of TFIID, binds to the TATA 
box and ensures subsequent gathering of the remaining general transcription factors (TFII-A, B, 
E, F, H) to the promoter region, where they lead RNA polymerase II to the transcription start 
site. Afterwards, RNA polymerase II creates a complementary RNA copy of the DNA during the 
elongation step which is polyadenylated at the termination step and transcription of the 
respective gene is accomplished. Further fine-tuning and activation or silencing of gene-
expression requires the activity of additional transcription factors (Maston et al. 2006; Spitz and 
Furlong 2012).  
Transcription factors 
Eukaryotic control of gene expression is much more complex than the mechanisms that exist in 
prokaryotes, which can be mainly attributed to the existence of transcription factors and their 
influence on RNA polymerase II activity. Controlling the transcription rate is crucial for the fine-
tuning of gene expression. Transcription factors are composed of a DNA-binding domain and a 
transactivating (or transrepressing-) domain as well as further domains responsible for the 
interaction with other proteins, as shown in Fig. 5 for STAT1. Their function is to recognize and 
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bind to specific, 6-10 nucleotide long DNA sequences (enhancer or silencer elements of target 
genes) and to interact with RNA-polymerase II to influence transcriptional activity either by 
blocking (repressors) or enhancing (activators) the action of the polymerase (Maston et al. 
2006). The respective regulatory elements can be located hundreds or thousands of basepairs 
upstream and downstream of the promoter region. Several public databases allow for the 
scanning of user-provided DNA-sequences for conserved transcription factor binding sites, as for 
example ‘Genomatix’,  ‘Transfac’ and ‘Jaspar’ (Matys et al. 2003; Vlieghe et al. 2006); the latter 
two were used within this PhD project.  
Currently, ChIP (chromatin immunoprecipitation) provides the method of choice to verify 
transcription factor binding sites within promoter regions of target genes. Briefly, the chromatin 
including the DNA-bound transcription factors is fragmented by sonication and subsequently 
immune-precipitated with an antibody for the analyzed transcription factor. After purification, 
the respective DNA-sequence can be amplified by PCR or detected by  microarray (then known 
as ChIP-chip) or deep sequencing (ChIP-Seq, Fig. 8) (Collas 2010). ChIP-Seq is a commonly 
used high-throughput method which allows for determination of genome-wide binding sites for 
a given transcription factor. A comprehensive study including ChIP-Seq data for STAT1 has 
been performed by Robertson et al. in Hela cells (Robertson et al. 2007).  
Apart from the ChIP analysis for binding sites in the promoter regions of target genes for the 
transcription factor of interest, other components of the transcription process can be 
investigated: For example ChIP-Seq can also be performed with an antibody, which recognizes 
the characteristic histone signatures (e.g. H3K4Me3) as explained above (Fig. 7) to search for 
transcriptionally active promoters (Young et al. 2011; Ntziachristos et al. 2012). 
In addition to transcription factors, co-activators and co-repressors mediate the interaction 
between general and specific transcription factors and influence transcription efficiency (Spitz 
and Furlong 2012). For example the co-activators CBP (CREB binding protein)/p300, which have 
been shown to interact with STAT1, exhibit histone acetyltransferase activity, enabling them to 
promote transcription by acetylation of histones (Bandyopadhyay et al. 2002) (Fig. 7). Along 
with the combinatorial control mediated by transcription factors and their tissue-specific 
distribution, these above mentioned factors and processes contribute to the specificity of 
transcription, which is a major reason for the general complexity of eukaryotic organisms. 
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Fig. 8: ChIP-Seq (scheme) 
Taken from http://www.bnl.gov/newsroom/news.php?a=11351 
(from top to bottom) Initial steps include (1) cross-linking of transcription factors to DNA, (2) 
fragmentation of DNA and binding of the specific antibody of choice followed by precipitation of the 
fragments which are bound by this antibody. (3) Those DNA fragments are subjected to high-throughput 
sequencing and (4) the respective sequences can be mapped to the genome. (5) Note that the number of 
enriched sequences corresponds to the height of the peak, which is obtained as a read-out of ChIP-Seq 
data. 
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1.4 Melanoma 
Composition of the skin and types of skin cancer 
The skin represents the largest and most versatile organ of the body. Apart from protection 
against infection, injury and temperature loss, one of its most important functions is to protect 
against UV radiation. The outermost part of the skin is divided into epidermis, dermis and 
adjacent subcutaneous tissue (Fig. 9).  
 
 
Fig. 9 Layers of the skin 
(Pictures from (Junqueira et al. 2005), chapter 17 ‘The skin’). (A) The outer layer of the skin is divided 
into epidermis, dermis and the adjacent subcutaneous tissue (hypodermis), ‘thick’ skin is shown in this 
picture. (B) Magnified view on the human epidermis, which is composed of the different layers (from 
outside to inside) stratum corneum, lucidum, granulosum, spinosum and basale and separated from the 
dermis by a basement membrane. Melanocytes as the melanin-producing cells of the skin are generally 
located in the stratum basale in the deepest part of the epidermis, just above the basement membrane. 
(C) Enlarged picture of the stratum basale with keratinocytes and a melanocyte. The arrow indicates a 
melanocyte which is surrounded by keratinocytes and melanin (brownish structure which covers the 
nuclei of the keratinocytes), which is secreted by melanocytes and is taken up by the cells in their vicinity.  
 
Keratinocytes represent the main components of the epidermis (> 90 % of the cells). Moreover, 
the epidermal layer contains squamous cells, basal cells and melanocytes which are all prone to 
skin cancer development. Named according to the cell type they develop from, basal and 
squamous cell carcinoma (often referred to as ‘non-melanoma skin cancer’) as well as 
melanoma represent the three most common types of skin cancer (AmericanCancerSociety 
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2012). For all of them, the number of cases has increased over the past couple of years (Garbe 
and Blum 2001; Thompson et al. 2005). Basal cell carcinoma is one of the most common skin 
tumors. It derives from the lowest layer of the epidermis (stratum basale, Fig. 9). Survival rates 
are extremely good as the tumor rarely metastasizes. Nevertheless, it grows invasively and can 
- if not treated - lead to a massive destruction of the surrounding tissue. Squamous cell cancer 
is less common, but metastasizes with a higher frequency. It develops from keratinocytes of the 
stratum spinosum (Fig. 9). Other types of skin cancer - though occurring much less frequently - 
are for example Merkel cell carcinoma, Kaposi’s sarcoma and others. While the mortality rates 
of basal and squamous cell carcinoma are relatively low (Stulberg et al. 2004), (metastatic) 
melanoma is less common, but a far more dangerous and aggressive type of skin cancer, 
leading to 5-year survival rates of < 5% (Miller and Mihm 2006). Melanoma contribute to the 
vast majority of deaths caused by skin cancer, although they only contribute to less than 5% of 
all skin cancer cases (AmericanCancerSociety 2012). The incidence of melanoma and non 
melanoma skin cancers has been increasing during the last couple of years (WHO, 
www.who.int) and it is estimated to rise even further. Fig. 10 illustrates a comparison of 
international age-standardized incidences of melanoma together with the respective mortality 
rates. Australia shows by far the highest incidence of melanoma: In 2008, incidence rates were 
60.5 cases/100.000 men and 39.3 cases/100.000 women (http://www.aihw.gov.au). 
 
 
 
Fig. 10: Melanoma: international comparison of age-standardized incidences  
(blue: men, red: women) and mortality rates (grey), calculated per 100.000 inhabitants (data from 2007-
2008 or the last year which was available, graph adapted from Robert-Koch-Institut Germany; 
(www.rki.de));. Data from Australia are from 2008 (age-standardized incidences) and 2007 (mortality 
rates) and obtained from the ‘Australian Cancer Incidence and Mortality books’, ACIM 
(http://www.aihw.gov.au). 
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Melanocytes and their normal function: production of melanin 
Melanocytes are the pigment-producing cells of the skin and located at the bottom layer of the 
epidermis (Fig. 9). Together with their derivative pigment melanin, their function is the 
protection of DNA from UV-radiation-induced DNA damages (Hu 2008). Melanogenesis is 
induced as soon as a part of the skin is exposed to sun. Briefly, tyrosinase catalyzes the 
conversion of tyrosine to 3,4-dihydrophenlyalanine (dopa) and to dopachinone, which is then 
subsequently converted to melanin. It accumulates in melanosome vesicles, which migrate to 
the tips of the melanocytes, where they get released and taken up by the surrounding 
keratinocytes (Park et al. 2009a). Every melanocyte has contact to approximately 30 
keratinocytes. Skin pigmentation in general is determined by the specific type of melanin 
pigment that is predominant: eumelanin is rather brownish, while pheomelanin causes the 
reddish color of red hair and freckles. Differences in pigmentation are inherited; for example red 
haired people, who usually exhibit fair skin have more pheomelanin than eumelanin (Mitra et al. 
2012). Also the size, number and density of melanosomes plays a role in skin pigmentation. 
Benign accumulations of melanocytes are referred to as ‘melanocytic nevi’ or ‘nevi’ (Markovic et 
al. 2007) and commonly known as ‘moles’. Melanoma can develop from pre-existing moles or 
they can derive from a new location on normal skin spontaneously.  
Melanoma – origin and development 
The WHO classifies melanoma in four different subtypes, i.e. superficial spreading melanoma 
(SSM), acral lentiginious melanoma (ALM), lentigo maligna melanoma (LMM), nodular 
melanoma (NM). They differ in several features as the age at which they mostly occur or in 
their location on the body. For example, LMM are most common in elderly people and develop 
from pigmented areas of the skin. NM occur in sun-exposed areas of the skin and develop 
quickly. SSM is the most common type of melanoma whereas acral lentiginous melanoma are 
quite rare and develop in palms, nails etc. (www.skincancer.org). 
The mechanical progression of healthy epidermal tissue to metastatic melanoma is a multi-step 
process and a known set of mutations accompanies the single steps towards malignancy (Miller 
and Mihm 2006) (Fig. 11). In normal skin or in a benign nevus, melanocytes proliferate slowly. 
The next step towards malignancy is a dysplastic nevus, which shows atypical growth behavior. 
Such spots can potentially be identified by the ‘ABCDE’-rule (which will be explained below, Fig. 
12), as they show suspicious asymmetry or borders, a large diameter or multiple colors. The 
following radial growth phase represents the first malignant stage of melanoma development 
and progression. Still, cells show low invasiveness and proliferation. Proliferation increases 
dramatically during the vertical growth phase, thus cells are able to penetrate the basement 
membrane, infiltrate the dermis and invade the connective tissue. In the last and metastatic  
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state, melanoma cells can spread over the lymphatic system as well as the blood and 
metastasize. 
 
 
 
 
Fig. 11: Histological progression of melanocyte transformation to melanoma is a multi-step 
process  
(Picture from (Miller and Mihm 2006), modified). 
A benign nevus shows normal growth behavior, although somatic BRAF mutations can already occur at 
this early stage. Loss of CDKN2A/PTEN is observed for dysplastic nevi, while the radial growth phase is 
characterized by increased Cyclin D1 expression and the tumor cells acquire the ability to penetrate the 
basement membrane. During the vertical growth phase, increased expression of N-Cadherin, αVβ3 
integrin and MMP-2 are observed while E-cadherin expression is lost and TRPM1 is reduced, which is 
absent in the following, metastatic phase. In this last phase of melanocyte transformation, melanoma 
cells are able to metastasize to other organs. CDKN2A – cyclin-dependent kinase inhibitor 2A, PTEN- 
phosphatase and tensin homolog, MMP – matrix-metalloprotease, TRPM - Melastatin. 
 
Genetic characteristics of melanoma 
Many cellular pathways have been described to be de-regulated in melanoma, which include the 
MITF (microphtalmia-associated transcription factor) pathway, the PI3K (phosphoinositide-3 
kinase)-Akt pathway, the RAS (rat sarcoma virus)-RAF-MEK (dual specificity mitogen-activated 
protein kinase kinase)-ERK (extracellular regulated kinase) pathway as well as the p16INK4A-
CDK4 (cyclin-depent kinase 4) -RB (Retinoblastoma) pathway. Table 2 provides an overview of 
the most important genes in melanoma and melanoma development. A selection of affected 
pathways and their functions will be explained in more detail below.  
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Table 2: Genes and cellular pathways important in melanoma  
(adapted from (Miller and Mihm 2006)) TF = transcription factor; TS = tumor suppressor; Onc = 
oncogene; VGP = vertical growth phase; RGP = radial growth phase; expr. = expression; oncogenes are 
marked in red, whereas tumor suppressors are shown in green. 
Pathway Gene/Protein  Normal function Changes in melanoma 
MAPK 
RAS 
N-RAS 
BRAF 
neuroblastoma RAS viral (v-
ras) oncogene homolog/ 
v-raf murine sarcoma viral 
oncogene homolog B1 
Oncogenes Sporadic activating 
mutation (N-RAS: 
G13R, BRAF: V600E) 
 
MEK Mitogen-activated protein 
kinase – extracellular-
regulated kinase 
Signal Transduction Up-regulated in RGP & 
VGP 
ERK1/2 
(MAPK) 
Extracellular-regulated 
kinase 1 / 2 (mitogen-
activated kinase) 
Signal Transduction Activity enhanced 
INK4A 
CDK 
Rb 
CDKN2A/ 
 INK4A 
Cyclin-dependent kinase 
inhibitor 2A / inhibitor of 
kinase 4A 
TS, negative regulator of 
cell proliferation 
Germline mutations, 
sporadic deletions, 
promoter inactivation 
CDK4 Cyclin-dependent kinase 4 Promoter of proliferation Familial germline 
mutations 
CCND1 Cyclin D1 Promoter of proliferation Sporadic amplification 
Rb Retinoblastoma TS, negative regulator of 
cell proliferation 
Phosphorylation  
G1/S transition 
ARF 
p53 
ARF Alternate reading frame 
(CDKN2A) 
TS, degrades MDM2 Germline mutations, 
sporadic deletions, 
promoter inactivation 
etc. 
p53 Tumor protein p53 TS, induces apoptosis and 
suppresses proliferation  
after DNA-damage 
Expr. usually present 
in melanoma 
MDM2 Mouse double minute 2 Targets p53 for 
ubiquitination & 
destruction 
Up-regulated in 
presence of ARF 
mutation 
PTEN 
Akt 
PTEN Phosphatase and Tensin 
homolog 
TS, counteracts PI3K 
activity 
Sporadic deletion 
PI3K Phosphatidylinositol 3 
kinase 
Signaling molecule for 
many growth factors 
Active, when PTEN is 
mutated 
Akt  
(PKB) 
Protein kinase B Onc, activated by PI3K, 
leads to increased cell 
survival 
Sometimes amplified 
MSH 
MITF 
MC1R Melanocortin receptor 1 Receptor for α-MSH affects hair and skin 
color 
MITF Micropthalmia-associated 
transcription factor 
TF Expr. decreased 
 
TYR Tyrosinase Pigment synthesis 
MLANA Melan-A Melanoma antigen 
recognized by T-cells 1 
TRPM1 Melastatin 1 ? 
BCL-2  Cell survival Variable up-regulation 
(in various phases of 
melanoma) 
Cell  
Adhesion 
molecules 
β-Catenin Adherens junction 
protein; 
also affects gene 
expression 
Sporadic mutations 
E-cadherin Cell adhesion molecule Reduced expr. in VGP 
N-cadherin Cell adhesion molecule Aberrant expr. in VGP 
αVβ3 integrin Dimer that forms cell 
adhesion molecule 
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A transcription factor of particular importance for melanoma development is MITF 
(microphthalmia-associated transcription factor). It is responsible for melanocyte development 
and controls their proliferation, survival and differentiation (Tsao et al. 2012). Amplified in 10-20 
% of melanoma, it has widely been described as oncogene, but has also been attributed tumor-
suppressive functions (Bell and Levy 2011). 
The CDKN2A locus 
The CDKN2A (cyclin-dependent kinase 2A) gene is a well-known melanoma susceptibility locus 
(Hussussian et al. 1994) (Table 2), which encodes for two proteins, p16INK4A and p14ARF. p16INK4A 
is deleted in about 50% of melanoma (Bennett 2008) while p14ARF is affected less often (Zuo et 
al. 1996; Soufir et al. 1998; Tang et al. 1999). Both act as tumor suppressors in the cell cycle 
by controlling G1  S transition via the phosphorylation status of Rb1. p14
ARF positively 
regulates p53 via MDM2 (murine double minute) and thus controls induction of p21WAF1/CIP1, 
which controls CDK2/Cyclin E–mediated phosphorylation of Rb1. p16INK4A inhibits the activation 
of CDK4 and CDK6, which are normally complexed with Cyclin D1 and p16INK4A can also 
phosphorylate Rb1. In an unphosphorylated form, Rb1 binds to the transcription factor E2F, 
thereby hindering it from expression of genes necessary for G1  S transition. Genetic defects 
in the CDKN2A locus concerning either of the two proteins result in uncontrolled cell 
proliferation as will be further discussed below (Fig. 42). 
The MAP-kinase pathway in melanoma 
The Ras-Raf-MEK-ERK-signaling cascade plays a prominent role in most cancer types. It is 
normally activated by growth factors via receptor tyrosine kinases, leading to cell proliferation 
and survival. Initial activation of Ras is a trigger for subsequent phosphorylation of single 
proteins along the Raf  MEK (MAPK/ERK kinase)  ERK path with each phosphorylation 
acting as an activation of the subsequent protein in the pathway. Consequently, constitutive 
activation of only one of the members can lead to uncontrolled proliferation and cancer. 
Members of the MAP-kinase pathway are mutated in many cancer types. NRAS (member of the 
Ras family together with KRAS and HRAS) is mutated in ~15-30 % of melanomas (Rosenfeld et 
al. 2008) while BRAF is mutated in ~60 % (Davies et al. 2002), mostly showing the BRAFV600E 
mutation. An inhibitor is available for clinical treatment of individuals with BRAFV600E mutations, 
which will be further discussed below. The importance of this kinase for melanoma development 
is emphasized by the fact that BRAF-mutated melanoma metastasize with a higher percentage 
than not mutated ones (Broekaert et al. 2010) and therefore show a more aggressive clinical 
progression (Long et al. 2011). As NRAS and BRAF mutations are mostly mutually exclusive, the 
majority of melanomas exhibit at least one of them (Glud and Gniadecki 2012).  
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The PI3K-Akt pathway in melanoma 
Upon stimulation by growth factors and hormones, the family of PI3K mediates the 
phosphorylation of the inositol ring on phosphoinositides, converting PIP2 (Phosphatidylinositol 
4,5-bisphosphate) to PIP3 (Phosphatidylinositol (3,4,5)-triphosphate). After phosphorylation, the 
second messenger PIP3 is required for phosphorylation of signaling proteins containing 
pleckstrin-homology domains, like the serine-threonine kinase Akt (Proteinkinase B), which 
subsequently activates other proteins that act on cellular growth, survival and the cell cycle 
(Cantley 2002). The tumor suppressor and phosphatase PTEN counteracts the PIP2  PIP3 
phosphorylation mediated by PI3K. All of the proteins mentioned above are prone to genetic 
changes in melanoma (Table 2): Akt3 (member of the Akt family of serine/threonine protein 
kinases together with Akt1 and Akt2) activity is increased in around 70 % of sporadic melanoma 
(Sharma et al. 2009) and loss of PTEN occurs frequently (Wu et al. 2003) while mutations 
within PI3K genes are rare (Davies 2012). Apart from genetic changes in the human skin, 
several external risk factors can influence melanoma development. 
Environmental and genetic risk factors 
The impact of sun exposure on melanoma development has been assessed in many studies and 
a firm connection has been established. Sun-derived UV radiation is thought to be the cause for 
around 86 % of melanomas (Parkin et al. 2010), as well as for the majority of mutations in 
melanoma (Pleasance et al. 2009). Already one blistering sunburn increases the general risk to 
develop melanoma (Lew et al. 1983), while the risk doubles after more than five sunburns at 
any age (Pfahlberg et al. 2001). Sunburns which have been acquired during childhood increase 
the risk even more. Of course, the geographical location of an individual has an important 
impact on daily sun-exposure and is enhanced in the southern hemisphere. Also UV-light from 
so-called ‘non-solar’ resources as tanning beds and sunlamps augment the melanoma burden. 
Interestingly, UV-tanning devices were listed in ‘group 1’ of the most dangerous cancer-causing 
substances by the International Agency for Research on Cancer (partner organization of the 
WHO), which also includes plutonium and cigarettes (El Ghissassi et al. 2009). Users of indoor 
tanning devices are 74 % more likely to develop melanoma than subjects who have never used 
them (Lazovich et al. 2010). Also the risk for squamous cell carcinoma (x 2.5) and basal cell 
carcinoma (x 1.5) is increased (Karagas et al. 2002).  
Apart from environmental factors, the genetic background of an individual also influences the 
development of this cancer. For example the number of nevi on the body correlates directly 
with the risk for melanoma as nevi have the potential to progress to a malignant state (Markovic 
et al. 2007). Immunosuppressed individuals or people suffering from Xeroderma pigmentosum 
exhibit a higher risk, which is also the case for individuals with a familial history of melanoma 
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(Cho et al. 2005a; Cho et al. 2005b) often showing germline mutations in the respective 
susceptibility genes (as listed in Table 2). 
Melanoma detection and current treatment options 
Once a melanoma has developed, early discovery is crucial. A commonly established way of 
melanoma self-control is the ‘ABCDE’-rule (Fig. 12). Here, features of existing moles or spots on 
the body get evaluated for their Asymmetry, Border irregularity, Color variation, Diameter and if 
they are Evolving (any itching, bleeding or crusting).  
 
 
Fig. 12: Images for illustration of the ‘ABCD’ rule 
As described in the text. Taken from NCI Visuals online (http://visualsonline.cancer.gov/) 
 
The ‘ugly duckling’ sign is a rather recent innovation. This analysis aims at identification of 
moles or spots that look totally different from the spots in the vicinity. Most affected sites for 
melanoma development are arms and legs for women and the back for men (Boyle et al. 1995; 
Tsai et al. 2005). Suspicious moles, which show abnormal growth behavior, color or even 
lesions should directly be presented to a dermatologist.  
The most obvious and elementary treatment option of malignant melanoma is physical excision 
of the primary tumour, which – like for most types of skin cancer - can be seen on the surface 
of the skin. If the tumor has not reached the radial growth phase yet and thus did not invade 
the basement membrane (compare Fig. 1, then referred to as ‘melanoma-in-situ ‘), the chance 
for formation of metastasis is extremely low (Bene et al. 2008). Nevertheless, except excision at 
early stages, no curative therapies exist and metastatic melanoma exhibit a severe resistance to 
available therapies. The 5-year survival rate for melanoma patients heavily depends on the time 
of detection: if detected before the tumor has penetrated the basement membrane, chances to 
survive are 98 %. However, this quickly drops to 62 %, when lymph nodes are affected and 
further to 15% when the tumor has metastasized (AmericanCancerSociety 2012). For clinical 
reports, staging of tumors is performed according to the American Joint Committee on Cancer 
(AJCC) (Balch and Soong 2008). Here, the vertical tumor thickness (divided into 5 stages 
according to Breslow (Breslow 1970), the mitotic rate, ulceration and the lymph node status are 
analyzed (Glud and Gniadecki 2012). Additionally, the ‘Clark’ classification, which characterizes 
the invasion level of the tumor (stages 0 to IV) has been widely used (www.skincancer.org). As 
mentioned above, when detected early, melanoma can be efficiently treated by surgical 
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resection. However, all therapeutics which are used to treat metastasized malignant melanoma 
to date merely increase survival by several months. Consequently, current treatment options are 
rather palliative and aim to minimize reccurence. Often, therapies against melanoma include 
administration of high-dose IFN-α-2b as an adjuvant treatment, which has, however, severe 
side effects such as fever, fatigue and weight loss. Around 50% of melanoma patients exhibit 
V600E mutations in the cellular kinase BRAF (Ascierto et al. 2012). In 2011, a targeted kinase 
inhibitor therapy was licensed. The BRAF-inhibitor Zelboraf® (also known as Vemurafenib, 
Roche) has been FDA-approved for treatment of late-stage melanoma patients who carry the 
V600E mutation and this treatment increases life expectancy by several months (Sala et al. 
2008; Flaherty et al. 2010). Nevertheless, none of the available treatment options (kinase 
inhibitors, chemotherapy) can entirely extinguish the malignancy (Chapman et al. 2011). 
Ipilimumab (Yervoy®, Bristol-Myers Squibb) which is also used for treatment of malignant 
melanoma, is a monoclonal antibody targeting CTLA-4 (cytotoxic T-lymphocyte antigen 4) to 
induce an antitumor immune response (Scheier et al. 2011). More drugs are currently under 
investigation in clinical trials, for example the monoclonal antibody Bevacizumab (Avastin®, 
Roche), which inhibits angiogenesis and has already been approved for the treatment of other 
cancer types. However, the most promising approach to date in immunotherapy against 
melanoma uses T-cells, which have been genetically modified to express receptors directed 
against tumor antigens, such as MAGE A3 and –A12 (melanoma antigen encoding gene) (Zhu et 
al. 2012).  
Melanoma and miRNAs 
As they are involved in virtually all cellular processes, clearly miRNAs are supposed to be also be 
involved in melanoma development and progression, as reviewed extensively during the last 
couple of years (Mueller and Bosserhoff 2009; Howell et al. 2010; Glud and Gniadecki 2012; 
Völler et al. 2013). This is supported by the fact that miRNAs have been shown to play decisive 
roles already in normal skin development and homeostasis (Botchkareva 2012; Schneider 
2012): Knockouts of the key miRNA processing enzymes DGCR8 (Yi et al. 2009) and Dicer 
(Bernstein et al. 2003) led to death of mice in early embryogenesis. Furthermore, individual 
miRNAs could be attributed important functions in skin development, as for example miR-203, 
which can promote epidermal differentiation (Yi et al. 2008). However, concerning malignant 
melanoma, relatively few studies on the function of miRNAs have been published so far in 
comparison to other cancer types. The majority of studies on miRNAs in melanoma established 
miRNA expression profiles in different healthy and diseased skin stages, i.e. healthy nevi, 
primary and malignant melanoma. Pilot studies in this area investigated microarray expression 
profiles in healthy melanocytes versus melanoma cell lines and reported distinct miRNA 
signatures (Zhang et al. 2006; Gaur et al. 2007; Mueller and Bosserhoff 2009). Along this line, 
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we have previously analyzed the miRNome of a set of melanoma cell lines and FFPE patient 
samples (Philippidou et al. 2010; Schmitz Ulf et al. 2013) and other groups have investigated 
blood samples of melanoma patients for screenings to identify potential biomarkers (Leidinger 
et al. 2010). Latest screening studies added previously unknown miRNAs (as miR-4291, miR-
4317 and miR-4324) to the miRNAs de-regulated in melanoma as the corresponding microarray 
experiments were based on the current version 19 in contrast to earlier studies (Sand et al. 
2012). Apart from those evaluations which concerned the whole miRNome, individual miRNAs 
have been subsequently connected with proteins involved in melanoma growth and behaviour. 
The first link between a single miRNA and melanoma tumorigenesis was the discovery that the 
transcription factor MITF (microphthalmia-associated transcription factor) was regulated by miR-
137 (Bemis et al. 2008) and also by miR-182 (Segura et al. 2009). MITF mediates melanocyte 
proliferation, survival and differentiation and primary as well as metastatic melanomas exhibit 
alterations in the connected pathway (Cronin et al. 2009) (Table 2). Also other well-known 
cancer-associated miRNAs, as for example the let-7 family, have been connected to melanoma: 
let-7a down-regulated integrin β3 (Muller and Bosserhoff 2008), which contributes to the 
invasive potential of melanoma cells and let-7b has been confirmed to target the cell cycle 
regulator Cyclin D1 (Table 2) (Schultz et al. 2008). Other examples for ‘key’ cancer-associated 
miRNAs with melanoma involvement are miR-34a, which is silenced in melanoma (Lodygin et al. 
2008), miR-155, which is over-expressed and negatively regulates melanoma growth  as well as 
the oncogenic miR-17-92 cluster, which is also over-expressed (Levati et al. 2009). Although 
only a small selection of melanoma-connected miRNAs was addressed here, it is certain that 
they play a pivotal role in general skin functions and melanoma development. This PhD project 
aims to decipher further miRNA-melanoma cellular networks, with the focus on STAT1-regulated 
miRNAs.
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2 Objectives 
The main focus of this PhD project was the investigation of miRNAs that could be induced by 
IFN-γ and that are regulated STAT1-dependently. By elucidating STAT1 regulation of miRNA 
expression and their respective target genes, an important objective was to identify new 
regulatory pathways for the growth control of melanoma and later, other cancer cells. Following 
this path, the aim was to identify and describe a complete regulatory line of events starting with 
cytokine stimulations of different melanoma cells → STAT induction → identification of STAT-
regulated miRNAs → identification and analysis of miRNA target genes → functional role of 
target genes in cancer. Apart from this major objective, another important issue was expression 
profiling of melanoma to find potential biomarkers. The main objectives of this PhD project are 
briefly summarized below: 
 
• Identification of differentially regulated miRNAs in untreated versus IFN-γ-stimulated cell 
lines (microarray): list potentially STAT1-regulated miRNAs  
• Validation of candidate STAT1-regulated miRNAs  
• In silico analysis of promoter regions of identified miRNAs 
• Subsequent identification of the role of STAT1-regulated miRNAs in defined cellular 
processes and their implication in melanoma development 
•  In silico identification of respective miRNA target genes 
• Experimental verification of potential target genes, which are likely to play a role in 
melanoma development and/or progression or exhibit other interesting cancer-related 
properties  
• Analysis of the functional relevance of miRNA-regulated target genes for the growth 
characteristics of melanoma cells: proliferation, migration/invasion, apoptosis. 
• Analysis of global and selected miRNA expression patterns in melanoma cell lines and 
patient samples 
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3 Materials 
Tables with the suppliers for all laboratory equipment as well as solution and buffer recipes can 
be found in the Appendix in (Table 8-Table 11). 
Cell lines 
Table 3: Human cell lines used in this study 
DSMZ = Deutsche Sammlung von Mikroorganismen und Zellkulturen (german collection of microorganism 
and cell cultures), RWTH = Rheinisch-Westfälische Technische Hochschule Aachen 
 
Cell line description Medium Company/ 
obtained from 
A375 melanoma, 
metastatic 
RPMI + 10 % FCS ATCC 
A375 (wt) 
A375 (F) 
A375 stable 
transfectants 
RPMI + 10 % FCS  
+ 400 µg/ml G418 
Dr. Marcin Kortylewski 
(Kortylewski et al. 1999)  
FM-55M1 melanoma late stage 
(metastatic) 
RPMI + 10 % FCS ESTDAB, Tübingen, Germany 
FM-55P melanoma, early 
stage (primary) 
RPMI + 10 % FCS ESTDAB, Tübingen, Germany 
G361 melanoma RPMI + 10 % FCS RWTH Aachen, Germany 
IGR-37 melanoma, late 
stage 
RPMI + 10 % FCS DSMZ, Braunschweig, Germany 
IGR-39 melanoma, early 
stage 
RPMI + 10 % FCS DSMZ, Braunschweig, Germany 
MelIm 
MelJuso 
melanoma RPMI + 10 % FCS Prof. Bosserhoff, Regensburg, 
Germany 
MeWo melanoma RPMI + 10 % FCS Prof. Schadendorf, Essen, 
Germany 
SK-Mel30 melanoma RPMI + 10 % FCS Prof. Böhm, Münster, Germany 
NHEM-M2 normal human 
epidermal 
melanocytes  
Melanocyte medium M2 PromoCell 
HaCat keratinocytes DMEM + 10 % FCS Prof. Fusenig, Heidelberg, 
Germany 
Hek293T human embr. kidney 
cells 
DMEM + 10 % FCS RWTH Aachen, Germany 
Jurkat Leukemia T cells RPMI + 10 % FCS RWTH Aachen, Germany 
MT4 T cells RPMI + 10 % FCS Dr. Devaux, Luxembourg 
 
FFPE (formalin-fixed paraffin-embedded) patient material 
Skin tissue samples from patients with either benign nevi or melanoma were collected at the 
Dermatology Department of the University Hospital of Freiburg (Germany) under supervision of 
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Prof. Dorothee Nashan and histopathologically examined to confirm clinical diagnoses. Upon 
excision, tissues were fixed in FFPE according to standard dermatohistopathologic techniques. 
In this PhD project, RNAs of 5 healthy skin samples, 4 benign nevi, 12 primary and 14 
metastatic melanoma samples were analyzed by qRT-PCR. 2The primary and metastatic samples 
were collected from different parts of the body from a total number of 5 melanoma patients. 
The study was approved by the ethical review board of EK Freiburg (reference 196/09) as well 
as by Luxembourg’s ethics comission, and written informed consent was obtained from healthy 
controls and live patients. 
Bacteria 
E. coli DH5 α (Invitrogen) were used for cloning experiments and were cultivated in LB medium.  
Vectors 
pmirGLO Dual Luciferase miRNA target expression vector  
(Promega, #E1330) 
pmirGLO was used for cloning of the luciferase constructs. The vector itself is designed for 
quantitative evaluation of microRNA activity and the corresponding mRNA regulation. miRNA 3´-
UTRs containing miRNA target sites or isolated target sites can be inserted 3´of the firefly 
luciferase gene (luc2), which represents the primary reporter gene. Thus, reduced firefly 
luciferase expression indicates the binding of endogenous or introduced miRNAs to the cloned 
miRNA target sequence. Furthermore, the vector contains a second luciferase gene, encoding 
the Renilla luciferase (hRluc-neo), which acts as an internal control reporter and is used for 
normalization purposes. The 3’-UTRs and the single binding sites of potential miR-29 target 
genes were inserted into the multiple cloning site (MCS) by standard cloning procedures as will 
be described below. 
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Fig. 13: pmirGLO vector (Promega) 
3’UTRs of CDK6 and PI3KR1 or isolated miR-29 binding sites were cloned into the multiple cloning site 
(MCS), which is located downstream of the firefly luciferase reporter gene (luc2) and upstream of the 
renilla luciferase gene (hRluc-neo fusion). The vector furthermore contains an ampicillin resistance (Amp) 
for selection of bacteria that contain the plasmid. 
 
Antibodies 
 
Table 4 : Antibodies 
Primary antibodies Dilution species company 
Actin (C4) 1:4000 rabbit Millipore 
CDK6 1:500 mouse Santa Cruz 
FIN13 1:3000 mouse BD 
IRF-1 (C-20) 1:1000 rabbit Santa Cruz 
P (Y701)-STAT1 1:1000 mouse BD 
p85α (PI3K) 1:1000 mouse Upstate 
STAT1 1:1000 mouse Santa Cruz 
Tubulin 1:4000 mouse Santa Cruz 
Secondary antibodies Dilution company 
HRP-labeled  
(for ECL detection) 
1:5000 Cell Signaling Technology 
fluorophor-coupled  
(for quantification in Licor) 
1:10.000 Licor Biosciences 
 
All primary antibodies were diluted in TBS-N + 0.01-0,1 % NaN3. Secondary antibodies for ECL-
detection were diluted in TBS-N and secondary antibodies for quantification in a mixture of Licor 
Blocking Buffer (1/5) and PBS + 0.1 % Triton (4/5). 
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miR-mimics/inhibitors and siRNA 
MiR-29a and miR-29b mimics and inhibitors and their respective negative controls (NC-mimic 
and NC-inhibitor) were obtained from Qiagen, whereas ‘ON-TARGET’ siRNA for CDK6 and the 
corresponding negative control were purchased from Dharmacon. 
Oligonucleotides 
Primers for amplification of mature miRNAs were purchased from Qiagen. All other 
oligonucleotides were self-designed in our laboratory, obtained from Eurogentec and are listed 
in Table 6 and Table 5. 
Software 
For text files and analysis of data Microsoft Office 2010TM was used, for further statistical 
analyses and graphs we used Graph Pad Prism5. MicroRNA target gene prediction was 
performed by in silico analysis of the 3´-UTR of potential miR-29 target genes using a 
combination of the open source databases TargetScan ((Friedman et al. 2009), 
http://www.targetscan.org/), DIANA-microT v3.0 ((Maragkakis et al. 2009), 
http://diana.cslab.ece.ntua.gr/micro-CDS) and microRNA.org ((Betel et al. 2008), 
http://www.microrna.org). Quantification of Western blots was performed with the analysis 
software V3.0 provided by Licor Biosciences whereas ECL-detected Western blot bands were 
detected with the program provided by ChemiStar (Intas) or the ImageLab™ software (Bio-Rad) 
and further processed with Adobe Photoshop CS3. The NCBI homepage 
(http://www.ncbi.nlm.nih.gov/) and Netprimer (http://www.premierbiosoft.com/netprimer/) 
were used for analysis of primer sequences and the Excel applet GeNorm (Vandesompele et al. 
2002) was used for qPCR normalization. The UCSC-tracks which have been used for the in silico 
analysis will be explained below. 
 
Table 5:  Primer sequences I 
Cloning primers and oligonucleotides used for the construction of luciferase constructs. 
 amplicon  sequence amplicon 
size (bp) 
cl
o
n
in
g
 
p
ri
m
e
rs
 f
o
r 
 
lu
ci
fe
ra
se
 
co
n
st
ru
ct
s 
CDK6  
3’UTR 
F 5’-TTTGCTAGCTGTATTAGTGTTTCTGCATTGCC-3’ 1607 
R 5’-TTTCTCGAGTTGGACAGTGATATTTCAACACC-3’ 
PI3KR1  
3’UTR 
F 5’-TTTGCTAGCACGTTCCTAAGCTGGAGTGCTT-3’ 1552 
R 5’-TTTCTCGAGCAGTCCAGAGCAGTGACAGTATGA-3’ 
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29a FC F 5’-TCGACTAACCGATTTCAGATGGTGCTAT-3’  
R 5’-CTAGATAGCACCATCTGAAATCGGTTAG-3’ 
CDK6-BS1 F 5’-TCGACATGGAGAGCACCATGTGGACAAG-3’ 
R 5’-CTAGACTTGTCCACATGGTGCTCTCCATG-3’ 
CDK6-BS2 F 5’-TCGACACTCAAAGCACCAAAACAGAGCATTCTG-3’ 
R 5’-CTAGACAGAATGCTCTGTTTTGGTGCTTTGAGTG-3’ 
CDK6-BS3 F 5’-TCGACTCATTCTAGCACCCAGTAAGACATCCAG-3’ 
R 5’-CTAGACTGGATGTCTTACTGGGTGCTAGAATGAG-3’ 
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Table 6: Primer sequences II 
Primers used for qRT-PCR of primary and precursor miRNAs, reference genes and mRNAs of target 
genes. 
 
amplicon 
 
sequence 
amplicon 
size 
(bp) 
primary 
miRNAs 
pri-29a~b-1 F 5’-GGGCTTTCTGGAACCAATCC-3’ 68 
R 5’-ACAATGCGATATCCTGTACAATTACAT-3’ 
pri-29b-2~c F 5’-AAGAGCAAAATACACTCTTGAGTT-3’ 63 
R 5’-AACCCCCTTCTCTACTGTCAC-3’ 
precursor 
miRNAs 
pre-29a F 5’-ATGACTGATTTCTTTTGGTGTTCA-3’ 64 
R 5’-ATAACCGATTTCAGATGGTGCTA-3’ 
pre-29b-1 F 5’-CTTCAGGAAGCTGGTTTCATAT-3’ 64 
R 5’-TGATTTCAAATGGTGCTAGACA-3’ 
pre-29b-2 F 5’-CTGGTTTCACATGGTGGCTTA-3’ 62 
R 5’-CACTGATTTCAAATGGTGCTAGATA-3’ 
pre-29c F 5’-GGCTGACCGATTTCTCCTGG-3’ 76 
R 5’-TCCCCCTACATCATAACCGATTT-3’ 
reference 
genes 
HPRT1 F 5’-TGGACAGGACTGAACGTCTT-3’ 77 
R 5’-GAGCACACAGAGGGCTACAA-3’ 
β-Actin F 5’-TGACCCAGATCATGTTTGAGA-3’ 108 
R 5’-AGTCCATCACGATGCCAGT-3’ 
CycloA F 5’-CAGACAAGGTCCCAAAGACA-3’ 139 
R 5’-CCATTATGGCGTGTGAAGTC-3’ 
TBP F 5’-ACCCAGCAGCATCACTGTT-3’ 127 
R 5’-CGCTGGAACTCGTCTCACTA-3’ 
Potential  
miR-29 
target 
genes 
DNMT3A F 5’-TATTGATGAGCGCACAAGAGAGC-3’ 111 
R 5’-GGGTGTTCCAGGGTAACATTGAG-3’ 
DNMT3B F 5’-GGCAAGTTCTCCGAGGTCTCTG-3’ 113 
R 5’-TGGTACATGGCTTTTCGATAGGA-3’ 
Bcl-2 F 5’-TGTGGAGAGCGTCAACCG-3’ 113 
R 5’-CCCAGCCTCCGTTATCCT-3’ 
PTEN F 5’-TAAGGACCAGAGACAAAAAGG-3’ 143 
R 5’-CATTGGAATAGTTTCAAACATCA-3’ 
Akt3 F 5’-AAAGGGAAGAATGGACAGAA-3’ 143 
R 5’-TATGATGGGTTGTAGAGGCA-3’ 
cdc42 F 5’-CGTGACCTGAAGGCTGTCAA-3’ 129 
R 5’-ACACACCTGCGGCTCTTCTT-3’ 
Mcl-1 F 5’-AGTATCACAGACGTTCTCGTAAGG-3’ 106 
R 5’-GCCACCTTCTAGGTCCTCTACA-3’ 
Dicer1 F 5’-GAAAATATCAGGTTGAACTGCTTG-3’ 116 
R 5’-GATAGGACAGCTCTTTAGTGAGTAGTAC-3’ 
CDK6 F 5’-CCAGCAGCGGACAAATAA-3’ 92 
R 5’-CCACAGCGTGACGACCA-3’ 
PI3KR1 F 5’-ATACCCGCACATCCCAGG-3’ 118 
R 5’-TGTATTCTTTGCTGTACCGCTC-3’ 
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4 Methods 
4.1 Cell culture 
All cells were grown in a humidified atmosphere with 5 % CO2 in T75 CELLSTAR
TM cell culture 
flasks in a Hera cell 100 incubator in 15 ml of the respective medium. All cell lines were 
routinely tested to be mycoplasma-negative by PCR, taken in to culture (from frozen aliquots) 
the week before the experiment and split after reaching 70-90 % confluence. Splitting was 
performed by detaching the cells with 200 mg/l Trypsin/EDTA (Versene) and subsequent 
division in new culture flasks with fresh medium. For storing, the content of a 10 cm-cell culture 
dish was pelleted for 5 min at 1400 rpm (Eppendorf centrifuge 5702); the pellet was dissolved 
in the respective medium containing 10 % DMSO. Cells were stored in CRYO.S™-tubes at -
80 °C for short term storage and in liquid nitrogen for longtime storage. Before seeding, cells 
were quantified with a Bürker cell counting chamber. 
4.2 Stimulations with cytokines 
Cytokine stimulation: time-course experiments 
For stimulation of melanoma cell lines and HEK 293T cells, 105 cells per well were seeded in 6-
well-plates in at least triplicates for each treatment. For Jurkat and MT4 T-cells, 105 cells per 
well were seeded in 12-well plates. Cells were either left untreated or stimulated with a final 
concentration of 50 ng/ml human IFN-γ, IFN-α, IFN-β or IL-27 for different periods of time and 
harvested all together at the end of the experiment, as indicated in Fig. 14. 
 
 
Fig. 14: Experimental setup of cytokine stimulation time-course experiments 
Cells were seeded at day 1 of the experiment and the stimulations at the different time points were 
performed as indicated above. For subsequent Western Blot analysis or RNA-extraction, cells were all 
harvested together at the end of the experiment. 
seeding
stimulations
collection
time
3h8h
day 1
72h 48h 24h
day 2 day 3 day 4
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Pre-treatment with Janus kinase inhibitor I (JII) 
Experiments with Jak-inhibitor 1 included a pre-treatment step with 5 µM of the inhibitor, which 
was added one hour before commencing cytokine stimulation. For all experiments, cells were 
collected all together at the end of the time course for further experimental analyses. 
Concentrations and length of treatment with inhibitor had previously been optimised in our 
laboratory (Kreis et al. 2007; Reinsbach et al. 2012). 
4.3 RNA extraction 
Isolation of total RNA from cell lines 
For all experiments except cloning of the 3’-UTRs and microarray analyses, total RNA of cell 
lines was extracted using TRIsure (Guanidium thiocyanate-phenol-chloroform extraction). 
Briefly, for adherent cells, the medium was aspirated and cells were washed once at RT with 1 x 
PBS. Cells were lysed directly in the culture dish by addition of 1 ml TRIsure per well. 
Suspension cells were washed with PBS, trypsinized and pelleted. The pellet was dissolved in 
1 ml of TRIsure. For both, the lysates were transferred to 1.5 ml Safe-Lock Eppendorf 
microcentrifuge tubes. Phase separation was carried out by adding 200 µl chloroform to each 
sample followed by a centrifugation step for 15 min at 4 °C at 13,200 rpm (Eppendorf 
centrifuge 5415D). The RNA accumulates in the (upper) aqueous phase, while DNA and 
proteins are discarded with the interphase and the (lower) organic phase. The upper aqueous 
phase was carefully collected and the RNA was precipitated after addition of 500 µl isopropanol 
and centrifugation for 10 min at 4 °C at 13,200 rpm (Eppendorf centrifuge 5415D).  Afterwards, 
the RNA pellets were washed three times with 1 ml EtOH (75 %), dissolved in DEPC-H2O and 
stored at -20°C until further use or at -80 °C for long-term storage. Quantity and purity of RNA 
samples were assessed by determining the ratios of absorbance at 260 nm/280 nm and 260 
nm/230 nm using a NanoDrop ND-2000c spectrophotometer.  
Isolation of total RNA from cell lines for subsequent microarray analyses 
For LC Sciences and Affymetrix miRNA microarrays, RNA was extracted with the miRNeasy kit 
according to the manufacturer’s protocol with an additional on-column DNase I digestion. 
DNase I treatment 
To degrade any DNA contamination in total RNA samples, DNAse I treatment was performed 
before the reverse transcription. Briefly, 2 µg of RNA were mixed with 2 µl of 10 x DNase I-
buffer, 0.5 µl DNase I (2 U/µl) and the respective amount of DEPC-H2O (up to a total volume of 
20 µl) on ice. The mixture was incubated at 37 oC for 10 min and then placed on ice. 0.5 µl of 
0.02 M EDTA was added to each sample (final concentration of 0.5 mM) to protect the RNA 
during the following heat-inactivating step. After vortexing, the DNase was heat-inactivated at 
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75 oC for 10 min. The DNase-treated RNA was re-quantified in Nanodrop to ensure RNA 
amounts between 50-90 ng/µl.  
Extraction of total RNA from FFPE patient material 
For FFPE-samples, five scalpel-scraped slices of FFPE tissue were pooled and RNA was extracted 
using the RT2-FFPE extraction kit. Quantity and purity of RNA samples were assessed using a 
NanoDrop ND-2000c spectrophotometer. 
4.4 Reverse transcription, quantitative Realtime PCR and Analysis 
Reverse Transcription to obtain cDNA for subsequent cloning 
Total RNA from A375 cells was extracted with the Nucleospin RNA extraction kit according to 
the manufacturer´s instructions. cDNA synthesis was performed with the Thermoscript RT-PCR 
system. Briefly, 500 ng RNA was incubated with 1 µl dNTPs (10 mM), 0.5 µl oligo dT (50 µM) 
and H20 (up to 10 µl) for 5 min at 65 °C and then placed on ice. After addition of 2 µl 5x cDNA 
buffer, 0.5 µl 0.1 M DTT, 0.5 µl RNaseOut, 1 µl of H20 and 0.5 µl of thermoscript polymerase 
the mixture was incubated for 1h at 50 °C and for 5 min at 85 °C. The resulting cDNA served as 
input for PCR amplifications as described below. 
Reverse Transcription for subsequent miRNA and mRNA expression analysis 
For FFPE samples and cell lines, 250 ng of total RNA was reversely transcribed using the 
miScript System according to the manufacturer’s instructions and as depicted schematically in 
Fig. 15. The system allows for simultaneous reverse transcription of mRNA and miRNAs. The 
reverse transcription mix includes a poly(A) polymerase to allow the addition of Poly(A) tails to 
miRNAs, which are not polyadenylated in nature. In the first step of the reaction, miRNAs get 
polyadenylated whereas the reverse transcription is performed in the second step. Additionally, 
a universal tag is added to the 3’-end of miRNAs and mRNAs, which is needed for later 
amplification during the real-time PCR. For reverse transcription, briefly, 250 ng of total RNA 
were diluted in DEPC-H2O to a total volume of 7.5 µl and mixed with 2 µl miScript RT Buffer and 
0.5 µl reverse transcriptase mix. Incubation times were 37 °C for 60 min followed by 95 °C for 5 
min. 
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Fig. 15: miScript system – schematic overview 
(from miScript handbook, Qiagen) Polyadenylation, reverse transcription and real-time amplification of 
miRNAs as described in the text. 
 
Realtime-qPCR 
Realtime polymerase chain reaction or quantitative real time polymerase chain reaction (qPCR) 
allows for amplification and simultaneous quantification of specific DNA fragments. Apart from 
Northern Blotting, microarray analysis or sequencing, it provides a standard method for 
detection and quantification of miRNAs and mRNAs (VanGuilder et al. 2008). It offers the 
opportunity to calculate absolute miRNA amounts, when standard concentrations are used in 
the same assay. However, mostly relative miRNA or mRNA expression levels are assessed and 
are determined with respect to a panel of so-called ‘house-keeping’ or reference genes, which 
show stable expression levels even after treatment (Bustin et al. 2009).  
For the quantification of mature miRNAs, real-time PCR was carried out on a CFX96 or CFX384 
detection system using 5 ng RNA input, 2 x iQ SYBR Green Supermix and 10 x miRNA-specific 
primer assay (Qiagen). To detect mRNAs and primary/precursor miRNAs, 25 ng or 125 ng RNA 
input, 2 x iQ SYBR Supermix and 5 pmol gene-specific primer pairs (Table 6) were used. 
Thermal cycling conditions for all reactions were 95 °C for 3 min, 39 x (95 °C for 15 s, 60 °C for 
30 s), 95 °C for 1 min, 60 °C for 1 min, followed by a melting-curve analysis: 60 °C to 95 °C, 
increment 0.5 °C for 20 s. 
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Analysis of realtime-qPCR results 
If not stated otherwise, expression analysis was performed using the GeNorm VBA applet for 
Microsoft Excel, version 3.5 (Vandesompele et al. 2002; Mestdagh et al. 2009). The add-in 
calculates a normalization factor (NF) which is based on the raw quantity of the house keeping 
genes (HKG), calculated from their respective cycle thresholds (Ct ‘s) with  
 
raw	HKG	quantity  	2		 
 
and     
	
NF  geometric	mean	of	raw	HKG	quantity 
 
wherein Ct min = minimum Ct of the respective house keeping gene for all samples. The 
housekeeping genes TBP (TATA-binding protein), HPRT (Hypoxanthine 
phosphoribosyltransferase 1), CycloA (Peptidylpropyl isomerase A) and β-Actin (see Table 6 for 
sequences) were used for normalization of mRNA amplification and primary / precursor miRNAs 
and RNU1A, RNU5A (RNA, U1A/5A, small nuclear) and SCARNA17 (small Cajal body-specific 
RNA 17) (all from Qiagen) for mature miRNAs. After determination of the NF, the gene of 
interest (GOI) is normalized by dividing the raw gene of interest quantity by the normalization 
factor: 
	
raw	GOI	quantity  	2		 
     
      and 
 
normalized	GOI  	
raw	GOI	quantity
NF
 
 
For stimulation experiments, the normalized GOIs were then divided by the mean of the 
untreated control and the values of the single time points were subsequently averaged to obtain 
the relative expression (REL). Apart from normalization, the Genorm applet calculates a gene 
expression stability measure M for the reference genes, allowing for further quality control of 
the experiment and for elimination of genes with the most unstable expression. For our studies, 
analysis was performed based on the Genorm-calculated normalization factor of three reference 
genes with an M-value below 1.5 (in most cases < 0.5). 
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4.5 miRNA microarrays 
LC Sciences 
Total RNA from the NHEM, IGR39 and IGR37 lines was subjected to genome-wide microRNA 
expression profiling (miRBase, version 11.0) using the µParaflo® microarray technology as 
described on the web site of LC Sciences (Houston, TX, USA) and by us (Philippidou et al. 
2010). Briefly, total RNA (2-5 µg) was size-fractionated with a YM-100 Microcon filter (Millipore) 
to isolate small RNAs (<300 nt). These were subsequently 3’-poly(A) tailed and fused to 
nucleotide tags for later Cy3 and Cy5 dye labeling. Hybridisation of RNAs with the probes (which 
are complementary to target miRNAs (miRBase)) was carried out overnight on a µParaflo 
microfluidic chip. The respective hybridization images were collected by a laser scanner 
(GenePix 4000B, Molecular Device) and subsequently processed with the Array-Pro image 
analysis software (Media Cybernetics). Data analysis was performed by LC Sciences.  
Affymetrix 
Duplicate total RNA samples from A375 melanoma cells (stimulated for different periods of time 
with IFN-γ or including the pre-treatment with JII at the 72 h time point) were analyzed as 
published previously by members of our group (Reinsbach et al. 2012). Affymetrix GeneChip 
miRNA 2.0 Arrays (based on miRBase version 15, Affymetrix Datasheet P/N EXP00180) were 
performed at the microarray facility of the CRP Santé (Luxembourg), which included use of the 
FlashTag Biotin HSR RNA labelling kit (Genisphere, USA) according to the manufacturer’s 
instructions.  
4.6 Transfection of cells 
Mimic/inhibitor experiments 
105 cells/well were seeded in 6-well plates in antibiotic-free medium and transfected after 24 h 
with 50 nM of each miR-29a and miR-29b mimics, with 150 nM miR-29a inhibitor or with 
corresponding amounts of negative controls (NC-mimic or NC-inhibitor) using the 
DharmafectDuo transfection reagent according to the supplied protocol; 1 ml of medium was 
added 24 h after transfection. Efficient transfection was confirmed by qRT-PCR (Fig. 29). For 
miR-29 target gene expression, RNA and protein lysates were collected 24 h, 48 h and 72 h 
after transfection and subsequently analyzed by RT-qPCR and Western blot. 
Combination experiment with miR-29 inhibitor and IFN-γ 
2 x 103 cells/well were seeded in 96-well plates in antibiotic-free medium and transfected 24 h 
with 150 nM of miR-29a inhibitor or the same amount of negative control (NC-inhibitor) or were 
left untreated. For the combination experiment and for the samples with IFN-γ treatment only, 
stimulation (50 ng/ml IFN-γ) was performed 8h after transfection. 
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CDK6 siRNA transfection 
5 x 104 cells were transfected with 75 nM ON-TARGET siRNA or siRNA negative control (si-NC) 
24 h after seeding in 6-well plates using the HiPerfect transfection reagent according to the 
manufacturer’s instructions in a total volume of 1 ml antibiotic-free medium and 1 ml medium 
was added 24 h after transfection. CDK6 mRNA and protein levels were assessed after 24 h, 
48 h and 72 h to confirm efficient down-regulation (Fig. 38). 
4.7 Reporter gene assays 
Cloning of 3’-UTRs and single miR-29a binding sites  
For PCR amplification of 3’-UTRs, a ~1600 bp part of the 3’-UTR of two predicted miR-29 
target genes was amplified from A375 cDNA using primer pairs (Table 5) with incorporated XhoI 
(forward) or NheI (reverse) restriction sites. The CDK6 construct (1600 bp) contained three 
putative miR-29 binding sites, whereas the PI3KR1 construct (1567 bp) contained one binding 
site (Fig. 37). Briefly, 2 µl of cDNA were subjected to PCR using the Phusion DNA polymerase in 
a total reaction volume of 50 µl with 10 µl buffer, 1 µl dNTPs, 1 µl of each primer 
(forward/reverse, 100 µM), 0.2 µl polymerase, 2.5 µl DMSO and 32.3 µl H20. Cycling conditions 
(for 35 cycles) were 98 °C for 30 s (initial denaturation), 98 °C for 10 s (denaturation), 65°C for 
20 s (annealing), 72 °C for 15 s (extension) and 72 °C for 10 min (final extension). Purification 
of PCR products and all following purifications of plasmid DNA as well as separation of DNA 
after restriction digests were performed by cutting bands of appropriate size from a 1 % 
agarose gel under UV-light. Subsequent purification of the DNA from agarose gels was 
performed with the innuPREP DOUBLE pure kit according to the manufacturer’s instructions. 
For vector preparation for subsequent cloning, 2 µg of pmirGLO DNA were digested in a total 
volume of 30 µl with 3 µl NEB2 buffer, 3 µl BSA, 0.3 µl XhoI, 0.3 µl NheI and H20 (up to 30 µl). 
30 µl of purified PCR products (amplified 3´-UTRs) were digested with 5 µl NEB2 buffer, 5 µl 
BSA, 0.3 µl XhoI, 0.3 µl NheI and 9.4 µl H20. Both digestions were performed for 1.5 h at 37 °C, 
followed by a heat-inactivating step at 65 °C for 20 min. For subsequent cloning, linearized 
vector DNA was dephosphorylated to avoid re-ligation of the vector: after digestion, plasmid 
DNA was incubated for 1 h at 37 °C with 0.4 µl CIP upon addition of 2 µl NEB2 buffer and 18 µl 
H20 in a total volume of 50 µl. Linearized plasmid DNA and inserts were purified on a 1 % 
agarose gel.  
For ligation, 100 ng of digested vector DNA was incubated with inserts in two different molar 
ratios (vector to insert - 1:3 or 1:7) along with 2 µl of 10x ligase buffer, 0.5 µl T4 DNA ligase 
and H20 ad 20 µl overnight at 16 °C. Bacteria were transformed with ligated plasmids (as will be 
described below). 
For cloning of single miR-29 binding sites (CDK6, BS 1-3 and 29a full complementary site, 
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FC), oligo annealing was performed. Oligonucleotides (obtained from Eurogentec, Table 5) were 
diluted to a concentration of 10 µM. 2 µl of each forward/reverse oligo were incubated with 46 
µl of oligo annealing buffer for 2 min at 100 °C and then left on the heatblock to cool down to 
room temperature. For ligation, oligos were diluted 1:10 to obtain a concentration of 4 ng/ µl 
per oligo. 4 ng of oligo and 50 ng of linearized vector were ligated with 2 µl buffer and 0.5 µl of 
T4 DNA ligase at 16 °C overnight. 2 µg of pmirGLO plasmid were digested in a total volume of 
30 µl with 3 µl NEB2 buffer, 3 µl BSA, 0.3 µl XhoI, 0.3 µl XbaI and 21 µl of H2O for 1.5 h at 
37 °C and oligos were ligated into open vectors as described above. Purification was performed 
on a 1 % agarose gel as described before.  
Chemically competent E. coli cells were prepared for subsequent transformation of 
plasmids. For the starter culture, 2 ml LB medium was inoculated with a single colony of E. coli 
DH5 α and incubated overnight at 37 °C with 250 rpm (Certomat MOII, Sartorius). 20 ml of pre-
warmed LB were inoculated with the starter culture at 37 °C, 250 rpm (Certomat MOII, 
Sartorius) until the OD600 reached approximately 0.4. The culture was centrifuged at 4300 rpm 
(Heraeus Megafuge 1.0R) for 15 min at 4 °C and the pellet was then resuspended in 2 ml ice-
cold TSS buffer. 20 % glycerol was added and the cell suspension was dispensed in 300 µl 
aliquots to be stored at -20 °C until further use. 
For transformation of competent cells, an aliquot of competent bacteria was thawed on ice. 
150 µl of competent DH5 α bacteria were incubated with 100 ng of the ligated plasmid DNA for 
30 min on ice. The cells were subjected to heat shock at 42 °C for 90 s and placed on ice for 2 
min. 1 ml of LB-medium was added to the mixture, followed by pre-culturing at 37 °C with 
shaking at 250 rpm for 1 h. The cells were then centrifuged at 10.000 rpm for 1 min and plated 
on LB agar supplemented with ampicillin to a final concentration of 50 µg/ml. The plate was 
incubated overnight at 37°C. 
To verify correct insertion of the constructs (mini preparation), 2 ml LB medium 
supplemented with ampicillin (final concentration of 50 µg/ml) was inoculated with a single 
bacterial colony and incubated overnight at 37 °C with shaking (250 rpm). The cells were 
harvested by centrifugation at 13.000 rpm. For the following steps, plasmid DNA was purified 
using the 5prime Miniprep kit according to the instruction manual provided. Instead of the 
supplied elution buffer, 10 mM Tris (pH 8) was used.  
For analytical restriction digest after small scale plasmid isolation, plasmid DNA was 
incubated with the restriction enzymes XhoI and NheI for 1.5 h at 37 °C to confirm the 
presence of the correct ligation of 3’-UTR inserts in the pmirGLO vector. For oligo cloning, 
control digest was performed with XhoI and HindIII. For both, correct sizes were monitored on 
1 % agarose gels. DNA sequencing was performed to verify correct ligation of fragments into 
the pmirGLO vector, constructs were sequenced by GATC (Konstanz, Germany) and DNA 
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sequences were verified using the GATC viewer, which is provided on the GATC homepage 
(http://www.gatc-biotech.com/en/index.html). 
For subsequent preparative isolation of plasmid DNA (midi preparation), 100 ml LB 
medium supplemented with ampicillin (final concentration of 50 µg/ml) were inoculated with a 
single bacterial colony and incubated overnight at 37 °C with shaking (250 rpm, Certomat MOII, 
Sartorius). The cells were harvested by centrifugation at 4300 rpm (Heraeus Megafuge 1.0R). 
Plasmid DNA was purified using the Xtra Midi Plus kit according to the instruction manual 
provided.  
Luciferase reporter gene assays 
For luciferase assay, the dual luciferase reporter assay system was used according to the 
manufacturer´s instructions. The sequence parts of CDK6 and PI3KR1- 3’UTRs containing miR-
29 binding sites, CDK6 miR-29a single binding sites and the miR-29a full complementary 
sequence were cloned into the pmirGLO Dual Luciferase miRNA target expression vector 
downstream of the luciferase gene (see Table 5 for primer sequences and oligonucleotides). 
A375 cells were seeded at a density of 5 x 104 cells/well in 24-well plates 24 h prior to 
transfection. Cells were transiently co-transfected with 500 ng plasmid and 50 nM miR-29a 
mimic or negative control (NC-mimic) for 48 h and 72 h. Samples were lysed with 1x Passive 
Lysis Buffer for 15 min at room temperature. Lysates were transferred in 96-well plates and 
frozen at -20°C until the measurement for both time points was performed together.  
For measurement, 10 µl of lysate were transferred into a LIA luminescence 96-well plate. 
Measurement of firefly activity was performed after addition of 50 µl of LARII (luciferase assay 
reagent II) reagent per well and measurement of renilla activity was monitored after 
subsequent addition of 50 µl of Stop & Glo reagent per well. The firefly/renilla activity ratios of 
mimic-transfected samples were calculated and normalized to the respective ratios of the 
negative control-transfected samples for each construct and each time point. 2Significance was 
assessed by one-way ANOVA followed by a Bonferroni Post-Hoc test. 
4.8 Western blots and Licor quantification of protein levels 
Preparation of protein extracts from cell lines 
Adherent cells were washed 1x with PBS, followed by direct lysis on ice with Laemmli buffer. 
Generally 500 µl were used for 1 well from a 6-well plate, if confluent. Alternatively, suspension 
cells were pelleted in Eppendorf reaction tubes, the pellet was lysed in Triton lysis buffer for 10 
min on ice and Laemmli buffer was added to the solution. 
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SDS page and Western blotting 
Extracts containing equal amounts of protein were boiled for 5 min at 95 °C and 10-20 µl of 
each sample per lane were separated by 8-12 % SDS-PAGEs at 20-30 mA/gel. A protein 
standard ladder (Precision Plus ProteinTM Standard) was loaded to confirm the sizes of proteins 
investigated. The proteins were then transferred to a nitrocellulose membrane (for Licor 
quantification, see below) or PVDF membrane (the latter had been activated in methanol for 1 
minute before blotting, for ECL (enhanced chemoluminescence)-detection) in a semi-dry 
Western blotting chamber for 1 h at 48 V per blot. The membrane was blocked for 30 min at 
room temperature with blocking buffer. After three washes (5 min each) in TBS-N buffer, the 
membrane was probed with 10 ml of the respective first antibodies (Table 4) overnight at 4 °C 
with gently shaking. After three more TBS-N washing steps, it was subsequently incubated with 
the HRP (horseradish peroxidase)-labeled (for ECL detection) or fluorophor-coupled (for Licor 
quantification) secondary antibody of the respective species (Table 4) for 1h at RT with shaking. 
For ECL-detection, membranes were washed three times for 5 min in TBS-N and placed in ECL 
substrate reagent supplemented with H2O2 for 1 min. Membranes were exposed in the 
Molecular Imager ChemiDocTM XRS+ system or the ChemiStar system for various times and 
chemiluminescent signals were detected. Before re-probing, PVDF membranes were stripped for 
30 min at 70 oC in stripping buffer, washed in H2O, blocked for 30 min and incubated with the 
next antibody. Equal loading was confirmed by actin, tubulin or FIN13 loading controls for PVDF 
membranes.  
Licor quantification (Li-cor Biosciences) 
The Li-cor Odyssey Infrared Imaging System (Li-cor Biosciences) enables infrared fluorescence 
detection of protein signals by two independent infrared channels (700 nm and 800 nm). This 
technology allows for a wide dynamic range and thus accurate quantification of protein bands 
from membranes (www.licor.com). This is achieved by using fluorophor-coupled secondary 
antibodies instead of peroxidase-coupled ones as routinely used for ECL detection. For 
quantification of CDK6 and p85α protein levels, signal intensities of the different fluorophor 
channels 700 nm and 800 nm were assessed with the Odyssey imaging system at a resolution 
of 84 µm and analyzed with the provided software. CDK6 and p85α signals were normalized to 
the respective tubulin loading controls. 
4.9: Functional assays: Incucyte experiments 
The Incucyte machine is an automated live-cell imaging system which allows label-free and 
kinetic analysis of cell growth rates and morphology. It is positioned inside a standard cell 
culture incubator and equipped with a camera, which can e.g. photograph cells in phase-
contrast or detect fluorescence signals to provide raw data for subsequent quantification of 
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cellular growth rates or other analyses. After seeding or treatment of the cells, imaging can take 
place inside the machine under normal cell-culture conditions without removing the cells to RT 
in between (www.essenbioscience.com). 
Apoptosis assay 
2 x 103 cells/well were seeded in 96-well plates and transfected 24 h after seeding with the 
respective amounts of mimic, inhibitor or negative controls as described above (5.6). After 
transfection, cells were additionally incubated with 5 µM of NucView 488 Caspase detection 
reagent. The NucView reagent combines a caspase-3 substrate and a non-functional dye, which 
becomes functional and emits fluorescence upon enzymatic cleavage of the substrate. Thus, 
caspase activity in living cells can be followed up in real-time. 50 µM Etoposide was used as 
positive control for apoptosis and fluorescence was monitored by Incucyte over 72 h. For 
subsequent analysis, object counting thresholds were set to recognize fluorescent cells over 
background fluorescence of the medium and the number of fluorescent cells per well was 
calculated by the Incucyte software. 
Real-time proliferation assays  
All proliferation assays were performed by real-time monitoring in the Incucyte live-cell imaging 
system, which photographed cells in phase contrast every 3 h, taking 9 (for 96-well plate) to 25 
(for 6-well plate) pictures per well. For monitoring the growth of untreated melanoma cell lines, 
25 x 103 cells/well of eight untreated melanoma cell lines were seeded in 12-well plates and 
harvested after 96 h. To monitor basal miRNA levels in these cell lines, RNA was extracted and 
miR-29 species were amplified by qRT-PCR as described below. 
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4.10 In silico analysis of the miR-29 promoter region 
For the TSS (transcription start site) overview, all published TSSs on both miR-29 clusters, 
which were available before May 2012 were collected and converted to genome version 19 
(hg19) with the UCSC (University of California Santa Cruz) Liftover utility for coordinate 
conversion (http://genome.ucsc.edu/cgi-bin/hgLiftOver). The subsequent in silico analysis on 
the promoter region was performed based on the UCSC  Genome Browser (Kent et al. 2002) 
using the UCSC tracks described below, which are described in more detail on the UCSC 
homepage (http://genome.ucsc.edu/). The analysis included several characteristic features of 
promoter regions, which are explained below. The aim of this analysis was to overlay these 
characteristic features (conservation score, histone mark) with predicted and experimentally 
verified STAT1 binding sites in order to identify candidate STAT1 transcription factor binding 
sites which could be responsible for miR-29 regulation. 
Vertebrate Basewise Conservation by PhyloP  
(Siepel et al. 2005; Pollard et al. 2009) (found under ‘comparative genomics’) 
Evolutionary conservation of promoter regions, especially transcription factor binding sites is 
correlated with a higher possibility of actual usage of the site for transcription factor binding. 
The UCSC track shows a multiple alignment of the genomes of 46 vertebrate species and the 
corresponding evolutionary conservation. In the plots, conserved sites are represented in blue, 
with positive scores; sites shown in red and assigned to negative scores are considered to be 
fast-evolving. 
H3K4Me3 Mark  
(trimethylation of histone H3 lysine 4) (Ram et al. 2011)  
(found under ‘regulation’  ‘integrated regulation’ from ENCODE tracks) 
The H3K4Me3 signature is often found near active promoters because it changes the chromatin 
to a more open conformation, thus making it more accessible for transcription, as explained in 
the introduction (Fig. 7). The track shows the levels of enrichment of H3K4Me3 as investigated 
by ChIP-seq in K562 cells.  
Transcription Factor Binding Sites determined by ChIP-seq 
from ENCODE/Stanford/Yale/USC/Harvard (track ‘ENCODE transcription factor binding’  SYDH 
found under ‘regulation’) 
The track shows predicted transcription factor binding sites as determined by ChIP-seq 
experiments which were performed in IFN-γ-treated K562 leukemia cells and in HeLaS3 cells 
(for HeLaS3 data: (Robertson et al. 2007)(both experiments: Snyder laboratory, Stanford; IFN-γ 
treatment for 30 min). Both ChIP experiments were carried out with an STAT1 antibody (sc-
345). The bar (Fig. 26) represents the enrichment for binding of the transcription factor 
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together with the site having the greatest evidence of transcription factor binding (peak, here 
represented by a red line). According to UCSC, both measures are based on processed data 
(normalized data from pooled replicates). 
Predicted transcription factor binding sites based on ChIP-seq data 
Transcription factor ChIP-seq from ENCODE (found under ‘regulation’  integrated regulation 
from ENCODE tracks): This track also shows predicted transcription factor binding sites, in 
which the peaks from the ChIP-seq data were analyzed by a pipeline developed from Anshul 
Kundaje (for further details see UCSC (http://genome.ucsc.edu/)), which combined data from a 
panel of different cell lines. 
Putative pri-29a~b-1 transcription start sites 
Putative transcription start sites of the pri-29a~b-1 cluster were collected from literature 
(derived from in vitro experiments as well as computational predictions), converted to the 
human genome version hg19 and allocated to the pri-29a~b-1 promoter as shown in (Schmitt 
et al. 2012a) and references therein.  
Potential STAT1 binding sites  
(predicted by Jaspar and Transfac) 
For own investigation of the pri-29a~b-1 promoter sequence for potential STAT1 binding sites, 
we used the open-source website ‘Jaspar‘ (Vlieghe et al. 2006) as well as the commercial 
program ‘Transfac‘ (Matys et al. 2003) which both predict transcription factor binding sites in a 
given DNA sequence. 
GAS elements 
The sequence search for GAS elements in the promoter region was performed for the 
consensus sequences TT(C/A)CNNNAA(A/G) (Pagliaccetti et al. 2008) and TT(C/A)NNN(G/T)AA 
(Smith et al. 2012). 
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5 Results 
5.1  IFN-γ-induced miRNAs 
Identification of differentially regulated miRNAs in melanoma cell lines following 
cytokine treatment 
The main focus of this thesis was the identification and characterization of IFN-γ-induced 
miRNAs. To this end, there was a previous report showing that IL-6 induced STAT3-dependent 
up-regulation of miR-21 in multiple myeloma cells (Löffler et al. 2007). Here we turned our 
interest to IFN-γ, which is known to play pivotal roles in immune regulation (Schroder et al. 
2004; Borden et al. 2007) and regulation of growth behavior as was previously demonstrated 
for melanoma cells (Kortylewski et al. 2004). However, no STAT1-dependent miRNAs had been 
reported yet, and thus all 837 human miRNAs listed in the former miRBase version 11.0 were 
potential candidates. To investigate basal expression levels of miRNAs and their possible 
transcriptional regulations by STAT1 factors, IGR39 (representing early stage, primary 
melanoma) and IGR37 (late stage, metastatic melanoma from the same patient as IGR39) 
melanoma cell lines as well as NHEM (normal human epidermal melanocytes) were treated with 
50 ng/ml IFN-γ for different periods of time (3 h and 72 h) and total RNA of the cells was 
subsequently analyzed by miRNA microarray (LC Sciences, miRBase version 11.0). This initial 
miRNA microarray experiment served as a starting point for this PhD project to provide 
important information to the following questions: Firstly, it offered an overview on basal miRNA 
expression levels of the three (untreated) cell lines as well as on differentially expressed miRNAs 
within the untreated cell lines, which represented different melanoma stages (Fig. 16). The 
latter could be subsequently classified in up- or down-regulated miRNAs according to melanoma 
progression stages (NHEM  IGR39  IGR37) (Philippidou et al. 2010). In this study, we 
compared these array results on untreated melanoma cell lines with miRNA expression profiles 
of 88 cancer-related miRNAs by PCR-array which was performed on melanoma patient samples. 
Interestinlgy, miR-200c was consistently down-regulated with tumour progression in all samples 
(melanoma cell lines and patient samples). miR-146a and miR-155 levels were increased in 
patient samples, but decreased in cell lines with melanoma progression whereas miR-205 and 
miR-23b exhibited reduced expression levels in patient samples. Subsequent Ingenuity pathway 
analysis determined a de-regulated gene network around MITF, the key transcription factor in 
melanoma development (Philippidou et al. 2010; Schmitz Ulf et al. 2013).  
Secondly and of special importance for this PhD project, the microarray provided the 
fundamental information necessary for consecutive selection of potential STAT1-regulated 
miRNAs. All three cell lines exhibit a clearly distinct miRNA expression pattern after IFN-γ-
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stimulation, with IGR39 showing the highest number of regulations (Fig. 16). Furthermore, 
miRNAs which showed differential regulation between the three treatments (untreated, 3 h and 
72 h IFN-γ) could be allocated into several groups according to their distinct differential 
expression pattern (Fig. 16). The expression level of several miRNAs was already altered after a 
short time interval (3 h) and remained in this state even after 72 h (D1, U1, Fig. 16). Most 
miRNAs were either up-regulated or down-regulated over time with most regulations occurring 
solely at the late time point (72 h, D2 and U2, Fig. 16). Interestingly, especially in NHEM cells, 
differential expression levels over time partly exhibited ‘curve’-like shapes, f.e. a clear up- or 
down-regulation at the early time point (3 h) and returning to basal levels after 72 h of IFN-γ 
stimulation (C1, C2, Fig. 16). In addition to this clustering analysis, array results were analyzed 
for differential miRNA expression levels after IFN-γ-stimulation in comparison to the respective 
untreated control at both time points to identify a ‘working list’ of potentially STAT1-regulated 
miRNAs. This analysis led to further selection of a panel of seven microRNAs, which were 
differentially regulated in the cell lines analyzed and which were of interest for other biological 
reasons. Those included miR-21, miR-23a, miR-29a, miR-146a, miR-211, miR-1246 and miR-
1826 (Fig. 16). miR-211 was excluded from further experiments because it was found to be 
undetectable in most melanomas (data not shown) and as it was the focus of another study 
from our group where the functional role of this miRNA in melanoma was investigated (Margue 
et al. submitted). Interestingly, miR-1246 showed the strongest up-regulation after IFN-γ-
stimulation on the microarrays and has been reported to exhibit a high basal expression level on 
different array platforms (Zhang et al. 2011a; Piepoli et al. 2012), however, these findings could 
not be confirmed by qRT-PCR. This could be due to unspecific hybridization to the miR-1246 
probes or because current commercially available primers are not suitable for qPCR 
amplification of this miRNA.  
 
Fig. 16: Differentially expressed miRNAs on clustered heatmaps based on LC Sciences miRNA 
microarrays 
Heatmaps illustrate significantly differentially expressed miRNAs (p-value < 0.01, ANOVA) between the 
different treatments (untreated, 3 h or 72 h stimulation with 50 ng/ml IFN-γ, respectively). Single miRNAs 
showing differential expression are represented in the vertical area, whereas the three treatments are 
aligned horizontally. Note that every miRNA is spotted four times on the array, resulting in four rectangles 
per cell line and treatment. Colors represent Z-score values as indicated at the bottom. According to their 
differential regulation patterns, miRNAs can be divided into several groups: down-regulated (D) and up-
regulated (U) miRNAs as well as miRNAs regulated in a ‘curve’ (C) (with down-/up-regulation at the time 
points D1 = early (3 h) and late (72 h), D2 = late, U1 = early and late, U2 = late whereas the curve- 
regulation can be divided into C1 = down-regulation followed by return to basal level and C2 = up-
regulation followed by return to basal levels). miRNAs with a high differential expression over time which 
were selected for further analysis are marked in green. 
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Otherwise, differential expression of miRNAs in IFN-γ-stimulated samples in comparison to the 
untreated control was confirmed by qPCR for all miRNAs tested and different regulation patterns 
were detected in the different cell lines (Fig. 17). Efficient IFN-γ-stimulation was confirmed by 
induction of P-STAT1 and up-regulation of the STAT1 target gene STAT1 itself by parallel 
Western blot analysis (Fig. 17). Surprisingly, different regulation patterns for the same RNA 
samples were detected, when miRNA expression was normalized either to the housekeeping 
gene RNU6B or SCARNA17. For example in IGR37 cells, most of the analyzed miRNAs (miR-21, 
-23a, -29a, -146a, -1826) were found to be up-regulated, when referred to RNU6B, but were 
down-regulated, when SCARNA17 was used for normalization (Fig. 17). miR-21 was not induced 
in A375 and MeWo cells when normalized to SCARNA17, but was up-regulated when calibrated 
to RNU6B. Both genes are commonly used reference RNAs for qPCR amplification of miRNAs. 
Nevertheless, miR-29a and miR-1826 showed the most robust regulation of all miRNAs tested in 
the investigated cell lines and were thus selected for further analyses. Because the miR-1826 
sequence was later on identified to be a fragment of 5.8S rRNA (ribosomal RNA), it was 
removed from miRBase and thus from our list of human miRNAs of interest. Subsequently, the 
focus was set on the miR-29 family with its mature members miR-29a, -29b and -29c, which is 
one of the most important miRNA families to date, implicated in the regulation of various 
cellular processes (Kriegel et al. 2012; Schmitt et al. 2012a). For control purposes, miR-100 
(slightly down-regulated after IFN-γ stimulation) and miR-25 (stable levels) were selected. To 
circumvent the above described normalization problem and to be able to reliably identify the 
small expression changes typical for miRNAs (1.5 – 5 fold), the Genorm normalization method 
(for details see methods section) has been used for all following experiments, which uses a 
minimum number of three housekeeping genes (in our case RNU1A, RNU5A and SCARNA17), 
thus allowing for more accurate normalization of miRNA expression changes according to the 
MIQE-guidelines (Minimum Information for Publication of Quantitative Real-Time PCR 
Experiments) (Bustin et al. 2009). 
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Fig. 17: IFN-γ stimulation of three in melanoma cell lines: qPCR amplification of candidate 
miRNAs as selected from the LC Sciences microarray experiment 
(A,B) The miRNAs miR-21, -23a, -29a, -146a, -1246 and -1826 were amplified from A375, MeWo and 
IGR37 melanoma cell lines, which had been left untreated or stimulated with IFN-γ for 3 h, 8 h, 24 h, 48 
h or 72 h. Graphs show miRNA relative expression (REL) normalized to the house keeping genes 
SCARNA17 (A) or RNU6B (B) and to the untreated control. Bars ≙ mean with SD of technical triplicates; 
only single experiments are shown for other experiments. (C) Efficient STAT1-activation was confirmed by 
Western blot analysis. 
 
To gain a comprehensive view on the regulation of the miR-29 family, the expression of all miR-
29 species following IFN-γ-stimulation was addressed in detail: kinetics of both primary clusters 
pri-29a~b-1 and pri-29b-2~c, the different precursor molecules pre-29a, pre-29b-1, pre-29b-2 
and pre-29c as well as the mature miRNAs miR-29a and miR-29b were analyzed. Nevertheless, 
it must be noted that precursor primers can also amplify primary miRNAs and up-regulation of 
miR-29 precursors may partially reflect the pri-29a~b-1 signal. Expression of mature miR-29c, 
which is derived from the pri-29b-2~c cluster was not analyzed as it only bears one nucleotide 
difference to miR-29a (Fig. 4). 2Therefore, specific and correct qPCR amplification of miR-29c 
expression was not possible with the SYBR system (data not shown). 
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The pri-29a~b-1 cluster and mature miR-29a/29b are regulated by IFN-γ in 
melanoma cell lines 
To accurately assess the regulation of the miR-29 family by IFN-γ-induced STAT1, the 
melanoma cell lines MeWo and A375, as well as stably transfected A375 derivates were used for 
further stimulation experiments with IFN-γ. 2A375-STAT1(F) represent STAT1-dominant 
negative cells harboring a phenylalanine replacement of tyrosine residue 701 crucial for STAT1 
phosphorylation and dimerization (Kortylewski et al. 2004)(Fig. 5). 2Thus, transcription of STAT1 
target genes is abolished despite IFN-γ stimulation. 2The corresponding positive control cells 
A375-STAT1(wt) express the STAT1 wild-type construct instead (Kortylewski et al. 2004). 
2Stimulation of A375, MeWo and A375-STAT1(wt) cell lines with 50 ng/ml of IFN-γ induced a 
prominent STAT1 phosphorylation, which decreased after 48 h of IFN-γ treatment, whereas the 
STAT1-dominant negative cells A375-STAT1(F) only exhibited a delayed and weak P-STAT1 
signal after IFN-γ stimulation (Fig. 18), see also (Kortylewski et al. 1999)). 2Functional activity of 
the P-STAT1 transcription factor was confirmed by up-regulation of the STAT1 target genes IRF-
1 and STAT1 itself, which showed induced expression after 3 h and 8 h, respectively. 2Following 
stimulation, changes in miRNA expression levels were assessed by qRT-PCR. A375, A375-
STAT1(wt) and MeWo cell lines showed a strong and significant up-regulation (>5 fold) of the 
pri-29a~b-1 cluster, starting 24 h after IFN-γ stimulation, while expression of the pri-29b-2~c 
cluster was not altered (Fig. 18, upper panel). 2Accordingly, miRNA precursors pre-29a and pre-
29b-1 were also augmented whereas pre-29b-2 and pre-29c levels remained unaffected (Fig. 
18, middle panel). 2Subsequently, significant up-regulation of both mature miR-29a and miR-
29b following IFN-γ stimulation was confirmed (Fig. 18, lower panel). The two control 
amplifications of miR-100 (slightly down-regulated) and miR-25, which remained stable over 
time following IFN-γ stimulation confirmed the initial microarray-based expression profiles (Fig. 
18, lower panel). 2Except for minor expression changes of the Pri/Pre-miR-29 species after 72h 
of IFN-γ treatment, no up-regulation was detected in the A375-STAT1(F) dominant negative 
control cells, clearly suggesting that STAT1 activity is required for the IFN-γ-induced regulation 
of miR-29.  
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Fig. 18: 2 Expression profiles of miR-29 clusters in melanoma cells 
2A375-STAT1(F), A375-STAT1(wt), A375 and MeWo melanoma cells were stimulated with IFN-γ for 
different time points. 2(A) Western Blot analysis (representative blots of biological triplicates) confirms 
activation of P-STAT1 and induction of STAT1 and IRF-1 after IFN-γ stimulation while dominant negative 
A375-STAT1(F) cells show minor effects. 2(B) Time course study of miRNA-expression after IFN-γ-
stimulation. 2Graphs show relative expression (REL) from quantitative qRT-PCR data for the pri-29a~b-1 
and the pri-29b-2~c clusters, the precursors pre-29a/29b-1/29b-2/29c and mature miR-29a/29b/25/100. 
2Fold expression was calculated relative to the untreated control. Bars = mean with SD for biological 
triplicates. 2Statistical significance was tested with one-way ANOVA, followed by a Dunnett Post-Hoc test 
with * p<0.05, ** p<0.01 and *** p<0.001.  
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Detailed time course microarray experiment confirms IFN-γ-induced regulation of 
miR-29 
In the course of a master thesis project in our group (Reinsbach et al. 2012), a more detailed 
time course miRNA microarray experiment was performed using IFN-γ-stimulated A375 cells 
(including untreated, 30 min, 3 h, 6 h, 12 h, 24 h, 48 h, 72 h, 96 h time points). In parallel and 
as a negative control, cells had been pre-treated with Jak inhibitor 1 (JI1), which specifically 
inhibits Janus tyrosine kinases and subsequently prevented miR-29 up-regulation after IFN-γ 
stimulation. Optimal concentrations of inhibitor had previously been established in our 
laboratory. As shown in Fig. 19, the STAT1 phosphorylation for cells pretreated with JI1 was 
almost undetectable. 
 
 
 
Fig. 19: STAT1-activation after IFN-γ stimulation and abrogation of P-STAT1 signals 
following JI1-pretreatment 
Detailed IFN-γ kinetics in A375 cells (50 ng/ml IFN-γ or pre-treated with 5 µM JII followed by IFN-γ 
stimulation). Activation of P-STAT1 (left) and Jak-inhibition (right) were confirmed prior to microarray 
analysis of the corresponding RNA samples (Reinsbach et al. 2012). 
 
Following the confirmation of successful IFN-γ-stimulation, duplicate RNA samples of A375 cells 
from all time points (untr, 0.5 to 96 h) and from the 72 h JI1-pre-treated cells were subjected 
to miRNA-microarray (Affymetrix) (Fig. 20) and subsequent qRT-PCR validation of selected 
miRNAs (data not shown). Up-regulation of mature miR-29a and miR-29b after IFN-γ-
stimulation, as well as no modulation of miR-25 and slight down-regulation of miR-100 over 
time was confirmed (Fig. 20). No expression change in comparison to untreated cells was 
observed after JI1-pre-treatment and subsequent IFN-γ stimulation for any of the miRNAs, 
indicating that the transcriptional induction of miRNAs following IFN-γ-stimulation is Jak-
dependent and STAT-mediated. Altogether, these data substantiate the time-dependent up-
regulation of the expression of pri-29a~b-1 cluster as well as of the mature miRNAs miR-29a 
and -29b in melanoma cells, which is triggered by IFN-γ-induced STAT1 signaling.  
Interestingly, also miRNA star sequences showed differential regulation. The miRNA star 
(miR*)-sequences, as named on the microarray (and as explained before, introduction Fig. 3), 
represent the miRNA, which arises from the 3´-arm of the hairpin and is conventionally 
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considered as “minor” product. In this case, miR-29a* and miR-29c* were not induced whereas 
miR-29b-1* and miR-25* was up-regulated after IFN-γ-stimulation.  
 
 
 
Fig. 20: miRNA and miRNA* expression profiles in A375 cells 
Corresponding data were derived from a more detailed IFN-γ time course miRNA microarray experiment 
including cells treated with JI1 (72h JI1, IFN-γ stimulation for 72 h after pre-treatment with JI1, blue 
dots). 2Depicted are log2-values of the mean of duplicate microarray experiments. 
 
miRNAs from the  miR-23a/27a/24-2 clusters show strand-specific IFN-γ-induction  
Other IFN-γ-induced miRNAs from the detailed miRNA microarray experiment included also 
several miRNA star sequences which showed regulation patterns different to their partner 
duplex strands (Fig. 21). For example, miR-23a* and miR-27a* were up-regulated, whereas 
miR-23a and miR-27a did not exhibit differential expression following IFN-γ. For the second 
miR-23/27/24 cluster, all miR-23/27 species were down-regulated (Fig. 21). Interestingly, both 
clusters are composed of three miRNAs from different families each (miR-23/miR-27/miR-24). 
This leads to the suggestion that the cellular functions of miR-23a*/miR-23b* and miR-
27a*/miR-27b* could complement each other (Reinsbach et al. 2012).  
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Fig. 21: Strand-specific IFN-γ induction the miR-23a/27a/24-2 cluster and down-regulation 
of the miR-23b/27b/24-1 cluster 
(A) Genomic organization of both clusters miR-23a/27a/24-2 (chr 19, -) and miR-23b/27b/24-1 (chr 9, +) 
(B) miRNA and miRNA* expression profiles in A375 cells derived from the detailed IFN-γ time course 
miRNA microarray experiment including cells treated with JI1 (72hJI1, IFN-γ stimulation for 72h after pre-
treatment with JI1, blue dots). 2Depicted are log2-values of the mean of duplicate microarray 
experiments. 
 
Analysis of miR-29 regulation in other biological systems 
To investigate whether the observed regulation patterns are specific for melanoma cells or if 
they can be reproduced in other cell types, we performed the same stimulation experiments in 
HEK293T kidney cells and Jurkat T-cells and also used the type-I interferons IFN-α and IFN-β in 
preliminary stimulation experiments (Fig. 22). Up-regulation of mature miR-29a/b after IFN-γ-
stimulation and unchanged miR-25 levels were also observed in these two other cell lines (Fig. 
22), albeit miR-29a up-regulation was slightly weaker than in melanoma cells. Interestingly, also 
IFN-α and IFN-β-stimulation led to enhanced miR-29a and miR-29a expression in Jurkat and 
HEK cells, proving that also type-I-interferons can induce these miRNAs. However, effects were 
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stronger in Jurkat cells than in HEK cells and miR-29a/b induction after IFN-β stimulation was 
higher in comparison to IFN-α stimulation in Jurkat cells (Fig. 22). 
 
 
 
Fig. 22: Analysis of miR-29 regulation patterns in HEK293T and Jurkat cells 
Up-regulation of mature miR-29a/29b after IFN-α, IFN-β and IFN-γ stimulation in Jurkat T cells and 
HEK293T kidney cells. miR-25 levels remained unchanged in Jurkat cells and were slightly affected after 
IFN-α and IFN-β stimulation of HEK293T cells. Graphs show relative expression (REL). Bars = mean with 
SD for biological triplicates (IFN-γ) or technical triplicates (IFN-α, IFN-β). Statistical significance was 
tested with one-way ANOVA, followed by a Dunnett Post-Hoc test with * p<0.05, ** p<0.01 and *** 
p<0.001  
 
In addition to our findings for melanoma cells (Fig. 18) and previously published data on the 
role of miR-29 in various other cancer types (Sengupta et al. 2008; Wang et al. 2008; Zhao et 
al. 2010) miR-29 family members were also shown to be up-regulated in T-cells (Fig. 22).  
When analyzing potential target genes of miR-29 with publicly available databases and literature 
searches (see below, Fig. 33) we found that miR-29a/29b had also been reported to target the 
HIV (human immunodeficiency virus) -protein nef (negative regulatory factor) (Hariharan et al. 
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2005). Nef has a positive influence on HIV infectivity and replication by down-regulating cell 
surface molecules like CD4 (cluster of differentiation 4) and MHC (major histocompatibility 
complex) I and II (Kirchhoff et al. 2008). Following this interesting connection, we found in a 
report that miR-29a modulates HIV-production and infectivity (Nathans et al. 2009). With this 
information at hand we initiated initial experiments to investigate a potential connection 
between IFN-γ/miR-29a/nef in T-cells, using MT4 T-cells, which can be infected by HIV. MiR-
29a/b were up-regulated after stimulation of MT4 T-cells with IFN-α-, IFN-β- and IFN-γ. Follow-
up studies are currently being planned to investigate whether IFN-induced up-regulation of miR-
29a/b is sufficient to reduce nef expression in HIV-infected T-cells and to possibly decipher a 
new role for interferons and miRNAs during HIV infection. 
 
 
 
Fig. 23: Initial experiments on miR-29 in MT4 cells 
(A) Mature miR-29a/29b up-regulation after IFN-α-, IFN-β- and IFN-γ-stimulation (50 ng/ml) in MT4 T 
cells. Graphs show relative expression (REL). Bars ≙ mean with SD for biological triplicates. Statistical 
significance was tested with one-way ANOVA, followed by a Dunnett Post-Hoc test with * p<0.05, ** 
p<0.01 and *** p<0.001. (B) Efficient phosphorylation of P-STAT1 after stimulation (IFN-α-, IFN-β- and 
IFN-γ, 50 ng/ml) was confirmed by Western blotting. 
 
IL-27 induces a P-STAT1 response in melanoma cell lines and up-regulates miR-29 
For all following experiments, we focused again on melanoma cells. Members of our group had 
shown that although it belongs to the IL-6-type cytokine receptor family, IL-27 (interleukin 27) 
assumes IFN-γ-like functions in hepatoma cells and induces a STAT1 response (Schoenherr et 
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al. 2010). We tested whether IL-27 could also activate STAT1 in melanoma cells leading to up-
regulation of miR-29 as it was confirmed that IL-27 exhibits anti-proliferative activities on 
melanoma cell lines (Yoshimoto et al. 2008). The required receptors for IL-27 signal 
transduction are WSX-1 and gp130 (glycoprotein 130), which are known to be expressed on 
MeWo cells (Pflanz et al. 2004). Indeed, P-STAT1 activity as well as miR-29a/b up-regulation 
was confirmed in A375 and MeWo cells (Fig. 24). Also phosphorylation of STAT3 following IL-27 
stimulation could be detected in the early time points (3 h – 24 h). Interestingly, also the 
untreated samples showed a P-STAT3 signal, which can be explained by constitutive activity of 
STAT3 in cell culture experiments, which include wells with a high cell density (Kreis et al. 
2007). 
 
 
Fig. 24: IL-27 induces a STAT1-response in A375 and MeWo melanoma cell lines 
Time course study of miRNA-expression after IL-27-stimulation (50 ng/ml) in A375 and MeWo melanoma 
cells. (A) Western Blot analysis confirms activation of P-STAT1 and induction of STAT1 and IRF-1 after IL-
27 stimulation as well as activation of P-STAT3. (B) qRT-PCR: graphs show relative expression (REL) from 
quantitative qRT-PCR data for the mature miRNAs miR-29a, miR-29b, miR-25 and miR-100. Fold 
expression was calculated relative to the untreated control. Bars ≙ mean with SD for technical (A375) or 
biological (MeWo) triplicates. Statistical significance (MeWo) was tested with one-way ANOVA, followed 
by a Dunnett Post-Hoc test with * p<0.05, ** p<0.01 and *** p<0.001.  
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5.1  In silico analysis of the miR-29 promoter regions 
As miR-29 family members could be induced by STAT1, we next analyzed their respective 
promoter regions more closely. Both clusters of the miR-29 family are intergenic and currently 
there is no common agreement on their transcription start sites (TSSs). To taper the region 
which could be responsible for miR-29 regulation, a detailed literature search was performed on 
all published TSS coordinates for both clusters (Saini et al. 2007; Chang et al. 2008; Marson et 
al. 2008; Saini et al. 2008; Corcoran et al. 2009; Mott et al. 2010; Chien et al. 2011), which 
were then converted into the human genome version 19 (hg19) as described in more detail in 
our recent review (Schmitt et al. 2012a). So far, 14 different TSSs have been annotated for the 
miR-29 family (Fig. 25). TSS analysis revealed that the genomic locations of the published 
transcription start sites were distributed over a large distance.  
 
 
Fig. 25: Promoter organization and potential transcription start sites for miR-29 clusters 
1Potential TSSs for both clusters miR-29a~29b-1 (TSSab1-8) and miR-29a~29b-2 (TSSbc1-6) from 
literature, as described in (Schmitt et al. 2012a). 1Coordinates have been converted to genome version 
hg19/GRCh37 and are as follows: TSSab1 chr7:130.572.487; TSSab2 chr7:130.586.832; TSSab3 
chr7:130.596.983; TSSab4 chr7:130.597.889; TSSab5 chr7:130.598.020; TSSab6 chr7:130.598.638; 
TSSab7 chr7:130.598.268; TSSab8 chr7:130.800.298; TSSbc1 chr1:207.977.425; TSSbc2 
chr1:207.979.479; TSSbc3 chr1:207.985.009; TSSbc4 chr1:207.996.050; TSSbc5 
chr1:207.997.156;TSSbc6 chr1:207.037.276. The magnified insert (TSSab4-7) indicates a culmination of 
described TSSs and thus a putative promoter region of the miR-29a~29b-1 cluster. 
 
However, four of the TSSs for the miR-29a~29b-1 cluster accumulated in a 700 bp-region, 
which could be its most important regulatory region, while no refinement was possible for the 
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miR-29c~29b-2 cluster (Fig. 25). Genomic coordinates for those four transcription start sites 
were obtained by experimental (TSSab4 and TSSab5) (Chang et al. 2008; Mott et al. 2010) and 
computational (TSSab6 and TSSab7) analyses (www.switchgeargenomics.com). 
In silico analysis of the pri-29a~b-1 promoter region identifies a putative regulatory 
region containing two STAT1 binding sites 
After the region for the approximate location of the pri-29a~b-1 promoter had been narrowed 
down and to further confirm the STAT1-mediated regulation of this cluster, a comprehensive in 
silico examination of the region chr7:130,560,000-130,610,000 (hg19) was conducted, spanning 
the sequence 40.000 bp upstream and 10.000 downstream of the putative pri-29a~b-1 
transcription start site as described in Schmitt et al. (Schmitt et al. 2012a); an illustration is 
shown in Fig. 25. This analysis included the UCSC genome browser features ‘H3K4Me3 mark’, 
‘vertebrate conservation’ and also incorporated data from a ChIP-Seq experiment which had 
been performed on IFN-γ treated Hela cells within the ENCODE project (ENCyclopedia of DNA 
Elements) (Kent et al. 2002) (all features are further described in the methods section). This 
initial analysis identified a region (chr7:130,596,800-130,599,000; hg19) with high vertebrate 
conservation, a H3K4Me3-mark as marker for open chromatin and a prominent ChIP-Seq peak 
and also contained five of the putative transcription start sites described in literature (Fig. 26 A). 
We thus concentrated on the sequence mentioned above for the following analyses.  
By combination of several sequence searches and publicly available in vitro data and in silico 
analyses, we identified two STAT1 bindings sites (chr7:130597141-130597155 and 
chr7:130597778-130597792) within a conserved region of chromosome 7 in the promoter 
region of the pri-29a~b-1 cluster. The binding sites which could be responsible for pri-29a~b-1 
regulation have been predicted by two different algorithms (‘Jaspar’ and ‘Transfac’) (Fig. 26 B) 
and overlapped with ChIP-Seq-based data as well as ENCODE-predictions for STAT1 binding 
sites. Furthermore, they were located in close proximity of a H3K4Me3-mark (marker for open 
chromatin) and are located close to putative transcription start sites found in literature. 
Interestingly, transcription of the pri-29a~b-1 from the region described above would lead to a 
very long primary construct of ~36 kb. 
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Fig. 26: In silico analysis of a putative STAT1-regulatory region within the pri-29a~b-1 
promoter 
(A) Initial analysis on chr7:130,560,000-130,610,000 (hg19) included (from top to bottom) putative TSSs 
from literature (Fig. 25 and (Schmitt et al. 2012a)). ENCODE STAT1-ChIP-seq peaks from a ChIP 
experiment performed on IFN-γ-stimulated Hela cells, position of mature hsa-miR-29a and hsa-miR-29b-1 
sequences, H3K4Me3 peaks and vertebrate conservation scores (blue / positive scores: conserved sites; 
red / negative scores: fast-evolving sites) were all obtained from UCSC (Kent et al. 2002).  
(B) Detailed analysis on chr7:130,596,800-130,599,000 (hg19), magnified insert from (A). From top to 
bottom: ENCODE TF-ChIP-seq: STAT1 binding sites as predicted by the UCSC track ENCODE (Hudson and 
Snyder 2006; Euskirchen et al. 2007) transcription factor binding; GAS-search: GAS elements from 
computational screen for the consensus sequences TT(C/A)CNNNAA(A/G) (light green) (Pagliaccetti et al. 
2008) and from screen for consensus sequence TT(C/A)NNN(G/T)AA (green) which had been used by 
Smith et al. (Smith et al. 2012). Jaspar/Transfac: putative STAT1 binding sites predicted by Jaspar (dark 
blue) or Transfac (light blue); the red star indicates the sites found by both of the programs. TSS 
literature: potential transcription start sites collected from literature, as summarized in (Schmitt et al. 
2012a) and corresponding to TSS labelling from Fig. 25: TSSab3: (Chien et al. 2011) miRStart; TSSab4: 
(Mott et al. 2010); (TSS)ab5: (Chang et al. 2008); TSSab6 & TSSab7: UCSC: ’SwitchGear’. ENCODE 
STAT1 ChIP-seq and H3K4Me3 mark and vertebrate conservation: magnified insert from A), the red line 
indicates the middle of the STAT1-ChIP-seq-peak. 
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5.3  Functional characterization of miRNA-29 in melanoma 
The miR-29b-2~c cluster is undetectable in melanoma cell lines, melanocytes and 
keratinocytes 
2As both miR-29 primary clusters as well as the mature miR-29a/29b showed different basal 
expression levels in stimulation experiments and are known to be differentially expressed in 
several other types of cancer (Pekarsky et al. 2006; Stamatopoulos et al. 2009), we next 
analyzed the miR-29 basal expression profiles in a panel of melanoma cell lines, primary human 
melanocytes (NHEM-M2) and HaCaT keratinocytes (Fig. 27).  
 
 
 
Fig. 27: 2Analysis of miR-29 basal expression levels and proliferation of untreated melanoma 
cell lines 
2Comparison of basal expression levels of (A) primary miRNA clusters pri-29a~b-1 (blue/red/black bars) 
and pri-29b-2~c (grey bars) and (B) mature miR-29a (blue/red/black bars) and miR-29b (grey bars) in 
NHEM-M2, eight melanoma cell lines and HaCaT keratinocytes. Bars = mean of = 2(dCt) x102 with SD of 
biological triplicates (dct = ct target – ct GEOMEAN of 3 reference genes). (C) 2Mean growth curves of 
untreated melanoma cell lines over 4 days (biological quadruplicates). 2Melanoma cell lines with ‘low 
expression’ of pri-29a~b-1 and miR-29a show faster proliferation whereas cells with a relatively ‘high 
expression’ proliferate slower.  
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2Pri-29a~b-1 was strongly expressed whereas pri-29b-2~c was almost undetectable in all cell 
lines analyzed (Fig. 27). This is in accordance with previous studies reporting down-regulation 
of the pri-29b-2~c cluster in rhabdomyosarcoma (Wang et al. 2008) and B-cell lymphoma 
(Chang et al. 2008). Mature miR-29a consistently showed higher basal expression levels than 
miR-29b in all cell lines examined (Fig. 27). To exclude the possibility that the differences in 
expression levels mentioned above were caused by different primer efficiencies (e.g. miR-29a 
versus miR-29b primer and pri-29a~b-1 primer versus pri-29b-2~c), we tested the primer 
efficiencies of all miR-29 primer and confirmed them to be between 80% and 120% (data not 
shown).  
MiR-29a/29b expression levels inversely correlate with growth behavior of 
melanoma cell lines 
The classification of miR-29 as tumor-suppressor miRNA has been widely accepted and the 
possibility to use synthetic miR-29 as therapeutic agent in treatments of cancer seems to 
become increasingly realistic. 2Properties counteracting the development and spreading of 
cancer cells that have been observed in vitro and in vivo after miR-29 overexpression include 
reduced invasion and proliferation and induction of apoptosis (Xiong et al. 2010; Fang et al. 
2011). 2These findings prompted us to analyze a potential correlation of basal miR-29 
expression levels with cell growth. Proliferation of untreated melanoma cell lines was monitored 
over time (Fig. 27) in order to correlate it with miR-29a and pri-29a~b-1 basal expression levels 
obtained from cells harvested 96 h after seeding. NHEM-M2 primary melanocytes were not 
included in this experiment as they hardly proliferate. 2According to their expression levels, 
melanoma cell lines could be grouped in miR-29a and pri-29a~b-1 ‘low-expression’ lines (A375, 
MeWo, IGR39, WM9) and ‘high expression’ cell lines (FM55P, FM55M1, SK-Mel30, IGR37) (Fig. 
27). 2Generally, cell lines with lower miR-29a showed an increased proliferation rate compared 
to lines with higher basal miR-29a levels (Fig. 27). Furthermore, the inverse correlation between 
pri-29a~b-1/miR-29a expression and the proliferation rate of melanoma cell lines might suggest 
a potential involvement of miR-29 in anti-proliferative effects in melanoma cells.  
MiR-29a/b are responsible for growth inhibition of melanoma cells 
To follow up these initial findings on proliferation (Fig. 27), we applied miR-29a/29b mimics to 
A375 cells, which exhibit a relatively low miR-29a/29b basal expression and, vice versa, we 
applied a miR-29a inhibitor to FM55P cells, which have a high basal miR-29a/29b expression 
(Fig. 27). 2Proliferation assays with mimics and inhibitors and the corresponding amounts of 
scrambled controls, NC (negative control)-mimic and NC-inhibitor, corroborated that miR-29 
indeed inhibited growth of melanoma cells: transfection of miR-29a/29b mimics caused a 
remarkable reduction of proliferation as compared to NC-mimic-transfected A375 cells. 
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Fig. 28: 2 Proliferation assay of miR-29a/b-mimic-transfected and miR-29a-inhibitor-
transfected melanoma cells confirms the growth-inhibitory role of miR-29 
2Proliferation assay of (dark blue) mimic/inhibitor- and (light blue) NC (negative control)-mimic/NC-
inhibitor-transfected cells over 72h in (A) A375 and (B) FM55P cells; representative graphs of four 
independent experiments. 2Error bars depict SDs of technical triplicates. 2The inserted graphs (upper left 
corners) show the mean confluence of 4 biological replicates at 0 h and 72 h time points of the 
proliferation assay. 2Depicted are ratios of confluence of miR-29a/b-mimic / NC-mimic treated cells (A) 
and miR-29a-inhibitor / NC-inhibitor treated cells (B). Bars ≙ mean with SEM. Significance was assessed 
by a two-tailed t-test with * p<0.05, ** p<0.01 and *** p<0.001. 
 
In turn, FM55P cells, in which miR-29a was inhibited, proliferated faster than NC-inhibitor-
transfected control cells (Fig. 28). 2To confirm efficient transfection, miR-29a/29b tracking by 
qPCR was performed in parallel to the proliferation experiments (Fig. 29). 2Application of miR-
29b inhibitor was not possible as it turned out that the inhibitor itself was amplified by miR-29b 
primers in qRT-PCR, thus inhibition of miR-29b could not be properly monitored and controlled. 
2However, as shown in Fig. 27, miR-29b was generally expressed to a much lower degree than 
miR-29a, so that inhibition of miR-29a was considered to be more important regarding cellular 
effects. Furthermore, initial experiments on combinatorial miR-29a/29b inhibition revealed no 
additional or synergistic effects on potential target genes (see below) compared to miR-29a 
inhibition alone (data not shown). 
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Fig. 29: qRT-PCR tracking experiments to confirm efficient mimic/inhibitor transfection 
miR-29a/29b mimics were tracked in A375 cells (A) and miR-29a suppression after inhibitor transfection 
was quantified in FM55P cells (B) by qRT-PCR. 2Expression levels of miR-29a/29b were assessed 24h, 48h 
and 72h after mimic/inhibitor transfection; bars show means of biological triplicates with SD, relative to 
negative control (NC)-mimic/NC-inhibitor controls. 2Note that miR-29b transfection and/or amplification 
was more efficient than for miR-29a. 
 
In the course of the miR-29-mimic/inhibitor-experiments in melanoma cell lines we analyzed 
their impact on proliferation by measuring growth rates following IFN-γ stimulation. Dose-
dependent inhibition of proliferation by IFN-γ-treatment alone of up to 40 % was detected for 
A375 and MeWo cells (Fig. 30), and this was in line with previous findings for melanoma and 
other cancer cells (Garbe and Krasagakis 1993; Knüpfer et al. 2001; Kortylewski et al. 2004; 
Saha et al. 2010).  
 
 
 
Fig. 30: Proliferation assay following IFN-γ stimulation 
A375 (left) and MeWo (right) melanoma cell lines were left untreated or stimulated with 5, 25 or 50 
ng/ml IFN-γ and growth was monitored over 90 h. Error bars show SEM of technical triplicates. IFN-γ 
dose-dependently inhibited melanoma proliferation in both cell lines. 
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Both miR-29a/b and IFN-γ inhibited melanoma growth (Fig. 28,  Fig. 30) and inhibition of miR-
29a led to enhanced proliferation with respect to the control treatment (Fig. 28). These findings 
raised the question whether in course of a combined IFN-γ/miR-29a inhibitor treatment, 
inhibition of miR-29a would be able to compensate for the inhibition of proliferation mediated by 
IFN-γ (Fig. 31). Inhibitor/IFN-γ double treated cells indeed proliferated faster than NCI/IFN-γ 
treated ones (Fig. 31). However, growth differences were not very prominent and not 
consistently reproducible, probably due to the harsh effects of the double treatment on the 
cells. 
 
 
Fig. 31: Proliferation assay: combination experiment with miR-29 inhibitor and IFN-γ in 
FM55P-cells 
FM55P melanoma cells were left untreated, stimulated with 50 ng/ml IFN-γ or transfected with miR-29a-
inhibitor (Inh), the respective negative control (NC-inhibitor) or a combination of either of them with 50 
ng/ml IFN-γ. Left: as shown above, IFN-γ inhibited proliferation and mir-29a inhibitor transfection (Inh) 
led to enhanced proliferation in comparison to the scrambled control (NCI). Right: Following combined 
treatment, the proliferation rate of inhibitor/IFN-γ treated cells was higher than for NCI/IFN-γ treated 
cells. Error bars show SD of technical triplicates.  
 
Manipulation of miR-29a/b expression levels has no significant impact on apoptosis 
To expand the findings on miR-29-mediated cellular effects, apoptosis was monitored after 
transfection of miR-29a/b mimics and inhibition of miR-29a in A375 and FM55P melanoma cell 
lines by a caspase-3 based Incucyte assay (Fig. 32). Apoptosis rates for miR-29a/b mimic-
transfected cells were slightly enhanced in comparison to the control treatment and, vice versa, 
less apoptosis was observed when miR-29a was inhibited. It has been described previously that 
miR-29 induces apoptosis (Mott et al. 2007; Wang et al. 2011b). Here, effects were not very 
prominent and a reliable difference in apoptosis levels of miR-29a/b-mimic or miR-29a-inhibitor-
transfected cells in comparison to the respective negative controls could not be confirmed. 
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Fig. 32: Apoptosis assay of miR-29a/b-transfected A375 cells and miR-29a-inhibitor-
transfected FM55P cells 
Caspase-3 activity was monitored in Incucyte over 72h for miR-29a/b-transfected cells (29ab) in 
comparison to NC-mimic (NC-M)-transfected A375 cells (left) and for miR-29a-inhibitor (29a-Inh) in 
comparison to NC-inhibitor (NC-Inh)-transfected FM55P-cells (right). Graphs show the number of 
apoptotic cells per well (fluorescent cells with a fluorescence intensity above the background) as counted 
by the Incucyte software. Graphs show a representative replicate out of biological triplicates for each cell 
line, error bars show SD of technical triplicates. Etoposide (Eto) was used as positive control for 
apoptosis.  
 
5.4  The quest for miR-29a/b target genes 
MiR-29 is predicted to regulate more than 1000 human genes (TargetScanHuman 6.1). To 
further elucidate the role of the miR-29 family in melanoma, a combination of several 
algorithms (TargetScanHuman 6.1, Diana-microT v3.0, and miRanda) was consulted in order to 
compile a list of potentially interesting target genes, which carry predicted miR-29 target sites 
and could play a role in melanoma development and progression. As the three mature miR-29 
species share their seed sequence and the remaining mature sequences are very similar, the 
lists of target genes for miR-29a, -29b and -29c can be considered identical. Venn diagram 
analysis of the three target gene lists identified 97 targets as commonly predicted by the three 
programs (Fig. 33).  
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Fig. 33: Venn diagram of potential miR-29 target genes as predicted by Diana, miRanda and 
TargetScan 
The three programs were requested to search for miR-29a target genes. Venn diagram analysis 
(http://bioinfogp.cnb.csic.es/tools/venny/index.html) identified 97 target genes, which had been 
predicted by all three of the programs. 
 
To shorten this list of potential miR-29 target genes, the candidates were screened for their 
potential relevance in melanoma development and the list was expanded by several more 
candidates from literature analysis. Furthermore, this initial selection was cross-checked with 
data from a previous mRNA microarray experiment, which had been performed on a panel of 
five untreated melanoma cell lines (Master Thesis Project, Stefanie Schmitz). Expression 
analysis revealed that most of the potential target genes were either not expressed in the 
majority of cell lines or only showed a very low basal expression (data not shown). Based on 
this information, ten potential target genes were chosen for further tests (Fig. 33). The 
selection of potential miR-29 target genes is shown in Table 7.  
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Table 7: Selection of potential miR-29 target genes selected for further analysis 
(descriptions taken from http://www.ncbi.nlm.nih.gov/gene) 
Gene Name description 
Akt3 v-akt murine thymoma viral 
oncogene homolog 3 
Member of the Akt kinase family, which regulate cell signaling in 
response to insulin and growth factors  
Bcl-2 B-cell CLL/lymphoma 2 Integral outer mitochondrial membrane protein that blocks apoptotic 
death of several cells (f.e. lymphocytes) 
Cdc42 Cell division control protein 42 
homolog 
Small GTPase of the Rho-subfamily, involved in cell morphology, 
migration etc. 
CDK6 cyclin-dependent kinase 6 Important player in cell cycle; phosphorylates RB, which subsequently 
leads to G1/S transition 
Dicer1  Endoribonuclease, involved in miRNA processing 
DNMT3A 
DNMT3B 
DNA (cytosine-5-)-
methyltransferase A/B 
Catalyzes transfer of methyl group to DNA 
 involved in gene silencing 
Mcl-1 myeloid cell leukemia sequence 
1 
Member of Bcl-2 family; 2 isoforms: one enhanced cell survival, while 
the other one promotes apoptosis 
PI3KR1 Phosphoinositide-3-kinase 
regulatory subunit 
Subunit of PI3K, which is a signaling molecule for growth factors and 
hydroxylates phosphatidylinositols; involved in cell growth. 
proliferation etc. 
PTEN Phosphatase and tensin homolog Tumor suppressor; counteracts PI3K; negatively regulates the Akt-
pathway 
 
To further reduce and verify this target gene selection, expression levels of the potential target 
genes were evaluated by RT-qPCR 24h after transfection with NC-mimic as this represents the 
approximate control for the subsequent miR-29a/b-mimic-transfections (Fig. 34).  
 
 
Fig. 34: Expression of potential target genes in A375 cells after NC-mimic-transfection 
Basal expression level of target genes in A375 cells 24h after transfection of 100 nM NC-(negative 
control) mimic. Graphs show relative expression level with REL = 2(Ct target – Ct TBP) x 102 with SD of 
technical triplicates. Akt3, cdc42, CDK6, Mcl-1, PI3KR1 and PTEN show a high or moderate basal 
expression while Bcl-2, Dicer1 and DNMT3A/B only exhibit a low expression in A375 cells. 
 
Indeed, some of the target genes (DNMTA/B, Bcl-2, Dicer1) had very low basal expression 
levels whereas others (CDK6, cdc42, Akt3) were comparatively stronlgy expressed. 
Subsequently, the miR-29a/b mimic was applied to A375 cells to examine whether tentative 
target genes could be down-regulated (Fig. 35). 
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Fig. 35: Expression levels of target genes in A375 cells following miR-29a/b mimic 
transfection 
mRNA levels were assessed 24h, 48h and 72h after transfection of 50nM each miR-29a and miR-29b 
mimic and were normalized to NC-mimic controls (REL-values were obtained by dividing target gene 
mRNA levels after mimic treatment by target gene mRNA levels of the corresponding NC-mimic-treated 
cells). Bars show mean of technical replicates with the propagated error. 
 
mRNA levels of Akt3, Bcl-2, cdc42 remained unchanged after miR-29a/b mimic treatment, 
whereas a modest down-regulation was observed for PI3KR1 and PTEN (Fig. 35). Interestingly, 
Dicer1 and Mcl-1 were up-regulated, while a clear down-regulation was monitored for CDK6, 
DNMT3A and DNMT3B. The PI3K regulatory subunit (gene: PI3KR1; protein: PI3K/p85α) and 
CDK6 were selected for further analyses. Bcl-2, Dicer1 and DNMT3A/B showed a very low basal 
expression level in A375 cells (Fig. 34), hence a miR-29-mediated down-regulation would 
unlikely be of particular importance in the cellular context and therefore they were not 
considered any further. CDK6 had a high basal expression level, which was clearly reduced after 
mimic-transfection, while PI3KR1 exhibited a moderate basal expression and only a minor 
reaction to the treatment (Fig. 34, Fig. 35). Both genes play important roles in cell cycle control, 
cellular signaling and proliferation and had already been confirmed as miR-29 targets in several 
cancers (Garzon et al. 2009b; Park et al. 2009b; Zhao et al. 2010; Li et al. 2011), however not 
for melanoma. 
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MiR-29a/29b down-regulate CDK6, but not PI3K 
2To assess the effect of miR-29 on CDK6 and PI3K expression in melanoma, mRNA and protein 
levels were examined after miR-29 mimic or inhibitor treatments by qRT-PCR and quantitative 
immunoblotting, respectively (Fig. 36).  
 
 
Fig. 36: Effects of miR-29 on potential target genes CDK6 and PI3K 
(A,B) 2relative mRNA and protein expression levels (REL) of miR-29 target genes CDK6 (dark blue) and 
PI3K (light blue), assessed 24 h, 48 h and 72 h after mimic/inhibitor transfection compared to NC-
mimic/NC-inhibitor controls (REL-values were obtained by dividing target gene mRNA/protein levels after 
mimic/inhibitor treatment by target gene mRNA/protein levels of the corresponding NC-mimic/NC-
inhibitor treated cells); bars show means of biological triplicates with SD. Statistical significance was 
assessed by one-way ANOVA followed by a Bonferroni Post-Hoc test. (C) Down-regulation of miR-29 
target proteins CDK6 and PI3K is observed after IFN-γ stimulation of melanoma cells. 
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2Combined transfection of miR-29a/29b reduced CDK6 mRNA and protein levels in A375 cells as 
compared to scrambled controls whereas PI3K levels were not affected (Fig. 36A). 2In 
agreement with that, knockdown of miR-29a in FM55P cells resulted in a slight up-regulation of 
CDK6 levels while PI3K remained unchanged (Fig. 36B). These data indicate that miR-29 is 
involved in down-regulation of CDK6 protein while PI3K does not seem to be a specific target in 
melanoma cells. Upon analysis of protein levels, CDK6 was found to be down-regulated in 
response to miR-29 induction after IFN-γ stimulation in A375 cells and A375-STAT1(wt) but not 
in A375-STAT1(F) cells, suggesting STAT1 dependency (Fig. 36C). In contrast, PI3K levels were 
reduced in all three cell lines, hinting at STAT1-independent effects. 
CDK6 is a direct target of miR-29a 
To determine whether a direct interaction between target genes and miR-29 exist, we 
performed luciferase assays with reporter constructs containing a part of the CDK6 3´-UTR, its 
three single miR-29 binding sites as predicted by TargetScan (www.targetscan.org), a part of 
the PI3KR1-3´-UTR or the miR-29a full complementary sequence as a positive control (Fig. 37). 
Luciferase activity dropped by ~60 % for both time points, 48 h and 72 h, when the CDK6 3´-
UTR construct was co-transfected with miR-29a mimic in A375 melanoma cells. 2The 
corresponding single binding sites contributed to this suppression with 38 % (BS1), 34 % (BS2) 
and 35 % (BS3), though only 72 h after transfection (Fig. 37). 2This suggests that all three miR-
29 binding sites partake in the suppression of CDK6. 2Surprisingly, the PI3KR1 construct was 
also significantly suppressed by the miR-29a mimic in luciferase assays (Fig. 37) while only 
marginal effects had been observed on mRNA and protein level (Fig. 36). 2Taken together, 
these findings indicate that both CDK6 and PI3KR1 3´-UTRs are directly targeted by miR-29 in 
melanoma cells; however, only CDK6 suppression seems to be relevant in a cellular context. 
Because of these overall inconsistent results for PI3KR1, we continued our experiments only 
with CDK6. 
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Fig. 37: Luciferase assay experiments for 3’-UTR sequences of predicted miR-29 target genes 
CDK6 and PI3KR1 
(A) Schematic overview of CDK6 and PI3KR1 luciferase constructs with positions of conserved miR-29a 
binding sites predicted by TargetScan (bold) in the CDK6-3’UTR (BS1-3) and in the PI3KR1-3’UTR (BS) 
and corresponding miR-29a sequences (italics). (B) Luciferase activity in A375 cells transfected with 
constructs containing the positive control miR-29a full complementary sequence (29a-FC), parts of CDK6- 
or PI3K1-3’UTRs or CDK6 single binding sites (BS1-BS3) and miR-29a mimic or the same amount of 
negative control for 48 h and 72 h. Relative luciferase activity (as calculated by the ratio of firefly and 
renilla activities) of miR-29a-transfected samples was normalized to NC-mimic-transfected control 
samples (with luciferase activity of miR-29a-transfected samples divided by NC-mimic-transfected 
samples = 1 set to 100%). Bars show the mean of biological triplicates with SD, relative to NC-mimic 
controls for each construct. Statistical significance was tested with one-way ANOVA, followed by a 
Bonferroni Post-Hoc test with * p<0.05, ** p<0.01 and *** p<0.001. 
 
The direct miR-29 target CDK6 regulates the growth behavior in melanoma cells 
2To further explore the relevance of reduced CDK6 levels for the cell, we used siRNA against 
CDK6 and assessed proliferation over 72h in A375 and FM55P cells (Fig. 39). Reduction of CDK6 
mRNA and protein levels led to a clearly diminished proliferation in both cell lines. Efficient 
knockdown of CDK6 was confirmed by qRT-PCR and Western blotting (Fig. 38). 
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Fig. 38: Tracking of CDK6 mRNA and protein levels after si-RNA transfection 
2To confirm efficient knock-down by CDK6-siRNA, CDK6 expression was tracked in (A) A375 and (B) 
FM55P cells by Western blot (left) and qRT-PCR (right), which both confirm efficient knockdown of CDK6. 
For qRT-PCR, expression levels of CDK6 were assessed 24h, 48h and 72h after siRNA transfection; bars 
show means of biological triplicates with SD relative to negative control. 
 
 
 
Fig. 39: Effects of siRNA-mediated knockdown of CDK6 on proliferation of melanoma cells 
A375 (left) and FM55P (right) cells transfected with CDK6 siRNA (si-cdk6, light blue) show reduced 
proliferation in comparison to cells transfected with siRNA negative control (si-NC, blue). Results were 
reproduced in at least two biological replicates. 2The inserted bar diagrams (upper left corners) show the 
mean confluence of at least 3 biological replicates at 0h and 72h time points of the proliferation assay. 
Bars show ratios of confluence of si-CDK6 / si-NC; with SEM. Significance was assessed by a two-tailed t-
test with * p<0.05, ** p<0.01 and *** p<0.001. 
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MiR-29a and miR-29b are up-regulated in primary melanoma patient samples 
2MiR-29a/29b expression profiles were analyzed in FFPE melanoma patient samples from normal 
skin, nevi, primary and metastatic melanoma by qRT-PCR (Fig. 40). 2Nevi represent the most 
appropriate control samples as they contain predominantly melanocytes while normal skin 
samples are mostly composed of keratinocytes. 2In comparison to healthy skin and nevi, both 
miR-29a and miR-29b showed an up-regulation in primary melanoma samples whereas in 
metastatic tumors, expression levels were only slightly enhanced compared to healthy controls. 
2Closer sub-classification of the patient samples revealed, however, that only two of five 
patients demonstrated the enhanced miR-29a/29b expression, indicating that expression levels 
are heterogeneous and will have to be assessed in larger patient cohorts.  
 
 
 
Fig. 40: 2miR-29 expression in FFPE melanoma patient samples 
2Analysis of miR-29a (left) and miR-29b (right) basal expression of individual FFPE-patient samples from 
NS = normal skin, N = nevi, P = primary melanoma and M = metastatic melanoma of a total number of 
five patients. 2All graphs show 2-∆ct with ∆ct= (ctmiR-29a/29b– ctRNU5A). 
2Primary and metastatic tumor 
samples were sorted according to patients P1-5: P1-circles, P2-rectangles, P3-crosses, P4-triangles, P5-
asterisks. 
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6 Discussion 
Regulation of miRNA expression. The broad impact of miRNAs on the initiation, 
development and maintenance of cancer and other diseases but also their possible use as 
therapeutic compounds or targets has become increasingly evident over the past decade. 
Substantial experimental efforts have been undertaken to reveal miRNA sequences, their modes 
of actions and their roles in cellular homeostasis and malignancies. Along this line it became 
soon obvious that it is of particular importance to figure out how miRNAs themselves are being 
regulated in order to further understand miRNA-cancer-pathways and to be able to efficiently 
manipulate the abundance of these small non-coding RNA molecules. Generally, expression 
levels of miRNAs can be regulated transcriptionally, by epigenetic silencing, differential 
biosynthesis or different turnover times (Bartel 2004; Bueno et al. 2008; Krol et al. 2010b). 
Moreover, miRNAs have also been shown to be regulated by extracellular stimuli, e.g. cytokines 
like interferons (Pedersen et al. 2007).  
Cytokines play a pivotal role in the immune system by communicating cellular responses to 
inflammation and infections (O'Shea and Murray 2008). Nearly all cell types can come into 
contact with cytokines such as IFN-γ, which is mainly secreted by activated T and NK cells and 
which represents the most important Th1 (T helper type 1)– cytokine in innate and adaptive 
immunity to infection (Schroder et al. 2004; Saha et al. 2010). Generally, cytokines can activate 
transcription factors, subsequently leading to transcription of target genes including miRNAs. 
IFN-γ primarily triggers the JAK/STAT pathway resulting in a STAT1-mediated transcriptional 
activation of target genes. The importance of interactions between miRNAs and STAT 
transcription factors has very recently been summarized in a review (Kohanbash and Okada 
2012). Classical and well-described examples for miRNAs with connection to STATs are miR-21 
(Löffler et al. 2007) and miR-155 (Kutty et al. 2010), which both are regulated by STAT factors, 
while miR-29 represents a miRNA family which had not been associated to STATs before. 
 
Connecting the miR-29 family to Jak-STAT signaling. In this PhD project, the miR-
29a~29b-1 primary cluster as well as mature miR-29a/b were found to be specifically and dose-
dependently up-regulated after IFN-γ stimulation of melanoma, HEK and T-cells (Fig. 17, Fig. 
19, Fig. 22). IFN-γ stimulation of a control cell line expressing dominant-negative STAT1 (A375-
STAT1(F)) did not cause an up-regulation of miR-29, providing strong evidence that STAT1 is 
indeed mediating IFN-γ-induced effects on miR-29 expression levels (Schmitt et al. 2012b) (Fig. 
17). This finding was further strengthened by an experiment with a specific Jak inhibitor which 
abrogated STAT1 activation (Reinsbach et al. 2012).  
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The miR-29 family is one of the first ones described, is highly conserved among species and the 
increasing number of publications on single family members emphasizes their important role in 
many cellular processes of cancer biology. Along with miR-34, miR-15~16 and members of the 
let-7 family, miR-29 is currently the most prominent representative of miRNAs exhibiting 
predominantly tumor-suppressive properties (Calin et al. 2002; Garzon et al. 2009b; Hermeking 
2009; Buechner et al. 2011; Zhang et al. 2011b) and as reviewed in the course of this PhD 
project (Schmitt et al. 2012a). 
In general, human miRNAs, especially the majority of tumor suppressor miRNAs, are located in 
fragile regions of the genome and often show loss of heterozygosity in cancer (Calin et al. 
2004). However, miR-29 genes are encoded in chromosomal locations, which do not experience 
frequent genomic rearrangements (Douglass et al. 1985; Barr 2001). 1This suggests that 
transcriptional regulatory mechanisms are responsible for modulation of miR-29 expression 
levels rather than deletions, translocations or mutations. In line with our findings about the 
STAT1-dependent up-regulation of the miR-29a~29b-1 cluster, the contribution of other 
transcription factors to control miR-29 expression has been demonstrated. Transcriptional up-
regulation of miR-29a~29b-1 was mediated by the transcription factor CEBPα 
(CCAAT/enhancer-binding protein alpha) (Eyholzer et al. 2010). In addition, miR-29a and miR-
29c were up-regulated by canonical Wnt-signaling and SMAD3 (mothers against 
decapentaplegic homolog 3) induced miR-29b expression (Kapinas et al. 2009; Villarreal et al. 
2011). On the contrary, the miR-29a~29b-1 cluster was found to be negatively regulated by c-
myc, NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) and hedgehog 
signaling (with involvement of Gli as the responsible transcription factor) in different cell lines 
(Chang et al. 2008; Mott et al. 2010; Ma et al. 2011a). Taken together, it is likely that the 
transcriptional regulation of the miR-29 clusters is mediated by a combination of various 
transcription factors. Furthermore, STAT1 collaborating transcription factors like SP-1 (specificity 
protein 1), AP-1 (activator protein 1) or CEBP (CCAAT/enhancer-binding protein) presumably 
also play a role in the regulation process (Zhou et al. 1998; Wang et al. 2010). In this context it 
is noteworthy that several miRNAs in addition to miR-29 were IFN-γ-induced in our experiments 
and could play a role for the cellular context. For example, miR-155 was among the miRNAs, 
which were up-regulated upon IFN-γ stimulation (Reinsbach et al. 2012). Interestingly, SOCS1 
has been shown to be directly targeted by miR-let7a/b and miR-155 in hepatic stellate and 
human hepatoma cells, respectively (Su et al. 2011; Meng et al. 2012). Thus, IFN-γ-induced 
miR-155 expression might contribute to IFN-γ signaling by prolonging the STAT1 signal due to 
inhibition of SOCS1. 
Within this PhD project, STAT1-dependent up-regulation of the miR-29a~29b-1 cluster was 
reported, while miR-29b-2~29c was not IFN-γ-induced (Fig. 20). The results on miR-29a~29b-1 
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were further corroborated by in silico analyses: A combination of computational and 
experimental evidence identified two STAT1 binding sites as likely candidates for miR-29a~29b-
1-regulation inside a putative miR-29a~29b-1 promoter region containing several potential 
transcription start sites (Fig. 26). However, although several types of transcriptional regulation 
on the miR-29a~29b-1 cluster have been experimentally elucidated, disagreement about the 
corresponding transcription start sites continues to exist (Fig. 25). A considerable number of 
studies has contributed to the investigation of the transcription start sites of both miR-29 
clusters by computational and experimental methods (Saini et al. 2007; Chang et al. 2008; 
Marson et al. 2008; Saini et al. 2008; Corcoran et al. 2009; Mott et al. 2010; Chien et al. 2011) 
(www.switchgeargenomics.com). For the miR-29b-2~29c cluster, current data do not allow for 
a clear assignment of a TSS. However, for miR-29a~29b-1, the position of the most likely TSS 
could here be narrowed down to a 700 bp region around four predicted and partly 
experimentally validated TSSs which most likely contains the ‘real’ transcription start sites 
(Schmitt et al. 2012a) (Fig. 25). Possible reasons for the discrepancies in the reported TSSs 
could be the existence of multiple TSSs and/or differences due to the diverse experimental and 
computational methods that have been applied. 1Another source of variation may result from 
the use of different genome versions and GenBank assemblies causing variation of coordinates 
within the published data.  
 
MiR-29 family members exhibit deviating expression levels in different cellular 
contexts. Although both transcriptional activation and repression have been reported for miR-
29a~29b-1 regulation, the vast majority of publications report a down-regulation of miR-29 or 
its single members in cancer (Calin et al. 2005; Yanaihara et al. 2006; Eyholzer et al. 2010). 
These reduced expression levels could be confirmed within this project by screening a panel of 
melanoma cell lines for different miR-29 species and family members, which revealed almost no 
expression of the pri-29b-2~c cluster and a much higher basal miR-29a than miR-29b level (Fig. 
27). In tumor cells, reduced miR-29 expression is frequently observed and diminished 
expression of miRNAs in general is often associated with enhanced oncogenesis (Henry et al. 
2011; Nguyen et al. 2011). The difference in pri-29a~b-1 and pri-29b-2~c expression levels, 
which has been detected here, is consistent with the results in other types of cancer, in which 
the pri-29b-2~c cluster was mostly down-regulated (Pekarsky et al. 2006; Wang et al. 2008; 
Stamatopoulos et al. 2009). Also the revative expression levels of human mature forms of miR-
29a, miR-29b and miR-29c are divergent in different tissues (Sempere et al. 2004).  
Apart from differential regulation, miRNA stability could influence these expression differences: 
it can range from several hours (Bail et al. 2010) to weeks (van Rooij et al. 2007). For example 
Xiong et al. observed that transfected miR-29b duplexes were only stable for 4-7 days in HepG2 
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cells and were not detectable any more four weeks after transfection in nude mice (Xiong et al. 
2010). An even more rapid decay (8-12 hours) for miR-29 family members has been reported 
by others (Hwang et al. 2007; Zhang et al. 2011c). In addition to those findings, another 
explanation for miR-29b regulation has been suggested by Hwang et al. who found miR-29a 
highly expressed throughout the cell cycle, while miR-29b only exhibited high levels during 
mitosis (Hwang et al. 2007). Considering the large amount of time which cells spend for the 
whole cell cycle in contrast to mitosis, this could be a possible explanation for the enhanced 
miR-29a/miR-29b ratio found by us and others.  
 
The tumor-suppressing properties of the miR-29 family. The fact that miR-29 family 
members are often not expressed in cancer cells could be crucial for cancer cell growth: miR-29 
down-regulates important genes such as CDC42, TCL-1 and MCL-1, which normally confer 
tumor-suppressing traits. In this context, anti-proliferating as well as anti-invasive and pro-
apoptotic effects have been observed after miR-29 introduction into a variety of cancer cells 
(Fig. 41) (Xiong et al. 2010; Fang et al. 2011). Fig. 41 summarizes reported findings of miR-29 
functions in different cancer types. 
 
 
 
Fig. 41: Types of cancer in which miR-29 family members have been shown to exert tumor 
suppressive or oncogenic properties 
Tumor-suppressing properties have been demonstrated (among others) for RMS (rhabdomyosarcoma) 
(Wang et al. 2008), HCC (hepatocellular carcinoma) (Xiong et al. 2010; Fang et al. 2011), AML (acute 
myeloid leukemia) (Eyholzer et al. 2010), CLL (chronic lymphocytic leukemia) (Santanam et al. 2010), 
glioblastoma (Cortez et al. 2010) and lung and pancreatic cancer (Muniyappa et al. 2009) whereas tumor-
promoting properties have been observed for AML (Han et al. 2010), colorectal liver metastasis (Wang 
and Gu 2011) and breast cancer (Gebeshuber et al. 2009; Wang et al. 2011a). 
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Along this line, an inverse correlation between miR-29a/b expression and the proliferation rate 
of various melanoma cell lines has been observed in this project, which was corroborated in 
miR-29 mimic or -inhibitor transfected cells, whereas the pro-apoptotic effects could not be 
confirmed reliably (Fig. 27, Fig. 28, Fig. 32). These anti-proliferative effects of miR-29a/b on 
melanoma cell lines furthermore agree with current literature on miR-29 properties. As 
mentioned above, the tumor-suppressor functions which have been demonstrated for miR-29 
family members in different cell lines mostly include induction of apoptosis as well as a 
reduction of proliferation and invasion (Muniyappa et al. 2009; Cortez et al. 2010). Importantly, 
in vivo experiments in mice further confirmed these findings: re-expression of otherwise 
silenced miR-29 inhibited tumor growth of rhabdomyosarcoma (Wang et al. 2008) and reduced 
tumor formation by HCC (hepatocellular carcinoma) cells (Xiong et al. 2010) along with a 
decreased invasive potential, angiogenesis and metastasis in HCC-transplanted nude mice (Fang 
et al. 2011).  
In contrast to the majority of studies highlighting tumor-suppressive properties (Fig. 41), up-
regulation of miR-29b in highly metastatic breast cancer cells in comparison to low-metastatic 
types together with enhanced migration and invasion as well as increased resistance to 
apoptosis has been observed (Wang et al. 2011a). Also, elevated levels of miR-29a in patients 
with invasive breast carcinomas in comparison to benign samples from patients with non-
invasive hyperplasia have been reported (Gebeshuber et al. 2009). Interestingly and in line with 
these augmented levels of miR-29 in breast cancer and AML (Han et al. 2010), we have made 
similar observations in melanoma patient samples: miR-29a and 29b were up-regulated in 
primary melanoma relative to healthy nevi (Philippidou et al. 2010). Similarly, analysis of 
primary and metastatic melanoma patient samples during this PhD project revealed increased 
miR-29a/29b expression in some primary tumor samples in comparison to normal skin, nevi and 
metastatic tissue while all metastatic lesions had low levels of these miRNAs (Schmitt et al. 
2012b) (Fig. 40). Possibly, IFN-γ, which is produced by macrophages and/or T cells and NK-cells 
as a start of a signaling cascade and first line of defense against the developing tumors, induces 
miR-29 expression via STAT1, which in turn could act as tumor-suppressing miRNA 
counteracting manifestation of the cancer at early stages. The fact that miR-29a/29b were only 
up-regulated in two out of five primary melanoma patients is striking and requires further 
evaluation in a larger panel of patient samples including early neoplasia and advanced 
metastatic stages. Surprisingly, a recent study on cutaneous melanoma reported unchanged 
miR-29a and-29b expression levels while miR-29c was down-regulated in metastatic melanoma 
in comparison to primary tumor samples. However, no healthy control tissue or nevi were 
included in this study, hampering the interpretation of the results (Nguyen et al. 2011). Apart 
from the noteworthy exceptions in AML and breast cancer as mentioned above and in the report 
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on primary melanoma by Nguyen et al., miR-29 family members have consistently and 
predominantly been reported to be down-regulated and to assume tumor-suppressive 
properties in cancers.  
 
CDK6 and other miR-29 target genes. The importance of miR-29 regulation has been 
addressed above, however the role of miR-29 family members in cancer is mainly determined 
by their respective target genes. As for all miRNAs, the identification and analysis of mir-29 
target genes in various tissues and malignancies is of obvious importance. Down-regulation of 
several important cellular proteins by miR-29 family members has been reported, among others 
the DNA-methyltransferases DNMT3A and B (Fabbri et al. 2007a; Garzon et al. 2009b; Hand et 
al. 2012). 1DNMTs are involved in DNA-methylation of CpG islands causing epigenetic silencing 
of the corresponding genes. 1Interestingly, DNMT3 is frequently up-regulated in various 
malignancies such as hepatoma, lung, prostate, colorectal and breast cancer (Eads et al. 1999; 
Patra et al. 2002; Girault et al. 2003; Saito et al. 2003; Kim et al. 2006), which emphasizes the 
importance of this link between DNMTs and reduced miR-29 expression. 
1Other miR-29 target genes include extracellular matrix proteins such as collagens, de-
regulation of which can favor cancer growth and progression (Sengupta et al. 2008; van Rooij 
et al. 2008; Maurer et al. 2010). Also the matrix-metalloprotease MMP-2 (Liu et al. 2010; Fang 
et al. 2011), elastin and fibrillin 1 (van Rooij et al. 2008), laminin γ1 (Sengupta et al. 2008) and 
integrin beta 1 (Liu et al. 2010) have been confirmed as miR-29 target genes, which all have 
recently been discussed in a review by Kriegel et al. and summarized by us (Kriegel et al. 2012; 
Schmitt et al. 2012a). An overview on miR-29 target genes is shown in the Appendix. 
In this PhD thesis, CDK6 was for the first time confirmed as a direct miR-29 target in melanoma 
cells (Fig. 36, Fig. 37) (Schmitt et al. 2012b). It was furthermore demonstrated that knockdown 
of CDK6 expression resulted in reduced proliferation (Fig. 39) as it had been shown for other 
types of cancer before (Ismail et al. 2011; Whiteway et al. 2012). This suggests, that the 
inhibition of proliferation which was observed in miR-29a/b-mimic-transfected cells may largely 
be mediated via CDK6. CDK6 plays a pivotal role in control of G1/S cell cycle transition (Fig. 42) 
(Grossel and Hinds 2006) and loss thereof is a common event in neoplastic growth (Musat et al. 
2004). The special relevance of CDK6 activity for melanoma growth is emphasized by the fact 
that the gene which encodes tumor suppressor p16INK4A (an inhibitor of CDK6 and CDK4), which 
is transcribed from the CDKN2A melanoma susceptibility locus, is deleted in about 50% of 
melanoma patients (Hussussian et al. 1994; Bennett 2008) (Table 2, Fig. 42). This supports the 
tumor-suppressing functions of miR-29a/b and attributes obvious novel functions to miR-29 as 
CDK6 inhibitor in melanoma. It moreover suggests the hypothesis that enhanced miR-29a/b 
levels, which were up-regulated in some primary melanoma patient samples could take over the 
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tumor-suppressing properties of p16INK4A by inhibiting CDK6, even if the locus is deleted, 
subsequently preventing uncontrolled cell cycle progression (Fig. 43).  
 
 
 
Fig. 42: Interplay of miR-29 and CDK6 
The p16INK4A gene is encoded within the CDKN2A melanoma susceptibility locus and shows often 
mutations or deletions in melanoma (indicated by the red bolt). The p16INK4A protein acts as negative 
regulator of cell cycle progression by inhibiting the activation of CDK6, which is complexed with Cyclin D1 
during G1/S-phase of the cell cycle and can phosphorylate RB. If unphosphorylated, RB binds to the 
transcription factor E2F, thereby hindering it from expression of genes necessary for G1  S cell cycle 
transition. The latter is accomplished as soon as Rb and E2F dissociate after phosphorylation of Rb via 
Cyclin D1/CDK4/CDK6. miR-29 inhibits CDK6 in melanoma cells and could therefore act as a tumor 
suppressor. For reasons of clarity, this illustration only focuses on miR-29/ p16INK4A /CDK6/RB/E2F and 
does not show the CDKN2A melanoma susceptibility locus as well as p14ARF, p53, CDK4 and other 
participating proteins. 
 
Noteworthy, CDK6 has also been demonstrated to be a direct miR-29 target in mantle cell 
lymphoma (Zhao et al. 2010), acute myeloid leukemia (Garzon et al. 2009b) and cervical cancer 
(Li et al. 2011). Interestingly, the anti-proliferative effects of IFN-γ in many cancers (Garbe and 
Krasagakis 1993; Kortylewski et al. 2004; Mori et al. 2008) which have also been confirmed 
here (Fig. 30) can be explained by an attenuated G1/S transition and may in part be explained 
by a G1 arrest involving down-regulation of G1/S cyclins (Cyclins A and E) and CDK2/4 
(Kortylewski et al. 2004). Here we add CDK6 as another cyclin-dependent kinase which is 
involved in IFN-γ-mediated anti-proliferative effects. These anti-proliferative activities of IFN-γ 
and miR-29 as well as a STAT1-dependent induction of miR-29 expression following IFN-γ 
stimulation have been demonstrated in melanoma cells within this PhD project (Fig. 18, Fig. 20, 
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Fig. 27, Fig. 28, Fig. 30). A series of proliferation assays including combined IFN-γ/miR-29a 
inhibitor treatment indicated that the growth-inhibitory effects of miR-29a could be partially 
responsible for IFN-γ-mediated inhibition of proliferation in melanoma cells which, however, 
could not be confirmed reliably (Fig. 31). This was probably due to too much stress for the cells, 
which were suffering from the double treatment (IFN-γ stimulation plus miR-29 inhibitor 
transfection). Concerning a connection between IFN-γ and melanoma, at a first glance it seems 
questionable how IFN-γ as a cytokine can come into direct contact with melanocytes located in 
the outer layer of the skin. However, this has been recently addressed in an elegant study by 
Zaidi et al. who have shown that IFN-γ-producing macrophages are recruited to the UV-exposed 
skin, where they stimulate proliferation and migration of melanocytes as well as expression of 
genes implicated in immunoevasion and survival. Furthermore, analysis of 27 human melanoma 
samples confirmed that 19 contained IFN-γ-expressing macrophages (Zaidi et al. 2011). A 
scheme summarizing the key events is shown in Fig. 43. 
 
miR-29 and its importance for interferon signaling. Other reports have previously 
connected individual miRNAs to interferon signaling: for example, miR-155 was shown to inhibit 
IFN-γ-signaling in CD4+ T-cells (Banerjee et al. 2010) and miR-29a suppressed interferon-α-
receptor expression in the thymic epithelium (Papadopoulou et al. 2012), implying that IFN 
signaling in general may actively partake in the regulation of miRNA expression levels in cells.  
Moreover, the role of cytokines as inducers of miRNA expression has recently been proposed in 
several studies and examples for cytokine-induced miRNA up- or down-regulation range from 
pro-inflammatory signaling molecules like TNF-α and IL1-β (Roggli et al. 2010; Ruan et al. 
2012) to different types of interferons, which are of special interest as they are central players 
in tumor-immune system interactions (Dunn et al. 2006; Diamond et al. 2011). Pedersen et al. 
analyzed changes of miRNA expression levels in human hepatoma cells after IFN-β stimulation, 
and interestingly found two miRNAs to respond already within 30 min to the cytokine (Pedersen 
et al. 2007), while others exhibited a retarded response as it was mostly observed in this 
project. We have shown here that also IL-27 as well as IFN-α/β induced miR-29.  
2The concept of ‘cancer immunosurveillance’, defined as the immunological protection of a host 
against the development of cancer, has evoked much interest during the last decade: Mediated 
by the host’s immune system, it is triggered by immune recognition of stress ligands or antigens 
expressed on transformed cells.  
IFN-γ has long been recognized for its crucial role in defense against viral and bacterial 
infections as well as in tumor control (Dunn et al. 2006; Schreiber et al. 2011) and this PhD 
project provides evidence for a novel IFN-γ - miR-29 connection via STAT1, which has also been 
confirmed in T-cells (Fig. 23). These findings can be embedded in the context of already known 
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connections between interferons and miRNAs and the important regulatory role for miR-29 in 
the adaptive immune system which has only been unraveled during the past two years, as was 
recently reviewed (Liston et al. 2012; Schmitt et al. 2012a). In accordance with our findings in 
melanoma and T-cells, Smith et al. showed that IFN-γ-induced STAT1 leads to enhanced miR-
29a~b-1 expression in murine and human T-cells with a maximal peak of miR-29a/b expression 
at 48-72h. Moreover, IFN-γ itself (Ma et al. 2011a; Smith et al. 2012) as well as the 
transcription factors T-bet (Steiner et al. 2011; Smith et al. 2012) and Eomes (Eomesodermin = 
T-box brain protein 2) (Steiner et al. 2011), known inducers of the IFN-γ-gene, have recently 
been confirmed to be direct miR-29 targets, thus suggesting a negative regulation of IFN-γ 
expression by miR-29. These findings indicate that a regulatory loop could exist with IFN-γ 
inducing miR-29 expression via STAT1 and miR-29 subsequently repressing IFN-γ directly as 
well as indirectly by down-regulating the IFN-γ-inducing transcription factors T-bet and Eomes 
(Fig. 43).  
In addition to the newly discovered properties in melanoma, the herein described IFN-γ/miR-29 
regulatory loop also reveals new perspectives for the understanding of immunological host 
defense: interestingly, miR-29a/29b have both been reported to target the HIV-protein nef 
(negative regulatory factor) (Hariharan et al. 2005), which down-regulates cell surface 
molecules like CD4 and MHCI and II (Kirchhoff et al. 2008), thereby enhancing HIV infectivity 
and replication. These findings imply another potential regulatory line of events: IFN-γ, secreted 
rapidly in response to HIV infection (Twigg et al. 1999), triggers transcriptional activation of 
miR-29 that in turn down-regulates nef and thus may participate in host control of early HIV 
infection. This connection has been explored in preliminary experiments and IFN-γ-induced up-
regulation of miR-29a and miR-29b could be confirmed in T-cells, which can be infected by HIV-
1 (data not shown). Together with these findings, the overall results obtained in this PhD thesis 
can be described as a regulatory circuit: IFN-γ, which is e.g. secreted by macrophages following 
diverse assaults such as infections or UV light induces a STAT1-dependent up-regulation of miR-
29, which in turn can down-regulate IFN-γ directly or indirectly via T-bet and Eomes (Fig. 43). 
This study extends the current knowledge on the miRNA family miR-29, adding a novel 
regulatory loop involving IFN-γ-mediated Jak/STAT signaling in melanoma cells. The newly 
discovered signaling pathway of IFN-γ → P-STAT1 → miR-29a/b → down-regulation of CDK6 → 
inhibition of tumor growth points at new connections between the immune system, miRNAs, cell 
cycle control and potentially tumorigenesis, which could lead to novel concepts for future 
therapeutic approaches. Currently, melanoma patient samples are characterized for the well-
known mutations in BRAF, NRAS and KIT genes (Berger et al. 2012) or newly discovered 
genetic changes in MITF (Yokoyama et al. 2012). To further tailor personalized and targeted 
therapy options in the future, evaluation of selected miRNA expression levels could be an add-
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on to the routine clinical analysis. Optimal would surely be the use as biomarkers from blood as 
a non-invasive approach. For miR-29 however, this could lead to difficulties because at least in 
cell lines and tissue samples, it exhibits expression changes in most cancer types, as reported 
above. 
 
 
 
Fig. 43: Involvement of the miR-29 family in multiple cellular processes 
2UV-radiation triggers the recruitment of macrophages to the skin, which secrete cytokines like interferon 
gamma (IFN-γ). 2By binding to its receptors, IFN-γ signals through the Jak/STAT pathway triggering 
subsequent activation of STAT1, which then binds to GAS-elements in the promoter region of target 
genes and initiates their transcription. 2IFN-γ-induced, STAT1-dependent up-regulation of miR-29 causes 
a down-regulation of CDK6, a novel miR-29 target gene in melanoma, which plays a crucial role in G1/S- 
cell cycle transition and thus growth control of cancer cells. The genetic locus of the cell cycle inhibitor 
p16INK4A shows often deletions or mutations in melanoma and its function (inhibition of CDK6) might be 
compensated by miR-29a/b. 2IFN-γ-activating transcription factors T-bet and Eomes and IFN-γ itself are 
also targeted by miR-29.  
 
Furthermore, in a pilot biomarker study on melanoma samples, miR-29 had not been detected 
among the de-regulated miRNAs (Leidinger et al. 2010). Concerning therapeutic treatment 
approaches, miR-29 application in form of miR-29-mimicking oligonucleotides seems to have an 
effect on tumor growth in vivo in some cancer types. For example Fabbri et al. validated the 
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down-regulation of DNMTs 3A and 3B by all miR-29 family members and demonstrated reduced 
tumor sizes in mice engrafted with lung cancer cells that had been transfected with single miR-
29 family members (Fabbri et al. 2007a). The same group reported similar findings for AML and 
suggested the use of synthetic miR-29b as therapeutic agent (Garzon et al. 2009b).  
This PhD project has deciphered a previously unknown regulatory pathway around the miR-29 
family with importance for melanoma development. With its often tumor-suppressing functions, 
the miR-29 family lends itself to be explored further in future cancer therapy. However, before 
this becomes a feasible treatment option, we need to acquire a more complete systems-
biological view of the complex interactions of the miR-29 family, including the regulation of miR-
29 gene expression with respect to transcription factors, complete characterization of 
melanoma-specific target genes, and the interplay of miR-29 with other miRNAs. 
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7 Perspectives 
To further validate the STAT1 regulation of the pri-29a/b1 cluster, the potential STAT1 binding 
sites should be experimentally verified by ChIP analysis in melanoma cells. For the investigation 
of the cellular consequences of miR-29 up- or down-regulation, we examined proliferation and 
apoptosis in miR-29-mimic or inhibitor-transfected melanoma cell lines. To further follow up on 
this functional role of miR-29 in cancer-related processes, more functional assays (such as 
migration and invasion assays and cell cycle analysis) could be performed. Knowing the precise 
mechanisms and functional role of the miR-29 family members would be a pre-requisite to 
evaluate potential therapeutic approaches involving this miRNA family. 
Apart from the miR-29 family, on which the main focus was set after the first year of the PhD 
project, many other interesting miRNAs turned out to be potentially STAT1-regulated. For 
example miRNAs from the miR-23/27/24 clusters (chromosome 9 and 19) seem interesting 
because of their distinct regulation patterns and could be investigated further.  
Although this PhD project focused on IFN-γ as a well-known inducer of a prominent STAT1-
response, we also tested IFN-α and IFN-β for stimulation in several initial setup experiments for 
their ability to induce STAT1-dependent miRNAs. Follow-up studies could be performed 
especially using IFN-α as IFN-α 2B is still used for treatment of melanoma patients, but not 
much is known about its regulatory role on miRNAs. It would be interesting to further 
investigate whether different STAT factors induce specific sets of miRNAs or whether there is 
redundancy between the various STATs. 
Moreover, we also examined the miR-29a/b expression in FFPE patient material. Unfortunately, 
only mature miRNAs can be amplified from the total RNA of these samples whereas 
amplification of mRNAs or primary miRNA molecules is generally not possible. Thus, it would be 
important to analyze the miR-29a/b level as well as the expression of the primary and precursor 
molecules of the miR-29 tumor-suppressor family in a larger number of patients, ideally from 
‘fresh-frozen’ nevi, primary and metastatic samples. CDK6-expression could also be addressed. 
In this context, our group recently started a project in which we examine melanoma tumour 
material together with the corresponding blood samples from the same patients. The aim of the 
project is to investigate a melanoma-connected miRNA signature in blood and it would be 
interesting to find out if members of the miR-29 family belong to those circulating miRNAs. 
Finally, the results obtained during the course of this PhD thesis around the newly discovered 
pathway along IFN-γ  P-STAT1  miR-29  CDK6 should also be investigated in other types 
of cancer. 
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9   Appendix  
Suppliers 
Table 8: Machines / laboratory equipment 
Machines / laboratory equipment Supplier 
µ clear 96 well plates  Greiner 
-80°C freezer New Brunswick Scientific 
Autoclave 5075 ELV Systec  
Bürker Cell Counting Chamber  Marienfeld Superior 
Cell culture hood Faster BHA48 
Cell culture incubator Hera cell 100 Heraeus 
Centrifuge Megafuge 1.0R Heraeus 
Centrifuges 5702 and 5415D Eppendorf 
Certomat MOII (shaker) Sartorius 
CFX96 and CFX384 Real-time System  
C1000 Thermal Cycler 
Bio-Rad 
Electrophoresis power supply Amersham Biosciences 
Incucyte Essen Bioscience 
Lia (luminescence) white 96 well plates Greiner 
LI-COR Odyssey® Infrared Imaging System LI-COR Biosciences 
Luminescence Reader Fluostar Optima BMG labtech  
Molecular Imager ChemiDocTM XRS+ Bio-Rad 
Nano Drop 2000c Spectrophotometer Thermo Scientific 
Nunclon 96 well plates Thermo Scientific 
SDS PAGE chamber Biometra 
Semi-dry blotting chamber TransBlot SD Cell Bio-Rad  
Thermocycler Gene Amp PCR System 9700 Applied Biosystems 
Thermomixer compact Eppendorf 
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Table 9: Chemicals, solutions, ladders and enzymes. 
Chemicals not mentioned in the table were obtained from well-established companies. 
 
Chemicals, solutions, ladders and enzymes     Supplier 
1kb Plus DNA ladder Invitrogen 
Oligo annealing buffer Promega 
Acrylamide Applichem 
Agarose FisherScientific 
Ampicillin Carl Roth 
APS Sigma-Aldrich 
BSA (blocking buffer) Applichem 
BSA (restriction digestion) New England Biolabs 
CIP (alcaline phosphatase, calf intestinal) New England Biolabs 
DEPC Sigma-Aldrich 
DNase I New England Biolabs 
dNTP´s Invitrogen 
Ethanol VWR 
Etoposide Sigma-Aldrich 
FCS (fetal calf serum) PAA 
G418 (Geneticin) Gibco 
Glutamine Lonza BioWhittaker 
H202 Sigma-Aldrich 
IL-27 (human) R & D Systems 
Interferons (human, α,β,γ) Peprotech 
iQ SYBR green supermix Bio-Rad 
Isopropanol VWR 
Jak Inhibitor I Calbiochem 
NucView 488 Caspase Biotium 
Penicillin/Streptomycin Lonza BioWhittaker 
Phusion DNA polymerase Finnzymes 
Precision Plus ProteinTM Standard Bio-Rad 
Restriction enzymes New England Biolabs 
SDS Carl Roth 
SYBR® Safe DNA gel stain Invitrogen 
T4 DNA ligase  New England Biolabs 
TEMED GE Healthcare 
TRIsure Bioline USA 
Trypan blue stain Lonza BioWhittaker 
Trypsine Lonza BioWhittaker 
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Table 10: Commercial kits, transfection reagents, buffers, media, membranes, consumables 
 
Kits Supplier 
Dual-luciferase reporter assay system Promega 
Fast Plasmid Mini extraction kit 5 prime 
innuPrep DOUBLE pure kit  Analytical Jena 
miRNeasy kit Qiagen 
miScript Reverse Transcription Kit Qiagen 
Nucleobond Xtra Midi Plus Macherey Nagel 
Nucleospin RNA extraction kit Macherey-Nagel 
RT2-FFPE extraction kit SA Bioscience 
Thermoscript RT-PCR system Invitrogen 
Transfection reagents, buffers and media 
1x passive lysis buffer Promega 
Buffers for restriction digestion New England Biolabs 
Dharmafect Duo Dharmacon 
DMEM Lonza BioWhittaker 
HiPerfect Qiagen 
RPMI Lonza BioWhittaker 
Melanocyte medium M2 PromoCell 
Membranes and consumables  
(Whatman) chromatography paper GE Healthcare 
1.5 ml safe-lock reaction tubes Eppendorf 
Cell culture dishes Greiner 
CRYO.S™-tubes Greiner 
nitrocellulose membrane GE Healthcare 
PCR Sealers Microseal ‘B’ Film Bio-Rad 
PVDF membrane Carl Roth 
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Buffers 
Table 11: Buffer Recipes 
  
Blocking buffer 10 % BSA in TBS-N 
 0.01 % NaN3 
  
Laemmli buffer 20 % glycerol 
 10 % ß-mercaptoethanol 
 4 % SDS 
 0.125 M Tris-HCl, pH 6.8 
 0.002 % bromophenol blue 
  
DNase I buffer 10mM Tris-HCl 
(New England Biolabs) 2.5mM MgCl2 
 10mM CaCl2 
  
Stripping buffer 60 mM Tris/HCl pH 6,7 
 2 % SDS 
 100 mM β-mercaptoethanol 
  
1x PBS NaCl 8 g/L 
 KCl 0.2 g/L 
 KH2PO4 0.24 g/L 
 Na2HPO4 14.4 g/L 
  
TSS solution 1 g tryptone 
 0.5 g yeast extract 
 0.5 g NaCl 
 10 g PEG3350 
 5 ml DMSO 
 5 ml 1 M MgCl2 
  
5x DNA loading buffer 5 ml 10 x TBE 
 3 ml glycerol 
 2 ml H2O 
 3 µg bromophenol blue 
  
ECL solution 20 ml ECL solution (stock) 
 6.6 µl 30 % H2O2 
 H2O2 to be added freshly 
 
ECL stock 
 
 
The ECL solution pCA was used  
as described before 
(Haan and Behrmann 2007) 
  
 100 mM Tris/HCl pH 8.8 
 2.5 mM luminol 
 0.2 mM p-coumaric acid 
  
LB medium 10 g tryptone (1 %) 
 5 g yeast extract (0.5 %) 
 10 g NaCl (1 %) 
 H2O up to 1000 ml  
 to be autoclaved prior to use 
  
LB agar (bacteria plates) 10 g tryptone (1 %) 
 5 g yeast extract (0.5 %) 
 10 g NaCl (1 %) 
 up to 1000 ml H2O 
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 add 15 g agar-agar (1.5 %) 
 to be autoclaved prior to use 
  
10x PBS, 2 l 160 g NaCl   
 4 g KCl 
 4.8 g KH2PO4 
 28.8 g Na2HPO4 
 H2O up to 2 l  
  
10x SDS running buffer, 2 l 60 g Tris (0.25 M)  
 288 g glycine (1.92 M) 
 In 1.5 l H2O 
 add 50 ml 20 % SDS 
 H2O up to 2 l  
  
4x separating gel buffer, 1 l 181.7 g Tris 
(1.5 M Tris/HCl, pH 8.8) add 800 ml H2O 
 add 20 ml 20 % SDS 
 H2O up to 1 l  
  
4x stacking gel buffer,  
500 ml 
250 ml 1 M Tris /HCl pH 6.3 
(1 M Tris/HCl, pH 6.8) 200 ml H2O 
 10 ml 20 % SDS 
 H2O up to 500 ml  
  
Stacking gel (3 %) 3 ml 4x stacking gel buffer 
 7.2 ml H2O 
 1.8 ml 30 % acrylamide 
 100 µl 20 % APS 
 20 µl TEMED 
  
Separating gel (10 %) 3.5 ml 4x separating gel buffer 
 5.8 ml H2O 
 4.7 ml 30 % acrylamide 
 105 µl 20 % APS 
 20 µl TEMED 
  
10x TBE buffer, 2 l 216 g Tris 
 110 g boric acid 
 14.6 g EDTA  
 H2O up to 2 l  
  
10x TBS-N, 2 l 200 ml 1 M Tris/HCl 7.4 
 540 ml 5 M NaCl  
 20 ml NP-40 (IGEPAL A-630)  
 H2O up to 2 l  
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Confirmed direct targets of the miR-29 family 
Table 12: 1Confirmed direct targets of the miR-29 family 
(as extracted from literature search in April 2012); L = luciferase assay, mRNA = mRNA level; iv = in vivo 
(mice), WB = western blot; b = mainly b 
Target  L mRNA WB 29 
a/b/c 
Ref description 
DNMT3A  
 
 
DNA-
methyltransferases 
√ √ √ 29b (Garzon et al. 2009b)  
 
 
Methyltransferases 
 √ iv  29a (Hand et al. 2012) 
√ √ √ 29abc (Fabbri et al. 2007a) 
DNMT3B √ √ √ 29b (Garzon et al. 2009b) 
 √ iv  29a (Hand et al. 2012) 
√ √ √ 29abc (Fabbri et al. 2007a) 
Bim Bcl-2-like 11 √   29b (Kole et al. 2011)  
 
 
 
Members of Bcl-2 
family and others 
involved in apoptosis 
Puma p53 up-regulated 
modulator of apoptosis 
√   29b (Kole et al. 2011) 
Bmf Bcl-2-modifying factor √   29b (Kole et al. 2011) 
Bcl-2 B-cell lymphoma 2 √ √ √ 29abc (Xiong et al. 2010) 
Mcl-1  
Myeloid cell leukemia 
sequence 1 
√ no 
effect 
√ 29b (Mott et al. 2007) 
√ √ √ 29abc (Xiong et al. 2010) 
  √ iv 29ac (Ye et al. 2010) 
Hrk Activator of apoptosis 
harakiri 
√   29b (Kole et al. 2011) 
N-Bak Bcl-2 homologous 
antagonist 
√   29b (Kole et al. 2011) 
Adamts18 ADAM 
metallopeptidase with 
thrombospondin type 1 
motif, 18 
√   29abc (Ugalde et al. 2011)  
 
 
 
 
 
 
 
 
 
 
Extracellular matrix 
proteins 
COL15A1  
 
 
 
 
 
 
 
Collagens 
√ √  29c (Sengupta et al. 2008) 
COL1A1 √   29c  
√ √  29b (Liu et al. 2010) 
COL1A1 √ √ & iv  29b (van Rooij et al. 2008) 
COL1A2 √   29c (Sengupta et al. 2008) 
√ √ & iv  29b (van Rooij et al. 2008) 
COL3A1 √ √  29c (Sengupta et al. 2008) 
√ √  √ 29abc (Maurer et al. 2010) 
√ √  29b (Liu et al. 2010) 
√ √ & iv  29b (van Rooij et al. 2008) 
COL4A1 √ √  29c (Sengupta et al. 2008) 
COL4A2 √   29c  
COL4A1 √ √  29b (Liu et al. 2010) 
COL5A1 √ √  29b  
COL5A2 √ √  29b  
COL5A3 √ √  29b  
COL7A1 √ √  29b (Liu et al. 2010) 
COL8A1 √ √  29b  
Eln1 Elastin √   29b (van Rooij et al. 2008) 
Fbn1 Fibrillin1 √   29b  
Itgb1 Integrin β1 √ √  29b (Liu et al. 2010) 
Laminin γ1  √ √  29c (Sengupta et al. 2008) 
MMP-2  
Matrix metalloprotease 
√  √ 29b (Fang et al. 2011) 
√ √  29b (Liu et al. 2010) 
Osteonectin/  
SPARC 
secreted protein, 
acidic, cysteine-rich 
√ √  29ac (Kapinas et al. 2009) 
T-bet T-box transcription 
factor TBX21 
√ √  29b (Steiner et al. 2011)  
 
 Eomes Eomesodermin = T-box √ √  29b (Steiner et al. 2011) 
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brain protein 2  
 
 
Transcription factors 
HBP1 HMG-box transcription 
factor 1 
√   29abc (Ugalde et al. 2011) 
Mycn V-myc 
myelocytomatosis viral 
related oncogene, 
neuroblastoma derived 
√   29abc (Ugalde et al. 2011) 
YY1 Yin-yang 1 √  √   
iv 
29abc (Wang et al. 2008) 
 √ √ 29ab (Li et al. 2011) 
cdc42 Cell division control 
protein 42 homolog 
√  √ 29abc (Park et al. 2009b)  
Cell cycle proteins 
cdk6 Cyclin-dependent 
kinase 6 
√ √ √ 29abc (Zhao et al. 2010) 
 √ √ 29ab (Li et al. 2011) 
Dusp2 Dual specificity protein 
phosphatase 2 
√   29abc (Ugalde et al. 2011) Phosphatases 
Ppm1d Protein phosphatase 
1D 
√   29abc (Ugalde et al. 2011) 
PTEN Phosphatase and 
tensin homolog 
  √ 29b (Wang et al. 2011a) 
√ √ √ 29a (Kong et al. 2011) 
FUSIP1 FUS-interacting serine-
arginine-rich protein 1 
√ √  29c (Sengupta et al. 2008) RNA splicing 
Ifi30 Gamma-interferon-
inducible lysosomal 
thiol reductase 
√   29abc (Ugalde et al. 2011) Thiol reductase 
IFNAR1 Interferon alpha 
receptor 1 
√   29a (Papadopoulou et al. 2012) Cytokine signaling 
IFN-γ Interferon γ √   29abc (Ma et al. 2011a) 
Igf1 Insulin-like growth 
factor 1 
√ √ iv  29a (Hand et al. 2012) 
Il1RAP Interleukin-1 receptor 
accessory protein 
√ √ iv  29a (Hand et al. 2012) 
LPL lipoproteinlipase √ √ √ 29a (Chen et al. 2011) Lipase 
Narf Nuclear prelamin A 
recognition factor 
√   29abc (Ugalde et al. 2011) Nuclear protein 
nef Negative regulatory 
factor 
√  √ 29ab (Ahluwalia et al. 2008) Virulence factor (HIV) 
√   29a (Nathans et al. 2009) 
p85 α Phosphatidylinositol 3-
kinase, regulatory 
subunit α 
√  √ 29abc (Park et al. 2009b) Kinase 
  √ 29a (Pandey et al. 2010) 
PDPN Podoplanin √ √ √ 29b (Cortez et al. 2010) Membrane 
glycoprotein 
PMP22 Peripheral myelin 
protein 22 
√ √ √ 29abc (Verrier et al. 2009) Major component of 
myelin 
 
Tcl-1 
 
T-cell leukemia 1 
 √ √ 29c (Stamatopoulos et al. 2009) Co-activator of Akt 
√  √ 29b (Pekarsky et al. 2006) 
  √ 29b (Anastasiadou et al. 2010) 
TDG G/T mismatch-specific 
thymine DNA 
glycosylase 
√ √  29c (Sengupta et al. 2008) Glycosylase 
TTP Tristetraprolin √  √ 29a (Gebeshuber et al. 2009) mRNA degradation 
p42.3  √ √ √ 29a (Cui et al. 2011) unknown 
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Abstract 
MicroRNAs (miRNAs) are ubiquitously expressed small, non-coding RNAs that negatively regulate gene 
expression at a post-transcriptional level. So far, over 1000 miRNAs have been identified in human cells and their 
diverse functions in normal cell homeostasis and many different diseases have been thoroughly investigated during 
the past decade. MiR-29, one of the most interesting miRNA families in humans to date, consists of three mature 
members miR-29a, miR-29b and miR-29c, which are encoded in two genetic clusters. Members of this family have 
been shown to be silenced or down-regulated in many different types of cancer and have subsequently been 
attributed predominantly tumor-suppressing properties, albeit exceptions have been described where miR-29s have 
tumor-promoting functions. MiR-29 targets expression of diverse proteins like collagens, transcription factors, 
methyltransferases and others, which may partake in abnormal migration, invasion or proliferation of cells and may 
favor development of cancer. Furthermore, members of the miR-29 family can be activated by interferon signaling, 
which suggests a role in the immune system and in host-pathogen interactions, especially in response to viral 
infections. In this review, we summarize current knowledge on the genomic organization and regulation of the miR-
29 family and we provide an overview of its implication in cancer suppression and promotion as well as in host 
immune responses. The numerous remarkable properties of these miRNAs and their often altered expression 
patterns might make the miR-29 family promising biomarkers and therapeutic targets for various diseases in future.  
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Introduction 
MicroRNAs (miRNAs) are a class of small non-coding RNA molecules (~22 nt), whose main function is the 
negative regulation of gene expression at a post-transcriptional level. MiRNAs are expressed in all cell types and are 
involved in the control of fundamental cellular processes such as differentiation, apoptosis, proliferation, cell death 
and others [1-3]. In recent years, many diseases including almost all types of cancer have been connected to aberrant 
expression of miRNAs [4, 5]. The rapidly growing interest in various aspects of miRNA biology is reflected by the 
constantly increasing number of publications since their first discovery in 1999. For the current version 18 of 
miRBase, entries for newly identified miRNAs have risen to 18226 representing 168 different species [6]. The 
biogenesis of miRNAs has been extensively and expertly reviewed elsewhere [7-10]. 
The present review focuses on the human miR-29, a very important miRNA family whose members are increasingly 
recognized as tumor suppressors in a variety of malignancies. Since their sequence was added to miRBase in 2001 
[11], the number of publications on one or more members of the human miR-29 family rose quickly to 
approximately 100. Members of the miR-29 family have been shown to be implicated in many divergent cellular 
processes like extracellular matrix homeostasis [12], collagen expression [13], insulin signaling [14], ageing [15] 
and others. The number of confirmed targets for one or more family members (Table 1) is constantly rising, 
including many different protein classes ranging from transcription factors [15, 16], viral proteins [17] to growth 
factors [18], structural cell components [13] and others. Noteworthy, miR-29 members have been connected to 
diseases other than cancer, for example myocardial infarction [13], diabetes [14] and atherosclerosis [19]. The 
implication of the miR-29 family in diseases like myocardial infarction and renal injury has recently been reviewed 
[20]. The topic of the present review, however, is the involvement of miR-29 in malignancies: in a recent overview 
article on miRNAs in cancer, the miR-29 family resided among the topmost cancer-associated miRNAs [21]. Here, 
we will focus on the role of miR-29 in cancer and discuss the transcriptional regulation of this miRNA family, it`s 
tumor suppressing functions, it`s potential as a therapeutic target in cancer therapy as well as it`s exceptional tumor 
promoting properties. Furthermore, we will summarize several interesting findings, which attribute immune- 
modulating functions to miR-29 family members and discuss their potential role in immune responses to viral 
infections.   
 
The miR-29 family: genomic organization and transcriptional regulation of expression 
The miR-29 family is among the earliest ones discovered [11] and is highly conserved among species [6]. In 
humans, it is encoded by two clusters, miR-29a~29b-1 (chromosome 7q32.3) and miR-29b-2~29c (chr 1q32.2) (Fig. 
1A). MiR-29a and miR-29b-1 (GenBank accession number EU154353) as well as miR-29c and miR-29b-2 (EU 
154351 and EU154352) are co-transcribed by RNA-polymerase II as a polycistronic primary transcript from the 
minus strand [22, 23], only encoded 649bp and 504bp apart from each other, respectively. With identical seed 
sequences, miR-29 family members share most of their predicted targets. MiR-29b-1/b-2 both have the same mature 
sequence and miR-29a and 29c mature sequences only differ by one nucleotide (Fig. 1A). All family members are 
ubiquitously expressed in healthy tissue (microRNA.org). Chang et al. were the first to experimentally characterize 
the primary transcripts of both miR-29 clusters in B-cells. They found that the miR-29a~29b-1cluster is produced 
from the last intronic region of the primary transcript in contrast to the miR-29b-2~29c cluster, which is processed 
from the last exon of its corresponding transcript [22] (Fig. 1B). Both clusters, miR-29a~29b-1 and miR-29b-2~29c 
are intergenic with no protein-coding genes in close proximity. Currently, there is no common agreement on the 
TSSs of miR-29 family members.  
Both clusters of the miR-29 family are intergenic and currently there is no common agreement on their TSSs. So far, 
14 different TSSs have been annotated for the miR-29 family, which are shown (numbered consecutively) in Figure 
1C. In large-scale computational analyses focusing on multiple genomic features, Saini et al. predicted many 
boundaries of intergenic miRNA transcripts, among others the miR-29b-2~29c clusters’ 5’ and 3’ends (TSSbc1, Fig. 
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1C)[24] and in a different report the ends of miR-29a~29b-1 (TSSab8, Fig. 1C) and miR-29b-2~29c (TSSbc2, Fig. 
1C)[25]. In a study on embryonic stem cells, Marson et al. collected coordinates of H3K4me3-enriched loci from 
several cell lines and predicted different TSSs for the miR-29 clusters miR-29a~29b-1 (TSSab2, Fig. 1C) and miR-
29b-2~29c (TSSbc6, Fig. 1C)[26]. Corcoran and colleagues annotated the TSS of the miR-29a~29b-1 cluster 
(TSSab1) based on a Pol II ChIP-chip of A549 lung epithelial cells using an own ‘Core Promoter Prediction 
Program’ [27]. A study by Chang et al. provided the first RACE-experiments for the miR-29 family, which 
annotated the 5’- and 3’-ends of both clusters in a human Burkitt lymphoma cell line (TSSab5 and TSSbc4, Fig. 
1C)[22]. Mott et al. confirmed the miR-29a~29b-1 TSS by RACE in H69 non-malignant cholangiocytes (TSSab4, 
Fig. 1C), albeit with a 131 bp downstream shift to the one described by Chang (TSSab5) [23]. Finally, even more 
TSS predictions can be extracted from the miRStart website [28] (TSSab3 and TSSbc5, Fig. 1C) or from the UCSC 
genome browser feature ‘SwitchGear genomics’ (www.switchgeargenomics.com) (TSSab6 & TSSab7 for 
miR29a~29b-1 and TSSbc3 for miR29b-2~29c, Fig. 1C). 
Transcriptional regulation is thought to be the main mechanism for regulation of miRNA expression [7], but other 
controlling processes including epigenetic silencing [29] and different turnover or processing times [10] have also 
been described. Identifying the transcription factors, which regulate miRNAs or their respective host genes, in the 
case of intragenic miRNAs, is crucial for understanding regulation and different miRNA expression patterns in a 
healthy versus diseased cellular context. In a recent review by Kriegel et al. [20], known transcription factor binding 
sites in the promoter region of the miR-29 family have been summarized. The vast majority of publications report a 
down-regulation of miR-29 in cancer [30-32], which will be discussed in more detail below (see also Table 2). To 
some extent, decreased miR-29 levels can be explained by transcriptional repression and an overview of the current 
knowledge about miR-29 regulation is given in Figure 2.  
Although most recent publications report a clear down-regulation of the miR-29 family members in cancer, 
especially with progression, some studies have shown opposite effects with miR-29 being transcriptionally up-
regulated. The transcription factors CEBPA (CCAAT/enhancer-binding protein alpha), p53, SMAD3 (mothers 
against decapentaplegic homolog 3) and canonical Wnt-signaling have all been shown to activate the expression of 
miR-29 family members in various cell types [12, 15, 32-35] (Fig. 2A). In this context, we have recently observed a 
profound and robust up-regulation of miR-29 by the STAT1 (signal transducer and activator of transcription) 
transcription factor induced by interferon γ (IFN-γ) signaling in melanoma and T-cells (dashed box, Fig. 2A). These 
results will be further discussed below. Taken together, depending on the cellular context, several transcription 
factors directly up-regulate or repress the expression of the miR-29 family members and these data are crucial for 
further deciphering miR-29 regulatory networks (Fig. 2A).  
 
 
Involvement of the miR-29 family in cancer 
The predominantly tumor-suppressing properties of miR-29 in solid tissue cancers. Since their discovery, 
miRNAs have been implicated in malignancies and many studies on miRNA deregulation in all types of cancer have 
been carried out. Like protein-coding genes, miRNAs can be classified as being either ‘oncogenic’ or ‘tumor-
suppressive’. Mir-21, one of the first known ‘oncomirs’, has elevated expression levels in many human cancers [36] 
while the miR-29 family or its single members have been shown to be down-regulated in glioblastoma [37], lung 
cancer [30], prostate cancer [38], colon cancer [39], chronic lymphocytic leukemia [31] and many other 
malignancies (Table 2).  
Tumor-suppressor functions have clearly been demonstrated in glioblastoma cells, where the introduction of miR-
29b-mimicking RNA-duplexes was found to induce apoptosis and reduction of proliferation and invasion [37]. In a 
study involving a RMS (rhabdomyosarcoma) xenograft model, it was observed that re-expression of otherwise 
silenced miR-29 inhibited tumor growth in mice [40]. Nude mice showed reduced tumor formation by HCC 
(hepatocellular carcinoma) cells after transfection with miR-29b [41] and the same group later described that miR-
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29b inhibited the invasive potential of HCC cells, as well as angiogenesis and metastasis in HCC-transplanted nude 
mice [42]. Muniyappa et al. focused on a more general approach and compared miR-29a expression levels in various 
cancer cell lines with divergent invasive capacity [43]. A higher miR-29a expression was correlated with a lower 
invasiveness of NSCLC (non-small-cell lung carcinoma) cell lines and over-expression of miR-29a resulted in anti-
invasive and anti-proliferative effects in lung and pancreatic cancer cells [43].  
In contrast to the majority of studies highlighting tumor-suppressive properties, opposing expressing patterns and 
roles seem to exist in breast cancer and primary melanoma. Wang et al. reported an up-regulation of miR-29b in 
highly metastatic breast cancer cells in comparison to low-metastatic ones and showed that miR-29b promotes 
migration and invasion and increases resistance to apoptosis. However, healthy control tissue or primary tumor 
material for determining basal expression levels were not analyzed [44]. Similar to this study, Gebeshuber and 
colleagues recently reported enhanced levels of miR-29a in patients with invasive breast carcinomas in comparison 
to benign samples from patients with non-invasive hyperplasia [45]. MiR-29a transfection into mice had no effect 
on cell proliferation but resulted in enhanced lung metastasis. It remains to be clarified why Wang et al. only 
detected miR-29b while Gebeshuber et al. exclusively reported an up-regulation of miR-29a with neither group 
seeing differential regulation of the other miRNA in the same tissue. Nevertheless, both studies provide evidence 
that miR-29 may indeed have tumor-promoting traits in breast cancer and to our knowledge a down-regulation of 
miR-29 in breast cancer has not been reported so far. Interestingly and in line with elevated levels of miR-29 in 
breast cancer, we have recently made similar observations in melanoma patient samples: both miR-29a and 29b 
were up-regulated, however only in primary melanoma relative to healthy nevi while expression levels in metastatic 
melanoma were decreased even below the levels scored in nevi [46]. Surprisingly, a recent study on cutaneous 
melanoma reported unchanged miR-29a and-29b expression levels while miR-29c was down-regulated in metastatic 
melanoma in comparison to primary tumor samples [47] but again no healthy control tissue or nevi were included. 
Apart from these noteworthy exceptions in primary melanoma and breast cancer, miR-29 family members have 
consistently and predominantly been reported to be down-regulated and to assume tumor-suppressive properties in 
solid tissue cancers.  
 
Properties of the miR-29 family in hematological malignancies. In acute myeloid leukemia (AML), most studies 
have demonstrated a down-regulation of miR-29 in patient material or malignant cell lines. Eyholzer et al. reported a 
suppression of miR-29b expression in AML patient-derived bone marrow samples and showed that the whole miR-
29a~29b-1 cluster was blocked in the disease [32]. They reasoned that this was due to the disruption of CEBPA-
expression in AML and could further prove that the CEBPA transcription factor indeed mediates miR-29b 
expression. In contrast to this, a recent study suggested oncogenic properties of miR-29a in AML. Purified leukemia 
stem cell (LSC)-blast populations of AML patients had up-regulated levels of miR-29a and over-expression of miR-
29a led to the acquisition of the self-renewal capacity of myeloid progenitors and subsequently to the development 
of a myeloproliferative disorder, which progressed to AML in a mouse model [48]. A possible explanation for the 
contradictory results on miR-29 in AML could be the different clinical sample and cell types that were used: patient-
derived bone marrow [32] or PBMCs [49], versus purified human LCSs [48]. 
In addition to acute leukemia, miR-29 has been implicated in chronic leukemia, mainly CLL. Again, most 
publications describe a down-regulation of miR-29 members in CLL patients: miR-29a, -b and –c levels were 
reduced in lymphocytes of CLL-patients and miR-29c was also down-regulated in PBMCs [31, 50-52]. In this 
context, reports by Santanam and colleagues emphasized how crucial adequately controlled samples are, especially 
when comparing miRNA expression levels. Interestingly, they reported that miR-29 decreased when expression 
levels from aggressive CLL samples were normalized to samples from indolent CLL [52] while an up-regulation of 
miR-29 was detected when indolent and aggressive CLL were compared to normal CD19+ lymphocytes [53]. 
Furthermore, the group hypothesized that miR-29 can contribute to the pathogenesis of CLL. This was demonstrated 
in miR-29a~b-1 –transgenic mice, which developed a CLL phenotype in comparison to wild-type mice indicating an 
oncogenic potential for miR-29 in chronic leukemia after over-expression [53].  
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Taken together, a substantial body of evidence on the role of miR-29 and its family members in human malignancies 
has been collected over recent years, spanning many different solid tumors as well as several types of leukemia. 
Like other miRNAs, miR-29 appears to have an important role in development, progression and control of cancer 
and many of the cited studies also addressed the potential of miR-29 in disease-associated prognosis and therapy. 
Most studies corroborate that miR-29 mainly exerts tumor-suppressive properties, which are subsequently lost when 
it is silenced in cancer and the cellular homeostasis is changed depending on the functional role of the target genes 
in the respective type of cancer (Tables 1 & 2). Potentially opposing roles and up-regulated expression levels have 
been reported for AML, primary melanoma and breast cancer. Nevertheless, differential expression patterns of miR-
29 family members in many cancer types offer some potential for the development of targeted therapy once the 
downstream target genes have been clearly identified.  
 
 
Selected miR-29 target genes and their potential involvement in cancer suppression. Beyond assessing the 
expression levels of the miR-29s in different cancer types, it is crucial to identify their target genes in order to 
decipher cancer-associated cellular pathways and networks that might be regulated by miR-29. Table 1 summarizes 
experimentally confirmed miR-29 targets with potential functional roles in various aspects of cancer biology.  
Several groups have independently established that miR-29 family members target and thus down-regulate the 
methyltransferases DNMT3A and DNMT3B (DNA-methyltransferases) [18, 54, 55] (Table 1). DNMTs are 
involved in DNA-methylation of CpG islands causing epigenetic silencing of the corresponding genes. Hyper-
methylation is a normal regulatory mechanism, but can be fatal if tumor suppressor genes are silenced, which has 
been shown for p16INK4A (CDKN2A, cyclin-dependent kinase inhibitor 2A) in lung carcinoma cells [56]. 
Interestingly, DNMT3 is frequently up-regulated in various malignancies such as hepatoma, lung, prostate, 
colorectal and breast cancer [57-61]. An inverse correlation was shown for miR-29c and DNMT expression levels in 
cutaneous melanoma with high expression of miR-29c and low expression of DNMTs in primary melanoma and the 
reverse situation in metastasis [47]. Fabbri et al. validated the down-regulation of DNMTs 3A and 3B by all miR-29 
family members [55] and demonstrated reduced tumor sizes in mice, engrafted with lung cancer cells that had been 
transfected with single miR-29 family members. These important findings provide first indications towards the 
potential miR-29s might have in therapeutic treatment approaches of cancer.  
Another important group of miR-29 targets with a role in cancer progression is the Bcl-2 family (B-cell lymphoma 
2), which encodes genes involved in the regulation of apoptosis [62]. Interestingly, the pro-apoptotic members Bim 
(Bcl-2 like 11), Puma (p53 up-regulated modulator of apoptosis) and Hrk (activator of apoptosis harakiri) as well as 
the anti-apoptotic n-BAK (Bcl-2 homologous antagonist) and Bmf (Bcl-2-modifiying factor) can all be targeted by 
miR-29 [63]. Among the most prominent members, Bcl-2 itself and Mcl-1 (myeloid cell leukemia sequence 1), both 
anti-apoptotic, have been experimentally validated to be direct miR-29 targets in multiple cell types [41, 64, 65]. All 
these studies suggest that decreased expression of miR-29 leads to an up-regulation of Bcl-2 and Mcl-1 and 
consequently to protection of cells from apoptosis, which in turn promotes tumorigenesis. 
Other miR-29 target genes include extracellular matrix proteins, de-regulation of which can favor cancer growth and 
progression. Confirmed miR-29 target genes include collagens [13, 66, 67], the matrix-metalloprotease MMP-2 [42, 
68], elastin and fibrillin 1 [13], laminin γ1 [66] and integrin beta 1 [68], which have recently been summarized in a 
review [20]. Although many targets with distinct functions in numerous cellular processes and different cells types, 
tissues and diseases have been put forward, no ‘universal’ miR-29 target gene seems to exist, which is de-regulated 
in most cancers (Table1). Depending on the cellular context, not all targets are similarly found to be down-regulated 
after mimic treatment. For example, down-regulation of the methyltransferases DNMT3A and DNMT3B was shown 
in AML, lung cancer and liver tissue [18, 54, 55], but could not be confirmed in nasopharyngeal carcinomas [69]. 
Nevertheless, cell-type specific target genes may offer the possibility for a more precise and targeted therapeutic 
intervention by miRNAs with potentially less side effects. 
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MiR-29: a player in immunological host defense? 
 
Apart from direct regulation affecting biogenesis or processing speed mediated by genetic factors and epigenetic 
silencing, miRNAs have also been shown to be indirectly regulated by cytokines like interferons [70]. Cytokine 
signalling plays a pivotal role in the immune system by communicating cellular responses to inflammation and 
infections [71]. Nearly all cell types can come into contact with cytokines such as IFN-γ, which is mainly secreted 
by activated T and NK cells and represents the most important Th1 (T helper type 1) –cytokine in innate and 
adaptive immunity to infection [72]. Generally, cytokines activate transcription factors, which subsequently lead to 
transcription of target genes including those encoding miRNAs. IFN-γ primarily triggers the JAK/STAT pathway 
resulting in a STAT-mediated transcriptional activation of target genes. The importance of interactions between 
miRNAs and STAT transcription factors has very recently been summarised in a review by Kohanbash and Okada 
[73]. In this context, we have found that miR-29a/b was specifically and dose-dependently up-regulated after IFN-γ 
stimulation of melanoma and T-cells. Using a STAT1 dominant-negative control cell line as well as specific Jak 
inhibitors, we have established that this activation is mediated by STAT1 (manuscript in preparation). Along that 
line, we have also investigated the dynamic regulation of miRNA expression profiles following IFN-γ-induced gene 
transcription and observed temporal changes in levels of about 10% of all miRNAs including miR-29a and -29b in 
response to STAT1-activation [74].  
Other reports have previously connected individual miRNAs to interferon signaling: for example, miR-155 was 
shown to inhibit IFN-γ-signaling in CD4+ T-cells [75] and miR-29a suppressed interferon-α-receptor expression in 
the thymic epithelium [76], implying that IFN signaling in general may actively partake in the regulation of miRNA 
expression levels in cells. Recently, two excellent publications provided further insights into the implication of the 
miR-29 family in immune responses. Ma et al. [77] showed that miR-29a and -29b were down-regulated in IFN-γ-
secreting T-cells. Furthermore, they observed a down-regulation of miR-29a and -29b and an up-regulation of IFN-γ 
in activated NK cells and T-cells following infection of mice with Listeria monocytogenes or Mycobacterium bovis. 
By luciferase reporter gene assays, IFN-γ was confirmed to be a direct target of all miR-29 family members and this 
suggests an immunosuppressive role for miR-29 in bacterial infections with the specific down-regulation of IFN-γ 
by miR-29.These findings were confirmed by an experiment in mice transgenically expressing a ‘sponge’ target to 
compete with endogenous miR-29 targets [16]. These mice showed increased Th1-responses and better resistance to 
mycobacteria. Interestingly, Steiner et al. proved that the transcription factors T-bet and Eomes (Eomesodermin = T-
box brain protein 2), both of which are known inducers of IFN-γ production in helper T-cells, were directly targeted 
by miR-29a and -29b, thus facilitating an immune response to intracellular pathogens [16]. Both publications 
suggest that miR-29 negatively regulates IFN-γ production. As mentioned above, we generally see a clear induction 
of miR-29 expression following IFN-γ stimulation and have shown this regulation to be STAT1-dependent. These 
findings indicate that a regulatory loop exists with IFN-γ inducing miR-29 expression via STAT1 and miR-29 
subsequently repressing IFN-γ directly as well as indirectly by down-regulating the IFN-γ-inducing transcription 
factors T-bet and Eomes (Figure 2B).  
Apart from immune responses to bacterial infection, the miR-29 family has also been implicated in immune 
reactions to viral infections. Cellular miRNAs can down-regulate viral protein-coding genes and partake in host-
pathogen interactions, supporting antiviral mechanisms of the host defense. For example, interferon-β rapidly 
elevates the expression of several cellular miRNAs in Hepatitis C-infected cells and in turn, some human miRNAs 
like miR-196 and miR-448 down-regulate viral genomic RNA and viral replication is controlled and reduced [70]. 
For EBV (Epstein-Barr virus) it was reported that EBV-encoded LMP1 (latent membrane protein 1) suppresses the 
Tcl-1 (T-cell leukemia 1) oncogene through miR-29b [78] (Fig. 2B). More interestingly, several studies have 
connected the miR-29 family to HIV. Hariharan et al. reported that miR-29a/29b targets the HIV-nef protein 
(negative regulatory factor) [79]. Nef is a membrane-associated accessory protein able to down-regulate cell-surface 
molecules like CD4, MHCI and II, which enhances virion infectivity and stimulates viral replication [80]. By miR-
29-induced reduction of nef levels, overall protein expression and HIV-1 replication was slowed down [17][patent 
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US 2007/0087335 A1; Brahmachari et al.]. Nathans et al. confirmed the ability of miR-29a to bind to the HIV-1 
3’UTR and reported a high conservation of the otherwise variable nef sequence, which is targeted by the miRNA 
seed region. They found that miR-29a is highly abundant in HIV-infected T-lymphocytes and HIV-1 infection 
induced elevated miR-29a expression in HEK 293T cells. Mimicking miR-29a efficiently suppressed HIV-
production and infectivity, confirming miR-29a as a cellular repressor of HIV-1 mRNA expression. Also, miR-29a 
enhanced HIV-1 mRNA interactions with P bodies and the RISC (RNA-induced silencing complex) proteins 
resulting in an accumulation of viral mRNA at P bodies for translational suppression and thereby reducing the 
infectivity of HIV [81]. It is noteworthy that in contrast to the reports where induced expression of miR-29 after 
HIV-infection and a potential antiviral role of the miR-29 family have been demonstrated, two other publications 
came to different conclusions, both reporting a down-regulation of miR-29 in HIV-infected PBMCs [82, 83] and 
patients [83]. Nevertheless, accumulating evidence suggests that miR-29 could be useful for the control of HIV 
infection at early stages [17, 81], however, the high variability and quick mutation rates of the HIV-genome might 
hamper therapeutic interventions with chemical or miRNA-based drugs.  
 
 
Potential for cancer diagnosis and therapy 
 
Mir-29: potential predictive biomarkers. Several studies have already described the potential of miR-29 family 
members as biomarkers for a variety of malignancies and assessment of miR-29 expression in serum or in various 
types of cancer-derived tissues could contribute to predictions about disease onset and prognosis. In chronic 
leukemia, expression of miR-29 family members discriminated between CLL samples with good and bad prognosis: 
in a patient group with unmutated IgVH (rearranged immunoglobulin heavy-chain variable region gene) and high 
expression of ZAP-70 (70kDa zeta-associated protein), both of which are known predictors of poor prognosis in 
CLL, miR-29a, -29b-2 and -29c had low expression levels and were included in a signature group of 13 miRNAs as 
potential prognostic markers for CLL [31]. In agreement with that, Stamatopulous and colleagues showed that miR-
29c levels significantly decreased in subjects with poor prognosis. Furthermore, miR-29c levels could predict 
individual treatment-free survival and overall survival in a cohort of 110 CLL patients with long-term follow-up 
[50] and likewise, low expression of miR-29c and miR-29b was associated with disease progression in some CLL 
cases [51]. Similarly, Wang et al. reported a down-regulation of miR-29a in PBMCs of AML patients compared to 
healthy individuals [84]. 
MiR-29 was also suggested as a prognostic marker for hepatocellular carcinoma as it was frequently down-regulated 
in HCC (hepatocellular carcinoma), which correlated with a worse prognosis for those patients [41]. A decreased 
expression level of the miR-29 family was furthermore associated with a shorter survival of patients with MCL 
(mantle cell lymphoma) [85]. In colorectal cancer (CRC), serum miR-29a was found to be significantly higher 
expressed in patients suffering from advanced CRC or colorectal liver metastasis than in CRC patients without 
metastasis [86] and very recently, Weissmann-Brenner et al. have shown that high expression of miR-29a was 
associated with longer disease-free survival of stage II CRC patients  [87]. Likewise, miR-29a was significantly 
over-expressed in serum from ovarian cancer patients [88]. For a variety of cancers, the miR-29 family holds 
promise to become a prognostic and predictive biomarker, however, detection protocols, reference tissues or blood 
samples, and appropriate controls need to be standardized in order to ensure reliable and correct measurements of 
miRNA levels. This is even more important for detecting and distinguishing members of the miR-29 family, whose 
expression changes may potentially be small and who share substantial sequence homology.   
Mir-29 as therapeutic tools or targets. Beside their potential function as non-invasive biomarkers and prognostic 
factors for disease outcome, a few research groups have begun to delineate miR-29’s capacity as therapeutic agents, 
for example in leukemia treatment. A common issue in the development of leukemia is aberrant DNA hyper-
methylation, which silences tumor suppressor genes involved in hematopoiesis [89, 90]. As described above, studies 
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by Garzon and Fabbri showed that miR-29 family members target DNA methyltransferases and thus induce global 
hypo-methylation in lung cancer and AML, leading to a reduction of tumor growth in nude mice [54, 55]. The same 
group also described a positive correlation between high levels of miR-29b and improved clinical responses to 
Decitabine, a DNMT-inhibitor used for treatment of AML patients [91]. Both Decitabine and miR-29 have hypo-
methylating effects. Thus, the authors suggested that miR-29b levels might be useful in predicting potential 
Decitabine responses in AML patients. Furthermore, synthetic miR-29b could be used as a therapeutic DNA hypo-
methylation agent for leukemic blasts because over-expression of miR-29b has been shown to reduce global DNA-
methylation, thus inducing apoptosis [54]. Since miR-29 family members mainly exhibit tumor-suppressive 
functions and are often down-regulated in human cancers, re-introduction of synthetic miR-29 at specific tumor sites 
could become a possible treatment option. Vice versa, anti-miR-29 oligonucleotides could be applied in rare cases, 
where one or more miR-29 family members are over-expressed in human cancers (Table 2), similar to applications 
of other antagomirs, which are currently under investigation [92]. However, several issues need to be assessed 
before miR-29 or other miRNAs can be used in clinical applications, the most important of which are efficient 
delivery of miRNAs to target tissues, their potential side effects and their stability[93, 94] . 
In this context, it has been shown that miRNA stability can range from several hours [95] to weeks [96]. Xiong et al. 
observed that transfected miR-29b duplexes were only stable for 4-7 days in HepG2 cells [41] and were not 
detectable any more four weeks after transfection in nude mice. In HeLa cells, synthetic miR-29b was already 
degraded after several hours [97]. Using artificial RNA-duplexes in the same cell line, Zhang et al. also found that 
miR-29 family members decay very rapidly, after 8-12 hours [98]. The question of half-lives for endogenous as well 
as synthetic miRNAs in the cells is important and will influence if and how applicable certain groups of miRNAs are 
for future use in clinical interventions.  
 
 
Summary and Conclusions 
 
The increasing number of publications on miR-29 family members emphasizes their important role in many cellular 
processes of cancer biology. The family is one of the first ones described and is highly conserved among species. 
Several studies have contributed to identifying the transcription start sites and managed to narrow down a possible 
region, at least for the miR-29a~29b-1 cluster. MiR-29 targets and down-regulates a diverse set of mRNAs with 
often survival-promoting properties and by doing so, miR-29 can reduce tumor growth and proliferation. In 
concordance with this, the vast majority of studies reports a down-regulation of miR-29 in different cancers and 
clearly assigns tumor-suppressive functions to this microRNA family. Future studies will have to establish the 
reasons for some seemingly tissue-specific exceptions, where miR-29 has tumor-promoting properties. The 
advances in clinical applications of antagomirs and mimics (miR replacement therapy) certainly hold potential for 
future treatment of diseases where miR-29 and others miRNAs are deregulated. However, the use of miRNAs as 
drugs is still in its infancy and questions about delivery, stability and potential side effects remain to be solved 
before a safe and effective treatment options will become available.  
Several groups have begun to decipher the role of miR-29 in immune responses to viruses and bacteria and have 
described opposing immune-modulating properties against intra- or extracellular pathogens. More studies including 
a wider range of different pathogens will be necessary to specify the functional role of miR-29 in immune responses 
to infectious agents.  
Another very interesting connection has been established between the miR-29 family, IFN-induced Jak/STAT 
signaling and as such immune responses to pathogens or potentially to cancer. Interferons are key coordinators of 
interactions between tumors and the immune system. Tumor-infiltrating immune cells can secrete cytokines that 
could trigger transcriptional up-regulation of miR-29 family members, which in turn down-regulate potentially 
oncogenic mRNAs. The concept of “immunoediting” has been introduced to explain observable anti-tumor 
responses that are mainly mediated by interferons as well as opposing effects where the immune system appears to 
promote cancer growth [99, 100]. STAT transcription factors, which are activated by cytokine signaling, have long 
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been recognized as important mediators of the crosstalk between immune and cancer cells [101, 102]. Considering 
our and other recent findings [103], we argue that miRNAs, and especially miR-29 could assume important 
functions in coordinating interferon-induced responses to suppress transformation into cancer cells: IFN-γ can 
specifically up-regulate miR-29, which in turn may suppress target genes involved in tumorigenesis. In this context, 
it will be interesting to investigate whether some cell types that have generally low levels of miR-29 may have 
acquired resistance to interferons, which would normally drive transcription of these miR genes. MicroRNAs in 
general and miR-29 in particular might be part of the sought after intercellular targets that are mediating the 
interferon-induced immune response to cancer.     
Many recent studies corroborate on the potential use of the miR-29 family as predictive biomarkers for early 
diagnosis of malignancies and other diseases, either alone or in a panel of validated disease-specific miRNAs. 
However, expression levels have to be assessed more accurately in larger patient cohorts paying attention to 
appropriate controls, standardized techniques and amplification protocols, before miRNAs can routinely be used as 
diagnostic tools [104, 105]. Some progress has also been made towards the use of synthetic miRNAs as therapeutic 
agents or tools [106]. With its often tumor-suppressing functions, the miR-29 family lends itself to be explored 
further in future cancer therapy. Once important issues of miR delivery and stability are solved, replacement therapy 
with synthetic miR-29 in cancers where expression levels are low or absent can be envisaged. However, before this 
becomes a feasible treatment option, we need to acquire a more complete systems-biological view of the complex 
interactions of the miR-29 family, including characterization of disease-specific target genes, transcription factors, 
and their interplay with other miRNAs.  
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Table 1: Confirmed direct targets of the miR‐29 family 
Target    L  mRNA  WB  29 a/b/c  Ref  description 
DNMT3A 
 
 
 
DNA‐methyltransferases 
√ √ √ 29b [54]   
 
 
Methyltransferases 
√ iv 29a [18] 
√ √ √ 29abc [55] 
DNMT3B 
√ √ √ 29b [54] 
√ iv 29a [18] 
√ √ √ 29abc [55] 
Bim  Bcl‐2‐like 11  √ 29b [63]   
 
 
 
Members of Bcl‐2 family 
and others involved in 
apoptosis 
Puma 
p53 up‐regulated modulator of 
apoptosis 
√ 29b
[63] 
Bmf  Bcl‐2‐modifying factor √ 29b [63] 
Bcl‐2  B‐cell lymphoma 2  √ √ √ 29abc [41] 
Mcl‐1 
 
Myeloid cell leukemia 
sequence 1 
√ no 
effect 
√ 29b
[64] 
√ √ √ 29abc [41] 
√ iv 29ac [65] 
Hrk  Activator of apoptosis harakiri √ 29b [63] 
N‐Bak  Bcl‐2 homologous antagonist √ 29b [63] 
Adamts18 
ADAM metallopeptidase with 
thrombospondin type 1 motif, 
18 
√ 29abc
[15] 
 
 
 
 
 
 
 
 
 
 
 
Extracellular matrix 
proteins 
COL15A1   
 
 
 
 
 
 
 
Collagens 
√ √ 29c [66] 
COL1A1 
√ 29c
√ √ 29b [68] 
COL1A1  √ √ & iv 29b [13] 
COL1A2 
√ 29c [66] 
√ √ & iv 29b [13] 
COL3A1 
√ √ 29c [66] 
√ √  √ 29abc [67] 
√ √ 29b [68] 
√ √ & iv 29b [13] 
COL4A1  √ √ 29c [66] 
COL4A2  √ 29c
COL4A1  √ √ 29b [68] 
COL5A1  √ √ 29b
COL5A2  √ √ 29b
COL5A3  √ √ 29b
COL7A1  √ √ 29b [68] 
COL8A1  √ √ 29b
Eln1  Elastin  √ 29b [13] 
Fbn1  Fibrillin1  √ 29b
Itgb1  Integrin β1  √ √ 29b [68] 
Laminin γ1    √ √ 29c [66] 
MMP‐2 
 
Matrix metalloprotease 
√ √ 29b [42] 
√ √ 29b [68] 
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Osteonectin/  
SPARC 
secreted protein, acidic, 
cysteine‐rich 
√ √ 29ac
[35] 
T‐bet 
T‐box transcription factor 
TBX21 
√ √ 29b
[16] 
 
 
 
 
 
 
Transcription factors 
Eomes 
Eomesodermin = T‐box brain 
protein 2 
√ √ 29b
[16] 
HBP1 
HMG‐box transcription factor 
1 
√ 29abc
[15] 
Mycn 
V‐myc myelocytomatosis viral 
related oncogene, 
neuroblastoma derived 
√ 29abc
[15] 
YY1 
Yin‐yang 1 
√ 
√   
iv 
29abc
[40] 
  √ √ 29ab [107] 
cdc42 
Cell division control protein 42 
homolog 
√ √ 29abc
[34] 
 
Cell cycle proteins 
cdk6 
Cyclin‐dependent kinase 6 √ √ √ 29abc [85] 
√ √ 29ab [107] 
Dusp2 
Dual specificity protein 
phosphatase 2 
√ 29abc
[15] 
Phosphatases
Ppm1d  Protein phosphatase 1D √ 29abc [15] 
PTEN 
Phosphatase and tensin 
homolog 
  √ 29b [44] 
√  √ √ 29a [108] 
FUSIP1 
FUS‐interacting serine‐
arginine‐rich protein 1 
√ √ 29c
[66] 
RNA splicing
Ifi30 
Gamma‐interferon‐inducible 
lysosomal thiol reductase 
√ 29abc
[15] 
Thiol reductase
Ifnar1  Interferon alpha receptor 1 √ 29a [76]  Cytokine signaling
IFN‐γ  Interferon γ  √ 29abc [77] 
Igf1  Insulin‐like growth factor 1 √ √ iv 29a [18] 
Il1RAP 
Interleukin‐1 receptor 
accessory protein 
√ √ iv 29a
[18] 
LPL  lipoproteinlipase  √ √ √ 29a [19]  Lipase
Narf 
Nuclear prelamin A 
recognition factor 
√ 29abc
[15] 
Nuclear protein
nef 
Negative regulatory factor √ √ 29ab [17]  Virulence factor (HIV)
√ 29a [81] 
p85 α 
Phosphatidylinositol 3‐kinase, 
regulatory subunit α 
√ √ 29abc [34]  Kinase
√ 29a [14] 
PDPN  Podoplanin  √ √ √ 29b [37]  Membrane glycoprotein
PMP22 
Peripheral myelin protein 22 √ √ √ 29abc
[109] 
Major component of 
myelin 
 
Tcl‐1 
 
T‐cell leukemia 1 
  √ √ 29c [50]  Co‐activator of Akt
√ √ 29b [52] 
√ 29b [78] 
TDG 
G/T mismatch‐specific 
thymine DNA glycosylase  √ 
√ 29c
[66] 
Glycosylase
TTP  Tristetraprolin  √  √ 29a [45]  mRNA degradation
p42.3    √ √ √ 29a [110]  unknown
L = luciferase assay, mRNA = mRNA level; iv = in vivo/mice, WB = western blot; b = mainly b 
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Table 2: Summary of studies reporting an up- or down-regulation of one or more miR-29 family members in cancer  
  Down‐regulation of miR‐29 family members in cancer   ↓ 
type of cancer  sample types  miRNA ref 
acute myeloid leukemia 
(AML) 
patient bone marrow  29b  [32] 
PBMCs  29a  [84] 
 
chronic lymphocytic leukemia 
(CLL) 
  29abc  [31] 
patient lymphocytes  29bc  [51] 
  29bc  [52] 
PBMCs  29c  [50] 
malignant cholangiocytes  cell line  29b  [64] 
colorectal cancer  tissue  29  [39] 
glioblastoma  tissue  29b  [37] 
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  Up‐regulation of miR‐29 family members in cancer   ↑ 
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breast  tissue  29a  [45] 
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primary melanoma  tissue  29ab  [46] 
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Figure Legends 
 
Figure 1:  
A) Scheme of miR-29 genomic organization: miR-29a~29b-1 and miR-29a~29b-2 are encoded as a cluster on Chr7 
q32.3 and Chr1 q32.2, respectively (left panel). Mature sequences of the miR-29 family members are shown on the 
right. Note identical mature sequences for miR-29b-1 and miR-29b-2. Seed regions are highlighted by a box and 
nucleotides differing between members are underlined, the single nucleotide difference between miR-29a and miR-
29c is shown in italics (right panel). B) Human primary transcripts of the miR-29 genes. Exons (E1-4/5) are shown 
as white boxes, introns as connecting lines; hairpin structures illustrate the coding position of precursor sequences. 
A scale is given below. C) Promoter organization and potential transcription start sites for both clusters miR-
29a~29b-1 (TSSab1-8) and miR-29a~29b-2 (TSSbc1-6) from literature, as mentioned in the text. Coordinates have 
all been converted to genome version hg19/GRCh37 and are as follows: TSSab1 chr7:130.572.487; TSSab2 
chr7:130.586.832; TSSab3 chr7:130.596.983; TSSab4 chr7:130.597.889; TSSab5 chr7:130.598.020; TSSab6 
chr7:130.598.638; TSSab7 chr7:130.598.268; TSSab8 chr7:130.800.298; TSSbc1 chr1:207.977.425; TSSbc2 
chr1:207.979.479; TSSbc3 chr1:207.985.009; TSSbc4 chr1:207.996.050; TSSbc5 chr1:207.997.156; TSSbc6 
chr1:207.037.276.  
 
 
Figure 2: 
A) Overview of miR-29 family members and their regulation: transcriptional activators and repressors of the miR-
29a~29b-1 and miR-29a~29b-2 clusters are shown that actively influence miR-29 expression levels. The dashed box 
indicates our recent findings on miR-29 regulation by STAT1. (Note that SMAD3 activates miR-29b only and 
canonical Wnt-signaling induced miR-29a and 29c only. B) Immune-modulatory effects of miR-29 and interaction 
with pathogens (as described in “MiR-29: a player in immunological host defense?”).  
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Background: The type-II-cytokine IFN-γ is a pivotal player in innate immune responses but also assumes functions
in controlling tumor cell growth by orchestrating cellular responses against neoplastic cells. The role of IFN-γ in
melanoma is not fully understood: it is a well-known growth inhibitor of melanoma cells in vitro. On the other
hand, IFN-γ may also facilitate melanoma progression. While interferon-regulated genes encoding proteins have
been intensively studied since decades, the contribution of miRNAs to effects mediated by interferons is an
emerging area of research.
We recently described a distinct and dynamic regulation of a whole panel of microRNAs (miRNAs) after
IFN-γ-stimulation. The aim of this study was to analyze the transcriptional regulation of miR-29 family members
in detail, identify potential interesting target genes and thus further elucidate a potential signaling pathway
IFN-γ→ Jak→ P-STAT1 → miR-29 → miR-29 target genes and its implication for melanoma growth.
Results: Here we show that IFN-γ induces STAT1-dependently a profound up-regulation of the miR-29 primary
cluster pri-29a~b-1 in melanoma cell lines. Furthermore, expression levels of pri-29a~b-1 and mature miR-29a and
miR-29b were elevated while the pri-29b-2~c cluster was almost undetectable. We observed an inverse correlation
between miR-29a/b expression and the proliferation rate of various melanoma cell lines. This finding could be
corroborated in cells transfected with either miR-29 mimics or inhibitors. The IFN-γ-induced G1-arrest of melanoma
cells involves down-regulation of CDK6, which we proved to be a direct target of miR-29 in these cells. Compared
to nevi and normal skin, and metastatic melanoma samples, miR-29a and miR-29b levels were found strikingly
elevated in certain patient samples derived from primary melanoma.
Conclusions: Our findings reveal that the miR-29a/b1 cluster is to be included in the group of IFN- and
STAT-regulated genes. The up-regulated miR-29 family members may act as effectors of cytokine signalling in
melanoma and other cancer cells as well as in the immune system.
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In the past decade, small non-coding microRNAs
(miRNAs) have been identified as new and important
players in post-transcriptional gene regulation and ever
since, their expression patterns and cellular functions
have been investigated in cancer and other diseases [1,2].
MiRNA biogenesis can be differentially regulated [3], but
generally starts with the generation of a primary (pri-)
miRNA transcript (several thousand nucleotides long),
which is subsequently processed into a 70–80 nucleotide
precursor form (pre-miRNA), which, following nuclear
export, is then cleaved into the ~22 nucleotide mature
miRNA. One strand of the mature duplex is incorporated
in the RISC (RNA-induced silencing complex), where
it recognizes, binds to and represses mRNA target
sequences [1]. MiRNAs are involved in many fundamen-
tal cellular processes as they are estimated to control
>50% of all protein-coding genes in mammals [4].
Consequently, they have been implicated in the regula-
tion of processes that promote cancer growth or con-
versely, in processes that might prevent cancers from
developing. For instance, a cancer cell can emerge fol-
lowing the over-expression of so-called “oncomirs” (such
as the miR-17-92 family, miR-21, -155, etc.) which down-
regulate tumor-suppressors that control cell proliferation.
On the other hand, miRNAs that function as tumor-
suppressors by targeting cellular oncoproteins (such as
let-7 family members, miR-15a, -16, -29, etc.) are fre-
quently down-regulated in cancer tissues [5]. Therapeu-
tics opting to replace the diminished tumor-suppressor
miRNAs are currently being investigated and seem
promising, as miRNAs exhibit high stability as well as
high specificity for their target mRNAs [5,6].
A disease where patients are in urgent need of more
effective treatments is advanced melanoma, the most
aggressive form of skin cancer. Metastatic melanoma
exhibit a severe resistance to therapy leading to 5-year
survival rates of below 5% [7]. Around 50% of patients
exhibit V600E mutations in the cellular kinase BRAF
[8]. Recently, the BRAF-inhibitor ZelborafW has been
approved for treatment of late-stage malignant melanoma
patients with V600E mutations, increasing life expectancy
by several months [9,10]. Nevertheless, except excision at
early stages, no curative therapies exist. Routinely, ther-
apies against melanoma include IFN-α as an adjuvant
treatment. Interferons are cytokines and constitute a
major part of the innate immune response, but they are
also recognized for their anti-proliferative properties. We
and others have shown that the type-II-cytokine IFN-γ
mediates growth inhibition of cancer cells by activating
the transcription factor STAT1 [11,12]. After IFN-γ
stimulation, STAT1 forms homodimers, which bind to
GAS (IFN-γ-activated sequences) elements in the pro-
moter regions of target genes. Very recently, we havefound several miRNAs to be dynamically regulated fol-
lowing stimulation with IFN-γ [13]. One of the first con-
nections between cytokine-induced Jak/STAT signaling
and miRNAs has been established by Löffler et al., who
showed that IL-6 increased the expression of oncogenic
miR-21 via STAT3 activation in myeloma cells [14]. The
signaling cascades involving IL-6 or IFN-α/β/STAT3/
miR-21 and others have been confirmed in several types
of cancer and diseases [15-17].
In the current study, we have focused on the biochem-
ical analysis of individual miRNAs regulated by IFN-γ
which we have recently identified in a detailed-time
course microarray experiment [13], and further concen-
trated on the interesting miRNA family miR-29 with its
three mature members, miR-29a, -29b and -29c. It is
transcribed into two primary transcripts, pri-29a~b-1
and pri-29b-2~c, from chromosomes 7 and 1, respect-
ively. MiR-29 family members target the expression of
proteins such as methyltransferases, extracellular matrix
proteins and transcription factors [18-20], which are
potentially involved in triggering enhanced invasion,
migration or proliferation of cells. They are silenced or
down-regulated in many types of cancer and have con-
sequently been assigned tumor-suppressing properties,
although in some cases also oncogenic roles have been
reported [21,22]. Here, we demonstrate a specific and pro-
found IFN-γ-induced, STAT1-dependent up-regulation
of miR-29a and -29b in melanoma cells and importantly,
also increased expression in primary melanoma patient
samples (but not in metastatic tumors) whereas the
second cluster pri-29b-2~c was consistently undetectable.
Moreover, we provide evidence for the tumor-suppressing
properties of miR-29 family members: inhibition of melan-
oma cell proliferation could be mediated by miR-29a,
which down-regulated CDK6 (cyclin-dependent kinase 6),
an important player in cell cycle G1/S transition. Our
findings identify the pri-29a~b-1cluster as a novel IFN-γ-
regulated gene and open up new connections between
miRNAs, interferon signaling and malignant melanoma,
which could lead to novel concepts for potential treat-
ment options in the future.
Results
To investigate possible transcriptional regulations of
miRNAs by STAT transcription factors, several melanoma
cell lines were treated with IFN-γ for different time
intervals and were subsequently analyzed by miRNA
microarray as previously described [13]. The top 10
IFN-γ-induced miRNAs from a microarray experiment,
which showed highest differential expression compared
to untreated cells, and detailed time-course expression
profiles thereof are depicted in Figure 1A and Additional
file 1: Figure S1. For further analysis, we focused on
the miR-29 family, as its mature members miR-29a and
hsa-miR-29a: 5’-U AGCACCA UC UGAAAUCGGUUA-3’
hsa-miR-29b: 5’-U AGCACCA UU UGAAAUCAGUGUU-3’
hsa-miR-29c: 5’-U AGCACCA UU UGAAAUCGGUUA-3’
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Figure 1 Top 10 IFN-γ-up-regulated miRNAs. (A) Ten miRNAs with highest positive fold changes (as determined by previous microarray
experiments [13]) include miR-29 family members (left). Detailed time course profiles are shown in Additional file 1: Figure S1. The miR-29 family
is transcribed from the respective antisense strand from two genetic clusters of chromosomes 7 (pri-29a~b-1) and 1 (pri-29b-2~c) (right).
The three mature forms miR-29a/29b/29c share the same seed region (grey box). Differences between the mature sequences are underlined;
a nucleotide difference between miR-29a and miR-29c is shown in italics. (B) The presumed pri-29a~b-1 promoter region [22-24] contains five
GAS-elements G1-5 (TT(C/A)CNNNAA(A/G)) and two ISRE-elements I1-2 ((G/A)(G/A)AANNGAAA(C/G)) (GRCh37/hg19).
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tested melanoma cell lines and because of its interesting
properties regarding tumor biology. To identify the pres-
ence of potential IFN-response elements, we performed
in silico screening of the promoter region 5 kb upstream
of a putative transcription start of pri-29a~b-1 [22-24]
and found five GAS-elements (TT(C/A)CNNNAA(A/G))
and two ISRE (interferon stimulated response element)-
elements ((G/A)(G/A)AANNGAAA(C/G)) (Figure 1B).
For control purposes, we selected miR-100, which was
slightly down-regulated after IFN-γ stimulation and
miR-25, whose levels were not induced in the micro-
array experiments. Other regulated candidates included
several miRNA star sequences (“miR*” which here repre-
sents the miR strand, which arises from the 3’-arm of the
hairpin, while the 5’-arm would be the guide or parent
strand and is conventionally considered as “minor”
product) which are currently being further assessed in
our laboratory (Figure 1, Additional file 1: Figure S1).
The pri-29a~b-1 cluster and mature miR-29a/29b are
regulated by IFN-γ
For stimulation experiments with IFN-γ, melanoma cell
lines MeWo and A375, as well as stably transfected
A375 derivates were used. A375-STAT1(F) represent
STAT1-dominant negative cells harboring a phenylalaninereplacement of tyrosine residue 701 crucial for STAT1
phosphorylation and dimerization [12]. Thus, transcrip-
tion of STAT1 target genes is abolished despite IFN-γ
stimulation. The corresponding control cells A375-
STAT1(wt) express the STAT1 wild-type construct instead
[12]. To accurately assess the regulation of the miR-29
family by IFN-γ-induced STAT1, we performed time
course experiments (Figure 2). Stimulation of A375,
MeWo and A375-STAT1(wt) cell lines with 50 ng/ml of
IFN-γ induced a prominent STAT1 phosphorylation,
which decreased after 48h of IFN-γ treatment, whereas
the STAT1-dominant negative cells A375-STAT1(F) only
exhibited a delayed and weak P-STAT1 signal after IFN-γ
stimulation (Figure 2A, see also [25]). Functional activity
of the P-STAT1 transcription factor was confirmed by
up-regulation of the STAT1 target genes IRF-1 and
STAT1 itself, which showed induced expression after
3h and 8h, respectively.
Following stimulation, changes in miRNA expression
levels were assessed by qRT-PCR (Figure 2B). A375,
A375-STAT1(wt) and MeWo cell lines showed a strong
and significant up-regulation (>5 fold) of the pri-29a~b-1
cluster, starting 24h after IFN-γ stimulation, while ex-
pression of the pri-29b-2~c cluster was not altered
(Figure 2B, upper panel). Accordingly, miRNA precursors
pre-29a and pre-29b-1 were also augmented whereas
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Figure 2 Expression profiles of miR-29 clusters in melanoma cells. A375-STAT1(F), A375-STAT1(wt), A375 and MeWo melanoma cells were
stimulated with IFN-γ for different time points. (A) Western Blot analysis (representative blots of biological triplicates) confirms activation of
P-STAT1 and induction of STAT1 and IRF-1 after IFN-γ stimulation while dominant negative A375-STAT1(F) cells show minor effects. (B) Time course
study of miRNA-expression after IFNγ-stimulation. Graphs show relative expression (REL) from quantitative qRT-PCR data for the pri-29a~b-1 and
the pri-29b-2~c clusters, the precursors pre-29a/29b-1/29b-2/29c and mature miR-29a/29b/25/100. Fold expression was calculated relative to the
untreated control and SDs are shown for biological triplicates. Statistical significance was tested with one-way ANOVA, followed by a Dunnett
Post-Hoc test with * p<0.05, ** p<0.01 and *** p<0.001. (C) MiRNA and miRNA* expression profiles in A375 cells derived from a more detailed IFN-γ
time course miRNA microarray experiment including cells treated with JI1 (IFN-γ stimulation for 72h after pre-treatment with JI1, black and grey
dots). Depicted are log2-values of the mean of duplicate microarray experiments.
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(Figure 2B, middle panel). Subsequently, significant up-
regulation of both mature miR-29a and miR-29b fol-
lowing IFN-γ stimulation was confirmed (Figure 2B,
lower panel). The two control amplifications of miR-100
(slightly down-regulated) and miR-25, which remained
stable over time following IFN-γ stimulation confirmed
the initial microarray-based expression profiles (Figure 2B,
lower panel). Similar regulation patterns were also found
in Jurkat and MT4 T-cells and in HEK293T kidney cells
(for mature miR-29a, miR-29b, and miR-25, Additional
file 2: Figure S2). Except for minor expression changes of
the Pri/Pre-miR-29 species after 72h of IFN-γ treatment,
no up-regulation was detected in the A375-STAT1(F)
dominant negative control cells, clearly suggesting that
STAT1 activity is required for the IFN-γ-induced regula-
tion of miR-29 family members.
Figure 2C shows expression results of a detailed time
course microarray experiment using IFN-γ-stimulated
A375 cells. In parallel and as described before, cells had
been pre-treated with Jak inhibitor 1 (JI1), which specif-
ically inhibits Janus tyrosine kinases and subsequently
prevented miR-29 up-regulation after IFN-γ stimula-
tion [13].
Altogether, these data substantiate for the first time
a time-dependent up-regulation of the expression of
pri-29a~b-1 cluster as well as of the mature miRNAs
miR-29a and -29b in melanoma cells, which is trig-
gered by IFN-γ-induced STAT1 signaling.
The miR-29b-2~c cluster is undetectable in melanoma cell
lines, melanocytes and keratinocytes
As both miR-29 primary clusters as well as the mature
miR-29a/29b showed different basal expression levels in
stimulation experiments and are known to be differen-
tially expressed in several types of cancer [26,27], we
next analyzed the miR-29 basal expression profiles in a
panel of melanoma cell lines, primary human melano-
cytes (NHEM-M2) and HaCaT keratinocytes (Figure 3A
and B). Pri-29a~b-1 was strongly expressed whereas pri-
29b-2~c was almost undetectable in all cell lines ana-
lyzed (Figure 3A). This is in accordance with previous
studies reporting down-regulation of the pri-29b-2~ccluster in rhabdomyosarcoma [28] and B-cell lymphoma
[23]. Also, mature miR-29a consistently showed higher
basal expression levels than miR-29b in all cell lines
examined (Figure 3B).
MiR-29a/29b expression levels inversely correlate with
growth behavior of melanoma cell lines
The classification of miR-29 as tumor-suppressor miRNA
has been widely accepted and the possibility to use syn-
thetic miR-29 as therapeutic agent in treatments of can-
cer seems to become increasingly realistic. Properties
counteracting the development and spreading of cancer
cells that have been observed in vitro and in vivo after
miR-29 overexpression include reduced invasion and
proliferation and induction of apoptosis [29,30]. These
findings prompted us to analyze a potential correlation
of basal miR-29 expression levels with cell growth.
Proliferation of untreated melanoma cell lines was moni-
tored over time (Figure 3C) in order to correlate the
growth rate with miR-29a and pri-29a~b-1 basal expres-
sion levels obtained from cells harvested 96h after seed-
ing. Melanoma cell lines were grouped in miR-29a and
pri-29a~b-1 ‘low-expression’ (A375, MeWo, IGR39,
WM9) and ‘high expression’ cell lines (FM55P, FM55M1,
SK-Mel30, IGR37) (Figure 3A and B). Generally, cell lines
with lower miR-29a showed an increased proliferation
rate compared to lines with higher basal miR-29a levels
(Figure 3C). Furthermore, the inverse correlation be-
tween pri-29a~b-1/miR-29a expression and the prolifera-
tion rate of melanoma cell lines might suggest a potential
involvement of miR-29 in anti-proliferative effects on
melanoma cells. To follow up these findings, we applied
miR-29a/29b mimics to A375 cells, which exhibit a rela-
tively low miR-29a/29b basal expression and, vice versa,
we applied a miR-29a inhibitor to FM55P cells, which
have a high basal miR-29a/29b expression (Figure 3B).
Proliferation assays with mimics and inhibitors and
the corresponding amounts of scrambled controls, NC
(negative control)-mimic and NC-inhibitor, corroborated
that miR-29 indeed inhibited growth of melanoma cells:
transfection of miR-29a/29b mimics caused a remarkable
reduction of proliferation as compared to NC-mimic-
transfected A375 cells (Figure 3D). In turn, FM55P cells,
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triplicates. (C) Mean growth curves of untreated melanoma cell lines over 4 days (biological quadruplicates). Melanoma cell lines with ‘low
expression’ of pri-29a~b-1 and miR-29a show faster proliferation whereas cells with a relatively ‘high expression’ proliferate slower. (D,E)
Proliferation assay of (black) mimic/inhibitor- and (grey) NC-mimic/NC-inhibitor-transfected cells over 72h in (D) A375 and (E) FM55P cells;
representative graphs of four independent experiments. Error bars depict SDs of technical triplicates. The inserted graphs (upper left corners)
show the mean confluence of 4 biological replicates at 0h and 72h time points of the proliferation assay. Depicted are ratios of confluence
of 29ab-mimic/NC-mimic treated cells (D) and 29a-inhibitor/NC-inhibitor treated cells (E). Error bars show SEM. Significance was assessed by a
two-tailed t-test with * p<0.05, ** p<0.01 and *** p<0.001.
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http://www.biosignaling.com/content/10/1/41in which miR-29a was inhibited, proliferated faster than
NC-inhibitor-transfected control cells (Figure 3E).
MiR-29a/29b down-regulate CDK6, but not PI3K
MiR-29 is predicted to regulate more than 1000 human
genes (TargetScanHuman 6.1). We have used a combin-
ation of several algorithms (TargetScanHuman 6.1,
Diana-microT v3.0, microRNA.org) to compile a list of
potentially interesting genes, which carry predicted
miR-29 target sites. After detailed expression analysis of
potential candidates in melanoma cells and initial screen-
ing for their response to miR-29 mimic and inhibitor
treatment (data not shown), we concentrated on the
PI3K regulatory subunit (gene: PI3KR1; protein: PI3K/
p85α) and CDK6, which play important roles in cell cycle
control, cellular signaling and thus, proliferation. Both
have already been confirmed as miR-29 targets in several
cancers [31-34].
To assess the effect of miR-29 on CDK6 and PI3K
expression in melanoma, mRNA and protein levels were
examined after miR-29 mimic or inhibitor treatments by
qRT-PCR and quantitative immunoblotting, respectively
(Figure 4A and B). Combined transfection of miR-29a/
29b reduced CDK6 mRNA and protein levels in A375
cells as compared to scrambled controls whereas PI3K
levels were not affected (Figure 4A). In agreement with
that, knockdown of miR-29a in FM55P cells resulted in a
slight up-regulation of CDK6 levels while PI3K levels
remained unchanged (Figure 4B). These data indicate
that miR-29 is involved in down-regulation of CDK6
protein while PI3K was not specifically targeted in mel-
anoma cells. CDK6 was also down-regulated in response
to miR-29 induction after IFN-γ stimulation in A375
cells and A375-STAT1(wt) but not in A375-STAT1(F)
cells, suggesting STAT1 dependency (Figure 4C). In con-
trast, PI3K levels were reduced in all three cell lines,
hinting at STAT1-independent effects. To further prove
regulation of CDK6 by miR-29, we performed luciferase
assays with reporter constructs containing part of the
CDK6 3’-UTR, its three single miR-29 binding sites as
predicted by TargetScan (www.targetscan.org), part of
the PI3KR1-3’-UTR or the miR-29a full complementary
sequence as a positive control (Figure 4D). Luciferase
activity, as compared to the respective negative control,
dropped by ~60 % for both time points in A375 melanoma
cells when the CDK6 3’-UTR construct was co-transfected
with miR-29a mimic. The corresponding single binding
sites contributed to this suppression significantly with
38% (BS1), 34% (BS2) and 35% (BS3) (Figure 4E). This
suggests that all three miR-29 binding sites partake in the
suppression of CDK6. Surprisingly, the PI3KR1 construct
was also significantly suppressed by the miR-29a mimic
in luciferase assays (Figure 4E) while only marginal
effects had been observed on mRNA and protein level(Figure 4A,B). Taken together, these findings indicate
that both CDK6 and PI3KR1 3’-UTRs are directly tar-
geted by miR-29 in melanoma cells; however, only CDK6
suppression seems to be important in a cellular context.
To further explore the relevance of reduced CDK6 levels
in the cell, we used siRNA against CDK6 and assessed
proliferation over 72h in A375 (Figure 4F) and FM55P
cells (Figure 4G). Reduction of CDK6 mRNA and protein
level (Additional file 3: Figure S3) led to a clearly dimin-
ished proliferation in both cell lines.MiR-29a and miR-29b are up-regulated in primary
melanoma patient samples
Finally, we investigated miR-29a/29b expression profiles
in FFPE melanoma patient samples from normal skin,
nevi, primary and metastatic melanoma by qRT-PCR
(Figure 5). Nevi represent the most appropriate control
samples as they contain predominantly melanocytes
while normal skin samples are mostly composed of kera-
tinocytes. In comparison to healthy skin and nevi, both
miR-29a and miR-29b showed an up-regulation in pri-
mary melanoma samples whereas in metastatic tumors,
expression levels were only slightly enhanced compared to
healthy controls. Closer sub-classification of the patient
samples revealed, however, that only two of five patients
demonstrated the enhanced miR-29a/29b expression, in-
dicating that expression levels are heterogeneous and will
have to be assessed in larger patient cohorts.Discussion
Generally, expression levels of miRNAs can be regulated
transcriptionally, by epigenetic silencing or different turn-
over times [1,35,36]. The role of cytokines as inducers of
miRNA expression has recently been proposed in several
studies and examples for cytokine-induced miRNA up-
or down-regulation include pro-inflammatory signaling
molecules like TNF-α and IL1-β [37,38]. Interferons are
central players in tumor-immune interactions [39,40]. In
this context, the theory of ‘cancer immunosurveillance’,
defined as the immunological protection of the host
against development of cancer, has evoked much interest
during the last decade: mediated by the host’s immune
system, it is triggered by immune recognition of stress
ligands or antigens expressed on transformed cells.
IFN-γ has long been recognized for its crucial role in
defense against viral and bacterial infections as well as
in tumor control [40,41]. It primarily signals through the
Jak/STAT pathway and activated STAT1 homodimers
bind to GAS-elements in promoter regions of target
genes, while IFN-α/β signal additionally through ISRE–
elements. In our study, we have identified several GAS-
elements in the proposed pri-29a~b-1 promoter region.
IFN-γ stimulation of a control cell line expressing
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Figure 4 Effects of miR-29 on target genes CDK6 and PI3K. (A,B) relative mRNA and protein expression levels (REL) of miR-29 target genes
CDK6 (dark grey) and PI3K (light grey), assessed 24h, 48h and 72h after mimic/inhibitor transfection compared to NC-mimic/NC-inhibitor
controls; graphs show means of biological triplicates ± SD. (C) Down-regulation of miR-29 target proteins CDK6 and PI3K is observed after
IFN-γ stimulation of melanoma cells. (D) Schematic overview of CDK6 and PI3KR1 luciferase constructs with positions of conserved miR-29a
binding sites predicted by TargetScan (bold) in the CDK6-3'UTR (BS1-3) and PI3KR1-3'UTR (BS) and corresponding miR-29a sequences (italics).
(E) Luciferase activity in A375 cells transfected with constructs containing the positive control miR-29a full complementary sequence (29a-FC),
parts of CDK6- or PI3K1-3'UTRs or CDK6 single binding sites (BS1-BS3) and miR-29a mimic or NC for 48h and 72h. Relative luciferase activity of
miR-29a-transfected samples was normalized to NC-mimic-transfected control samples (luciferase activity of NC-mimic transfected samples was
set to 100%). Bars show means of biological triplicates ± SD for each construct. (F) A375 and (G) FM55P cells transfected with CDK6 siRNA
(black) show reduced proliferation compared to cells transfected with siRNA NC (grey). Results were reproduced at least in biological
duplicates. Inserted bar diagrams show the mean confluence of at least biological triplicates at 0h and 72h. Shown are confluence ratios of
si-CDK6/si-NC ± SEM. Significance was assessed by one-way ANOVA followed by a Bonferroni Post-Hoc test (A,B,E) or by a two-tailed t-test
(F,G). * p<0.05, ** p<0.01 and *** p<0.001.
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Figure 5 miR-29 expression in patient samples. Analysis of
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of individual FFPE-patient samples from NS = normal skin, N = nevi,
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cause an up-regulation of miR-29, providing strong evi-
dence that STAT1 is indeed mediating IFN-γ-induced
effects on miR-29 expression levels.
IFN-γ has anti-proliferative effects on cancer cells
including melanoma [11,12] and we show here that
miR-29a, which is induced by IFN-γ exhibited the
same effects. Overall effects on growth were relatively
small, but robust and reproducible, considering that we
only manipulated levels of one miRNA and only used
relatively small amounts of mimics/inhibitors (50 nM/
150 nM) to be as close as possible to physiological rele-
vance. However, IFN-γ may also facilitate melanoma pro-
gression: Zaidi et al. have shown that IFN-γ-producing
macrophages are recruited to the UV-exposed skin and
can stimulate proliferation and migration of melanocytes
as well as induce expression of genes implicated in
immunoevasion and survival. When added to trans-
planted melanoma, these skin-recruited macrophages
enhanced the growth and survival of melanoma. All these
effects were IFN-γ-dependent as demonstrated by anti-
body blocking of IFN-γ [42].In our study, analysis of primary and metastatic mel-
anoma patient samples revealed increased miR-29a/29b
expression in some primary tumor samples in compari-
son to normal skin, nevi and metastatic tissue while all
metastatic lesions had low levels of these miRNAs.
Possibly, IFN-γ, which can be produced by macro-
phages, T cells and NK cells induces miR-29 expres-
sion via STAT1. miR-29a/29b were only up-regulated
in two out of five primary melanoma patients. In this
respect, it is interesting to note that IFN-γ producing
macrophages have been observed in 70 % of melanoma
samples [42]. A further evaluation of a larger panel of
patient samples including early neoplasia and advanced
metastatic stages is needed where a special focus will
be placed on immune cell infiltration, interferon con-
centration and an interferon-responsive gene signature.
miR-29 has very recently been linked to interferon
biology: it directly targets IFN-γ [43,44], the transcrip-
tion factors Tbet and Eomes crucial for IFN-γ expression
[19,44], and the receptor IFNAR1 [45], thereby drastic-
ally affecting immune regulation such as T cell
polarization and thymic function.
While this manuscript was in preparation, IFN-γ in-
volvement in the regulation of miR-29 expression was
also reported by a group studying T cell activation and
polarization in autoimmune diseases [44]. We here con-
firmed IFN-γ-induced miR-29 up-regulation in T cells
(Jurkat and MT4, Additional file 2: Figure S2) and have
also observed this effect in human embryonic kidney
cells implying a regulatory mechanism of broader rele-
vance. Interestingly, also type I interferons led to an
up-regulation of miR-29 (Additional file 2: Figure S2).
Screening of a panel of melanoma cell lines for dif-
ferent miR-29 species and family members revealed
that the pri-29b-2~c cluster was almost not expressed
and that miR-29a exhibited a much higher basal ex-
pression level than miR-29b. In tumor cells, reduced
miR-29 expression is frequently observed and diminished
expression of miRNAs in general is often associated
with enhanced oncogenesis [5,46]. The difference in
pri-29a~b-1 and pri-29b-2~c expression levels, which we
w?>havedetected, is consistentwithother typesofcancer, in
which the pri-29b-2~c cluster was mostly down-regulated
[26-28]. The fact thatmiR-29 familymembers are often not
expressed in cancer cells could be crucial for cancer control:
miR-29 down-regulates important genes such as CDC42,
TCL-1 and MCL-1, which normally confer tumor-
suppressing traits. In this context, anti-proliferating as
well as anti-invasive and pro-apoptotic effects have
been observed after miR-29 re-introduction in a variety
of cancer cells [29,30]. In line with this, we show anti-
proliferative effects of miR-29 and confirm for the first
time CDK6 as a direct miR-29 target in melanoma cells.
This suggests that miR-29-mediated down-regulation of
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miR-29a/b-mimic-transfected melanoma cells. SiRNA-
mediated knockdown of CDK6 resulted in reduced
proliferation of melanoma cells similar to what has
been shown for other cancer types [47,48]. CDK6
plays a pivotal role in control of G1/S cell cycle tran-
sition [49] and loss thereof is a common event in
neoplastic growth [50]. Noteworthy, CDK6 has also
been shown to be a direct miR-29 target in mantle
cell lymphoma [31], acute myeloid leukemia [34] and
cervical cancer [32].
The numerous anti-proliferative effects of IFN-γ in
many cancers may in part be explained by a G1 arrest in-
volving down-regulation of G1/S cyclins (cyclins A and E)
and CDK2/4 [12]. Accordingly, we find that IFN-γ as well
as miR-29 exhibit anti-proliferative activities in melan-
oma cells involving down-regulation of cell cycle control
players such as CDK6. The relevance of CDK6 activity
for melanoma growth is further emphasized by the fact
that the tumor suppressor p16INK4A (an inhibitor for
CDK6 and 4) is deleted in about 50% of melanoma
patients [51,52]. Here, we describe for the first time that
CDK6 is a direct target of miR-29 involved in regulating
growth behavior of melanoma cells.Conclusion
Our study extends the current knowledge on the miRNA
family miR-29, adding a novel regulatory loop of IFN-γ-
mediated Jak/STAT signaling in melanoma cells. Figure 6
summarizes the proposed regulatory circuit involving
IFN-γ and miR29: IFN-γ, which is e.g. secreted by
macrophages following diverse assaults such as infections
or UV light induces a STAT1-dependent up-regulation of
miR-29, which in turn can down-regulate IFN-γ expres-
sion directly and indirectly via T-bet and Eomes. Down-
regulation of cell cycle regulators like CDK6 contributes
to IFN-γ-mediated growth arrest.
We report that the pri-29 b-2~c cluster is almost un-
detectable in melanoma, which might markedly reduce
the ability of the miR-29 family to exhibit its tumor-
suppressing properties in these cancer cells. The fact
that miR-29a and miR-29b had enhanced expression
levels in some primary melanoma patients but not in
metastatic tumor samples is in line with many studies
showing down-regulation or low levels of miR-29 in
various advanced cancers [21,22,31,53]. We hypothesize
that the reduced miR-29 expression in cancer cells could
be a consequence of diminished IFN-γ signaling in those
cells, which might already have escaped immune sur-
veillance [41]. In regard to the proposed regulatory cir-
cuit, our study may open new connections between the
immune system, miRNAs and growth control and thus,
tumorigenesis.Methods
Cell lines and patient samples
Melanoma cell lines A375 (American Type Culture Col-
lection, ATCC), A375-STAT1(F) and A375-STAT1(wt)
[25], FM55P and FM55M1 (European Searchable Tumor
Line Database and Cell Bank, ESTDAB), IGR39 and
IGR37 (Deutsche Sammlung von Mikroorganismen und
Zellkulturen, DSMZ), MeWo (Dr. D. Schadendorf,
Essen, Germany) and SK-Mel30 (Dr. M. Böhm, Münster,
Germany) as well as the T cell lines Jurkat and MT4
(Dr. C. Devaux, Luxembourg) were maintained in
RPMI 1640 supplemented with 10% FCS (PAA), 50 μg/ml
penicillin, 100 μg/ml streptomycin and 0.5 mmol/l
L-glutamine. The stably transfected A375 cell clones
A375-STAT1(F) and A375-STAT1(wt) were grown under
selective pressure with 400 μg/ml Geneticin (G418,
Gibco). HaCaT keratinocytes (Dr. N. Fusenig, Heidelberg,
Germany) and HEK293T were grown in DMEM supple-
mented with 10% FCS, 50 μg/ml penicillin, 100 μg/ml
streptomycin and 2.5% HEPES. NHEM-M2 (normal epi-
dermal human melanocytes, PromoCell) were cultured in
melanocyte growth medium M2 (PromoCell) and har-
vested after reaching ~50% confluence in a 10 cm2 cell
culture dish. All cells were maintained in a humidified at-
mosphere with 5% CO2 and were routinely tested to be
mycoplasma-negative by PCR. Reagents and media were
purchased from Lonza unless specified otherwise.
Ethical approval for use of the patient FFPE (formalin-
fixed paraffin-embedded) and healthy control samples
was obtained by the Ethical review board, Freiburg,
Germany (Reference 196/09). Collection, histopatho-
logical analysis, fixation and RNA extraction were per-
formed as described before [54]. In total, RNAs of 5
healthy skin samples, 4 benign nevi, 12 primary and 14
metastatic melanoma samples were analyzed by qRT-
PCR. The primary and metastatic samples were collected
from different parts of the body from a total number
of 5 melanoma patients. Basal miR-expression levels
were calculated as 2-Δct with Δct= (ct (miR-29a/29b) –
ct (RNU5A)) (Figure 5).
IFN-γ stimulation, RNA extraction, and miRNA microarray
analysis
For IFN-γ time course stimulation experiments, 100x103
cells/well were seeded in 6-well plates (Greiner). Cells
were either left untreated or stimulated with 50 ng/ml of
IFN-γ (PeproTech) for the time periods indicated. 5 μM
Jak inhibitor 1 (JI1, Calbiochem) pre-treatment was
included (72h JI1-time point) in the detailed time course
miRNA microarray experiment one hour before IFN-γ-
stimulation. Samples for RNA extraction and protein
lysates were collected altogether at the end of the treat-
ment for further analyses by qRT-PCR and Western
Blotting, respectively. Total RNA was extracted using
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with DNaseI (New England Biolabs) as described before
[54]. Quantity and purity of RNA samples were assessed
using a NanoDrop ND-2000 spectrophotometer. Global
miRNA expression levels were profiled on Affymetrix
GeneCHip miRNA 2.0 Arrays as described before [13].
Relative quantification of primary, precursor and mature
miRNAs and mRNAs
For FFPE samples and cell lines, 250 ng of total RNA
was reversely transcribed using the miScript Reverse
Transcription kit (Qiagen) according to the supplied
protocol. Real-time PCR was carried out on a CFX de-
tection system (Bio-Rad). For quantification of maturemiRNAs, 5 ng RNA input, 2x iQ SYBR Green Supermix
(Bio-Rad) and 10x miRNA-specific primer assay (Qiagen)
were used. To detect mRNAs, miRNA primary clusters
and precursors, 2x iQ SYBR Supermix and 5 pmol gene-
specific primers (for sequences see Additional file 4:
Table S1) were used together with 50 ng (mRNA detec-
tion) or 125 ng (primary/precursor miRNAs) RNA in-
put. PCR conditions for all qRT-PCR reactions were
95°C-3 min; 39x (95°C-15s; 60°C-30s); 95°C-1 min;
60°C-1 min, followed by a melt curve analysis (60°C to
95°C, increment 0.5°C for 20s) to confirm specificity of
the PCR primers. If not stated otherwise, Ct-values for
mRNA and miRNA species were normalized to at least
three housekeeping genes: TBP (TATA binding protein),
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CycloA (cyclophilin A) and β-Actin for mRNAs and
primary/precursor miRNAs; RNU1A, RNU5A (RNA,
U1A/5A small nuclear) and SCARNA17 (small Cajal
body-specific RNA 17) for mature miRNAs. Based on
the geometric mean of the three reference genes, a
normalization factor was calculated for each sample
using geNorm, a VBA applet for Microsoft Excel [55].
The relative amount of each target in each sample was
then corrected by dividing its amount by the corre-
sponding normalization factor. Fold changes were cal-
culated by dividing the normalized relative amount of
treated samples with the normalized relative amount
of the untreated sample that served as a control. Stat-
istical significance was tested with one-way ANOVA,
followed by a Dunnett Post-Hoc test. Except for the
FFPE patient samples, all experiments were performed
at least in biological triplicates. P values of <0.05 (*),
<0.01 (**) and <0.001 (***) were considered significant.Western blot analysis
Cell lysis, SDS-PAGE, ECL detection, stripping and re-
probing was performed as previously described [56,57]
using the following antibodies: Actin (C4, Milipore),
Tubulin, IRF-1, STAT1 and CDK6 (Santa Cruz), P-STAT1
(Cell Signaling), p85α (PI3K) (Upstate) and the corre-
sponding HRP-labeled (ECL detection, Cell Signaling
Technology) or fluorophor-coupled (quantification, Li-cor
Biosciences) secondary antibodies. For quantification of
proteins, signal intensities were assessed with a Li-cor
Odyssey Infrared Imaging System (Li-cor Biosciences)
and analyzed with the provided software. CDK6 and
p85α signals were normalized to the respective Tubulin
loading controls.Real-time proliferation assays
25 x103 cells/well of eight untreated melanoma cell lines
were seeded in 12-well plates and harvested after 96h of
real-time monitoring in the IncuCyte live-cell imaging
system (Essen Bioscience), which photographed cells in
phase contrast every 3h. RNA was extracted and miR-29
species were amplified by qRT-PCR as described before
[54] and above.
miRNA mimic/inhibitor transfection
100 x103 cells/well were seeded in 6-well plates
and transfected after 24h with 50 nM of each miR-29a
and miR-29b mimics or with 150 nM miR-29a inhibi-
tor or corresponding amounts of negative controls
(Qiagen) using the DharmafectDuo transfection reagent
(Dharmacon) according to the supplied protocol; effi-
cient transfection was confirmed by qRT-PCR (Additional
file 3: Figure S3). For miR-29 target gene expression, RNAand protein lysates were collected 24h, 48h and 72h after
transfection and subsequently analyzed by RT-qPCR and
western blot. Proliferation was monitored by the IncuCyte
cell-imaging system as described above.CDK6 siRNA transfection
50x103 cells were transfected with 75nM ON-TARGET
siRNA or siRNA negative control (si-NC) 24h after
seeding in 6-well plates using the HiPerfect transfection
reagent according to the manufacturer’s instructions
(Qiagen). Proliferation was monitored in the IncuCyte
as described above. CDK6 mRNA and protein levels were
assessed after 24h, 48h and 72h to confirm efficient
down-regulation (Additional file 3: Figure S3C,D).Luciferase reporter gene assays
The parts of CDK6 and PI3KR1 (Phosphatidylinositol
3-kinase) 3’UTRs containing miR-29 binding sites,
CDK6 miR-29a single binding sites and the miR-29a
full complementary sequence were cloned into the
pmirGLO Dual Luciferase miRNA target expression
vector (Promega) downstream of the luciferase gene
(see Additional file 4: Table S1 for primer sequences and
oligonucleotides). A375 cells were seeded at a density of
50 x103 cells/well in 24-well plates one day before trans-
fection. Cells were transiently co-transfected with 500 ng
plasmid and 50 nM miR-29a mimic or negative control
for 48h and 72h. Samples were lysed with 1x Passive
Lysis Buffer (Promega) and luciferase activity was mea-
sured using the Dual-Luciferase Reporter Assay System
(Promega) according to the manufacturer’s instructions.
Firefly was divided by Renilla activity and normalized to
the negative control for each construct. Significance was
assessed by one-way ANOVA followed by a Bonferroni
Post-Hoc test with * p<0.05, ** p<0.01 and *** p<0.001.
Additional files
Additional file 1: Figure S1. Schmitt_et_al_2012_Contains a graphical
representation of array results: Top 10 up-regulated miRNAs (as listed in
Figure 1A) after IFN-γ stimulation for the indicated time periods and 72h
JI1.
Additional file 2: Figure S2. Schmitt_et_al_2012_Contains bar
diagrams of qRT-PCR results: MiR-29a/29b up-regulation after IFN-γ-
stimulation and unchanged miR-25 levels in A) HEK293T kidney and B)
Jurkat T cells. C) MiR-29a/29b up-regulation after IFN-α-, IFN-β- and IFN-γ-
stimulation (50 ng/ml) in MT4 T cells.
Additional file 3: Figure S3. Schmitt_et_al_2012_Contains bar
diagrams of qRT-PCR results an western blots: Tracking of miR-29a/29b
mimics in A375 cells (A) and miR-29a suppression after inhibitor
transfection in FM55P cells (B); and knock-down of CDK6 mRNA (C) and
protein levels (D) in both cell lines.
Additional file 4: Table S1. within Schmitt_et_al_2012_Contains primer
sequences. Additional Figure legends: Schmitt_et_al_2012_ Contains
additional Figure legends. Powerpoint documents.
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lation or orchestrating their sequence-specific degradation. In this study, we investigated miRNA and miRNA
target gene expression patterns in melanoma to identify candidate biomarkers for early and progressive dis-
ease. Because data presently available on miRNA expression in melanoma are inconsistent thus far, we applied
several different miRNA detection and profiling techniques on a panel of 10 cell lines and 20 patient samples
representing nevi and primary or metastatic melanoma. Expression of selected miRNAs was inconsistent when
comparing cell line–derived and patient-derived data. Moreover, as expected, some discrepancies were also
detected when miRNA microarray data were correlated with qPCR-measured expression levels. Nevertheless,
we identified miRNA-200c to be consistently downregulated in melanocytes, melanoma cell lines, and patient
samples, whereas miRNA-205 and miRNA-23b were markedly reduced only in patient samples. In contrast,
miR-146a and miR-155 were upregulated in all analyzed patients but none of the cell lines. Whole-genome
microarrays were performed for analysis of selected melanoma cell lines to identify potential transcriptionally
regulated miRNA target genes. Using Ingenuity pathway analysis, we identified a deregulated gene network
centered around microphthalmia-associated transcription factor, a transcription factor known to play a key
role in melanoma development. Our findings define miRNAs and miRNA target genes that offer candidate
biomarkers in human melanoma. Cancer Res; 70(10); 4163–73. ©2010 AACR.Introduction
MicroRNAs (miRNA) are noncoding ∼22 nucleotide short
RNAs that typically downregulate expression of their target
genes. Nucleotides 2 to 8, the so-called “seed” region of miR-
NAs, bind to completely or partially complementary regions
in the 3′ untranslated region (UTR) of target genes, which are
generally present in multiple copies to amplify the regulatory
effects of the miRNA (1, 2). To date, 721 human miRNAs have
been identified (3), which are thought to regulate at least
30% of human genes. A recent in-depth analysis of human
3′ UTR sequences indicated, however, that even >60% of
human protein-coding genes have been under selective pres-
sure to maintain pairing to miRNAs (4).
miRNAs influence most fundamental biological processes
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American Asso Copyright © 2010 
cancerres.aacrjourDownloaded from through interference with mRNA translation or by reducing
the stability of the mRNA in the cytoplasm (5). Downregu-
lated target gene mRNAs can be detected by whole-genome
microarray technology, keeping in mind that translationally
repressed miRNA targets would be missed by such an ap-
proach (6).
Given the tremendous regulatory potential of miRNAs
and their often tissue-specific and disease-specific expres-
sion patterns (7–9), there is increasing evidence that miRNA
expression profiles could be indicative of disease risks and
burdens, and as such, miRNAs are being assessed as possi-
ble biomarkers to aid diagnosis and prediction of different
types and stages of cancers, including melanoma (10–12).
Melanoma arises from melanocytes, which are pigmented
cells present in the basal layer of the epidermis (13). The global
incidence of melanoma continues to rise faster than any other
malignancy, and despite considerable research efforts, no
efficient therapy is available to date. Once melanoma has
metastasized, the median 5-year survival rate is <5% (14).
Relatively few miRNA expression profiling analyses have
thus far included or focused on melanoma samples, and the
available data sets show little agreement with regards to ex-
pression patterns of individual miRNAs or the entire miR-
Nome. Using real-time PCR on 241 individual miRNAs, Gaur
and colleagues (15) have identified a set of 15miRNAs that dis-
tinguished melanomas from other solid cancers whereas
others (16) have described four melanoma-characteristic
miRNAs detected by microarray analysis with only miR-3354163
 ciation for Cancer Research
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Published OnlineFirst May 4, 2010; DOI:10.1158/0008-5472.CAN-09-4512common to both studies. Mueller and colleagues (17) have
recently described a more detailed analysis of miRNA ex-
pression in melanocytes versus seven different melanoma
cell lines based on miRNA microarray analysis. In primary
melanoma cell lines, a set of 49 miRNAs was found to be
strongly upregulated whereas 14 were downregulated; how-
ever, most of these had not been shown before to be sub-
stantially regulated in melanoma development. miRNA
expression in melanocytic nevi derived from formalin-fixed
paraffin-embedded (FFPE) samples has recently been inves-
tigated by Glud and colleagues, who, among others, have
shown that FFPE samples are useful sources for miRNA
profiling (18, 19).
Owing to the many factors that differed between these
studies (real-time PCR versus miRNA microarray approaches;
different microarray platforms and mirBase versions; differ-
ent sample types and melanoma cell lines) it is not surprising
that largely different miRNA sets were considered to be char-
acteristic for melanoma or melanoma progression. However,
thus far no miRNAs have been identified that would allow for
reproducible and specific distinction between early-stage or
late-stage melanoma samples from healthy melanocytes or
benign nevi in cell lines and patients.
To evaluate the discrepancies and/or concordances in
miRNA expression patterns that might result from different
technical approaches on different biological samples, we es-
tablished miRNA expression profiles in primary human
melanocytes [normal human epidermal melanocyte (NHEM)]
versus melanoma cell lines by miRNA microarray, real-time
miRNA reverse transcription–PCR arrays (RT2 Profiler),
followed by individual quantitative real-time PCR (qPCR)
validations. To then correlate cell line–derived expression
patterns with melanoma patients, we next analyzed FFPE pa-
tient samples including benign nevi, primary melanoma, and
metastatic melanoma samples. Cross-correlation of all miR-
NA expression data revealed that only miRNA-200c was com-
monly downregulated in different sample types robustly
detectable by the various technical approaches. Other miR-
NAs were only found to be significantly deregulated in either
cell lines or patients or could not be reproduced using differ-
ent detection techniques.
Finally, whole-genome arrays were used on melanoma cell
lines and melanocytes to identify possible target genes of
some of the differentially regulated miRNAs. We focused on
genes commonly deregulated in melanoma and inversely cor-
related their expression patterns with miRNAs predicted to
target such genes, identifying several possible miRNA/target
gene pairs likely to play a role in melanoma development.
Ingenuity network analysis identified with a high statistical
confidence deregulated pathway around the transcription
factors microphthalmia-associated transcription factor
(MITF), SRY-related HMG box (SOX10), and T-box transcrip-
tion factor 2.
Materials and Methods
Cell lines and cell culture. In total, nine melanoma cell
lines were analyzed: Wm9 (Dr. M. Böhm, Münster, Germany),Cancer Res; 70(10) May 15, 2010
American Asso Copyright © 2010 
cancerres.aacrjourDownloaded from FM55-M1 (European Searchable Tumor Line Database
and Cell Bank), IGR39 and IGR37 (Deutsche Sammlung von
Mikroorganismen und Zellkulturen), A375 (American Type
Culture Collection), 1102 (Dr. M. Kortylewski, City of Hope,
California), MeWo (Dr. Schadendorf, Essen, Germany),
and MelIm and MelJuso (Dr. A. Bosserhoff, Regensburg,
Germany). All cells were maintained in RPMI 1640 supple-
mented with 10% FCS, 50 μg/mL penicillin, 100 μg/mL strep-
tomycin, and 0.5 mmol/L L-glutamine. NHEMs from lightly
pigmented adult skin (PromoCell) were maintained in
serum-free and phorbol 12-myristate 13-acetate–free MGM-
M2 medium and were used at passage number 5 or 6. MCF-7
breast cancer cells (Dr. G. Vetter, Luxembourg) were grown
in DMEM supplemented with 10% FCS, 50 μg/mL penicillin,
and 100 μg/mL streptomycin. All cells were grown in a hu-
midified atmosphere with 5% CO2 supply and were routinely
PCR tested to be Mycoplasma negative.
Patient samples. Skin tissue samples from patients with
either benign nevi or melanoma were collected at the Der-
matology Department of University Hospital of Freiburg
(Germany) and histopathologically examined to confirm
clinical diagnoses. Upon excision, tissues were fixed in FFPE
according to standard dermatohistopathologic techniques.
In total, 3 pools of benign nevi (RNAs of two different do-
nors each) and 17 primary and subcutaneous melanoma
metastasis patient samples were analyzed (age and gender
information is included in Supplementary Table S1). Addi-
tionally, four breast cancer FFPE samples from two patients
were included in this study. The study was approved by the
ethical review board of EK Freiburg (reference 196/09), and
written informed consent was obtained from healthy con-
trols and live patients.
Total RNA extraction and quality control. Total RNA of
cell lines was extracted using TRIsure (Bioline USA, Inc.)
and treated with DNaseI (New England Biolabs) following
each manufacturer's instructions. For miRNA and whole-
genome microarray analyses, total RNA was extracted using
the miRNeasy kit (Qiagen) according to the manufacturer's
protocol with additional on-column DNaseI digestion. In
FFPE samples, for total RNA extraction, five scalpel-scraped
slices of FFPE tissue were pooled and processed using the
RT2-FFPE RNA Extraction kit (SABiosciences) according to
the supplied protocol. Quantity and purity of RNA samples
were assessed using a NanoDrop ND-100 Spectrophotome-
ter. For FFPE tissues, in particular, when RNA quantity or
quality was insufficient, samples were further processed by
standard ethanol precipitation and resuspended in appro-
priate volumes of DEPC-H2O to achieve total RNA concen-
trations of >350 ng/μL and absorbance ratios of > 1.8 (260/
280) and > 1.7 (260/230).
miRNA and whole-genome microarrays. Total RNA from
NHEM, IGR39, and IGR37 cells was subjected to (a) ge-
nome-wide miRNA expression profiling (miRBase, version
11.0) using the μParaflo microarray technology (LCSciences)
and (b) whole-genome expression profiling using GeneChip
Human Gene 1.0 ST arrays (Affymetrix). Gene network anal-
yses were performed with the Ingenuity Pathway Analysis
(IPA) software (Ingenuity Systems). Detailed methodologiesCancer Research
 ciation for Cancer Research
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Published OnlineFirst May 4, 2010; DOI:10.1158/0008-5472.CAN-09-4512Figure 1. A, top 25 gradually upregulated and downregulated miRNAs in metastatic (IGR37) versus primary (IGR39) melanoma cell lines established from the
same patient. AFUs were derived from at least duplicate miRNA microarrays (LCSciences). AFUs of >500 were selected and sorted, and log2 values of
AFU ratios were plotted. miRNAs marked with an arrow were further validated; the ones marked with an asterisk were confirmed by RT2 Profiler results.
B, relative expression of selected miRNAs in primary human melanocytes (NHEM, passage no. 5), a panel of nine melanoma cell lines, and MCF-7 breast
cancer cells (relative to SCARNA17 expression). Results are depicted as mean of biological triplicates ± SEM. Statistical analysis was performed using
a one-way ANOVA test, comparing results for each cell line to NHEM cells. ***, P < 0.001; **, P = 0.001–0.01; *, P = 0.01–0.05; no star, not significant
at P > 0.05.Cancer Res; 70(10) May 15, 2010www.aacrjournals.org 4165
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 on February 15, 2cancerres.aacrjournals.orgDownloaded from Figure 2. A, miRNA expression
profiling in melanoma patients (RT2
Profiler). Clustergram generated
from average miRNA Ct values of
individual FFPE patient samples
from nevi (3), primary melanoma
(7), metastatic melanoma (10), and
breast cancer samples (4). For
each patient group, average Ct
values were normalized to a panel
of four different housekeeping
genes (Supplementary Table S1).
The range of 2−ΔCt values is given
below the color scale. miRNAs that
were further validated by qPCR
are marked by an asterisk.Cancer Research
 h
013
Figure 2. Continued. B, miRNA
signatures for stages of melanoma
progression. miRNAs of
>2.0-fold upregulated (bold) or
downregulated relative to nevi
are shown for each patient group.
C, box plots showing triplicate
qPCR validations for nine selected
miRNAs of individually analyzed
patient samples (as in A).
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Materials and Methods.
Real-time PCR-based miRNA expression profiling. FFPE
patient samples were analyzed for the presence and differen-
tial expression of a panel of 88 cancer-related miRNAs using
cancer RT2 miRNA PCR arrays (called RT2 Profiler; SABios-
ciences) according to the manufacturer's instructions. Data
analysis was performed with the web-based software package
for the miRNA PCR array system (20).www.aacrjournals.org
American Asso Copyright © 2010 
cancerres.aacrjourDownloaded from miRNA and gene expression validation by real-time
qPCR. Briefly, 250 and 100 ng of total RNA from cell lines
and FFPE tissues, respectively, were reverse transcribed in
a 10-μL reaction volume with the miScript System (Qiagen)
following the manufacturer's instructions. To quantify ma-
ture miRNAs, real-time qPCR was carried out on a CFX96
Detection System (Bio-Rad) using 5 ng RNA input, 2× iQ
SYBR Green Supermix (Bio-Rad), and 10× miRNA-specific
primer assay (Qiagen). For the detection of cKIT and MITF,Cancer Res; 70(10) May 15, 2010 4167
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gene-specific primer pairs were used. Thermal cycling condi-
tions for all assays were 95°C for 3 minutes, 40 cycles at 95°C
for 10 seconds, and 60°C for 30 seconds, followed by melting
curve analyses. RNA input was normalized to endogenous
controls: SCARNA17 for miRNAs and TATA-binding protein
for protein encoding genes. The 2−ΔCt method was used to
calculate the fold relationships in miRNA or gene expression
among the tested samples (21).
miRNA target gene prediction. Three publicly available
databases, TargetScanHuman 5.1 (4), DIANA-microT v3.0
(22), and MicroCosm Targets Version 5 (3), were used for
miRNA target gene predictions. Predicted target genes in
combination with miRNA and whole-genome microarray da-
ta were used to visualize possible biological miRNA/mRNA
processes correlating to melanoma development and/or
progression.Results
miRNA expression profiling of primary human
melanocytes (NHEM) and melanoma cell lines. As a first
step, we analyzed the miRNome of two melanoma cell lines
from a single patient representing primary (IGR39) and me-
tastatic tumors (IGR37) and compared them to NHEM using
LCSciences microarray data and RT2 Profiler PCR arrays, fol-
lowed by individual qPCR validations for selected miRNAs
(Fig. 1, Supplementary Table S1). Figure 1A depicts the top
25 miRNAs upregulated and downregulated with tumor pro-
gression as detected by miRNA microarray. Sixteen miRNAs
(asterisk-marked) were also present on RT2 Profiler assays.
Of those, 12 had matching expression ratios (except for
miR-10a, miR-7, miR-181b, and miR-21) following tumor pro-
gression in cell lines (Supplementary Table S1) and melano-
ma patients (see Fig. 2A). This suggests that cell lines give
some indication of relevant expression patterns, but individ-
ual results may change in patient-derived samples. Complete
array-based expression profiles of all miRNAs (miRBase ver-
sion 11.0) served as a first base for selection of miRNAs to be
investigated further. Comparison of microarray results with
data from the RT2 Profiler revealed that 66 of the 88 common
miRNAs (75%) showed comparable results, with both of the
assays being clearly positive [Ct < 30 or arbitrary fluorescence
unit (AFU) > 500] or negative.
The expression levels of several miRNAs were further
validated by qPCR, extending the cell line panel to nine
different melanoma cell lines, NHEMs, and MCF-7 breast
cancer cells (Fig. 1B). qPCR results for NHEM, IGR39,
and IGR37 correlated with microarray-measured expression
levels for all tested miRNAs except let-7i, wherein levels
were lower in NHEM compared with IGR39 and IGR37.
Figure 1B further illustrates that some miRNAs have con-
siderably different expression levels in individual cell lines,
suggesting that profound variations would also be apparent
when analyzing the entire miRNomes of such cell lines.
Nevertheless, a few robustly regulated miRNAs seemed to
be useful candidates to distinguish between NHEMs andCancer Res; 70(10) May 15, 2010
American Asso Copyright © 2010 
cancerres.aacrjourDownloaded from melanoma cell lines in general: miR-155 and miR-146a with
decreased expression levels in all melanoma lines tested
and miR-25 and miR-23b (as well as miR-23a; data not
shown), which were consistently upregulated.
miRNA expression profiling of FFPE melanoma patient
samples. Due to the small amplicon size of miRNAs, FFPE
samples represent useful sources to analyze miRNA expres-
sion even when some degree of RNA degradation is apparent
(18). In total, 24 FFPE samples were analyzed by RT2 Profiler
arrays (Fig. 2A) followed by qPCR for selected miRNAs
(Fig. 2B). The heat map (Fig. 2A) depicts expression values
for 88 cancer-relevant miRNAs of four donor groups relative
to four different house-keeping genes (Supplementary
Table S1). Nevi (consisting of pools of RNAs extracted from
five healthy volunteers) showed very similar Ct values across
85% of analyzedmiRNAs. The primarymelanoma group repre-
sents mean expression values from seven individual primary
tumors, whereas the metastatic melanoma group consisted
of 10 different patient samples. The breast cancer group (four
samples from two patients) was included to allow for identifi-
cation of miRNAs that were distinct between the two cancer
types. miRNA-16, miRNA-27a, miRNA-125b, 199a-3p, 199a-21,
and 199a-205 were highly expressed in melanoma having
greater RNA levels than the four housekeeping genes (U6,
SNORD44, SNORD46, and SNORD47), whereas the breast
cancer group was characterized by highest expression of
miRNA-16, miRNA-100, miRNA-21, and let-7b (Supplemen-
tary Table S1). Figure 2B shows that each melanoma stage
bore a distinct miRNA signature. Considerable interpatient
variability (>2.0 Ct) among the different melanoma patient
groups was detected for <10% of the analyzed 88 cancer-
related miRNAs (Supplementary Table S1).
qPCR validation on duplicate RNAs extracted from individ-
ual FFPE samples revealed a generally good correlation when
compared with expression patterns achieved with averaged
values for the different patient groups. Figure 2C shows box
plots for nine selected miRNAs. Most striking were the levels
of miR-200c, miR-205, and miR-23b, which were strongly
downregulated in melanoma patients when compared with
nevi. miR-200c is further interesting, as it allows for discrimi-
nation between melanoma and breast cancer samples.
miR-363, miR-146a, and miR-155 were clearly upregulated
in all melanoma patients but not in breast cancer samples.
Interestingly, the latter two were consistently low or unde-
tectable in cell lines. In this context, it has recently been sug-
gested that miR-155 was a negative regulator of melanoma
proliferation, as its expression was downregulated or lost
in the majority of melanoma cell lines (23). Here, we also
monitored an almost complete loss of miR-155 in our panel
of cell lines (Fig. 1B); however, miR-155 was clearly detectable
in all of the 17 patient-derived samples, indicating that the
loss of miR-155 expression may be a tissue culture–related
phenomenon. Taken together, miR-155, miR-205, miR-146a,
and miR-23b emerged as useful markers to distinguish
between melanoma cell lines and patient samples relative
to human melanocytes and nevi, respectively.
Correlation of expression levels of selected miRNAs with
their predicted target genes. Whole-genome cDNA arraysCancer Research
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obtain a pattern of transcriptionally regulated candidate
genes that could serve as possible targets of some of the iden-
tified differentially regulated miRNAs. Scatter plots with
highlighted genes known to be important formelanoma devel-
opment and/or progression are shown in Fig. 3. Interestingly,
melanoma-associated antigen C2, a predicted (although non-
conserved) target of miR-200a, miR-200b, and miR-200c fam-
ily, was strongly expressed inmostmelanoma cell lines but not
in MCF-7 breast cancer cells, whereas inversely miR-200c ex-
pression was undetectable in all tested melanomas (Figs. 1B
and 2A; Supplementary Fig. S1). Expression of the receptor
tyrosine kinase cKIT, a confirmed target of miR-221/miR-222
(24), was augmented in IGR37, which showed correspondingly
low levels of miR-221. An inversely and perfectly correlated
expression pattern of miR-221 and cKIT was also confirmed
for all nine melanoma cell lines but interestingly not for the
MCF-7 cell line (Supplementary Fig. S1). miR-23a and miR-
23b, upregulated in melanoma cell lines, are predicted to tar-
get many genes, of which several were found to be reciprocally
downregulated in this data set [MITF (Supplementary Fig. S1),
TYR (tyrosinase), TRPM1 (transient receptor potential cation
channel 1), MLANA (Melan-A), and others]. All of these genes
have previously been implicated in melanoma development
(25–27). We further validated and confirmed the array-based
expression levels for four additional genes [CDKN1B (p27),
CDK6, E-cadherin, and N-cadherin] for NHEM, IGR39, and
IGR37 (Supplementary Fig. S2).www.aacrjournals.org
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IGR39, Ingenuity analysis identified 33 pathways with statis-
tical scores of >10 (score = −log (P value) from Fisher's exact
test analysis). Network no. 3 “skin development and function”
(score = 37) was selected based on statistical and biological
relevance for the study (Fig. 4A). We then prompted Ingenu-
ity to include miRNAs that were predicted to target the
strongly regulated and melanoma-relevant genes. The result-
ing network shows some of the known key players in mela-
noma development and progression with MITF regulating
the expression of several genes known to be involved in pig-
mentation and skin development, such as TYR, tyrosinase-
related protein 1, SILV (melanocyte protein Pmel 17), and
TRPM1, whose expression is inversely correlated with mela-
noma metastasis (25).
To evaluate the robustness of the interactions predicted by
the software, we analyzed gene levels of MITF and its tenta-
tive targeting miRNA-23a and miRNA-23b, as well as four
genes that have previously been shown to be regulated by
MITF (Fig. 4B; refs. 26, 28, 29). In IGR39 cells, wherein miR-
23a/miR-23b expression was highest, MITF levels were al-
most undetectable. Correspondingly, the expression patterns
of three of the four tested and potentially MITF-regulated
genes (miR-146a, let-7I, and cKIT) matched the expression
trends of the transcription factor, indicating that they could
indeed be regulated by MITF. miRNA-363, which is also reg-
ulated by MITF (28), was however an exception as such that
IGR37 had reproducibly undetectable levels of miR-363.Figure 3. Mapping of potential miRNA targets in gene expression profiles. Scatter graphs were generated by plotting normalized log expression data
obtained with IGR39 or IGR37 cells against those found with NHEM control cells. Each gray dot in the graphs corresponds to the expression value of a
particular gene found to be significantly differentially expressed (FDR < 0.05). Selected genes previously implicated in melanoma are highlighted in red
or blue (upregulated or downregulated in melanoma versus melanocytes, respectively). miRNAs computationally predicted to target some of the highlighted
genes are depicted in italics: red or blue (upregulated or downregulated in the respective melanoma cell line versus melanocytes, respectively), or
black (unchanged expression). Underlined are miRNAs that have been experimentally confirmed to regulate the respective target genes. For some genes, no
targeting miRNA was predicted by Targetscan or MicroCosm Targets.Cancer Res; 70(10) May 15, 2010 4169
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Published OnlineFirst May 4, 2010; DOI:10.1158/0008-5472.CAN-09-4512Figure 4. A, miRNA target map illustrating parts of the “skin development and function” network, which IPA identified to be highly significant in our
experimental data set (IGR39 versus NHEM). Central to this network is MITF and its predicted interactions with pigmentation-relevant and
melanoma-relevant proteins together with their subcellular localization. The node color intensity indicates the expression level of genes: red, upregulated;
green, downregulated in the comparison IGR39 versus NHEM. IPA-predicted miRNAs and their relative expression levels in our primary melanoma
patients are also shown (red, up; blue, down). B, relative expression levels of MITF of biological triplicates of NHEM, IGR39, and IGR37. Inverse expression
levels for miR-23a and miR-23b, which are predicted to target MITF, are shown above. Expression patterns for miRNA-363, miRNA-146a, let-7i, and
cKIT, suggested to be regulated by MITF, are shown in the bottom, all of which (except miR-363) show MITF-concordant expression trends.Cancer Res; 70(10) May 15, 2010 Cancer Research
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Published OnlineFirst May 4, 2010; DOI:10.1158/0008-5472.CAN-09-4512Taken together, computational pathway analysis proved to
be a useful tool to select key-regulated genes. Inversely cor-
related expression patterns of such selected genes and their
predicted miRNAs in an extended number of biological sam-
ples can point to regulatory relationships between miRNAs
and their tentative target genes.
Discussion
Recent years have seen a tremendous number of miRNA
profiling studies aiming at identifying unique miRNA
signatures for many diseases, for different stages thereof,
or for prediction of disease risks (9, 11). These efforts have
been paralleled by continuous discovery of new miRNAs
and by rapidly changing developments and improvements
in miRNA detection techniques. Given the different techni-
cal approaches applied to miRNA profiling (various micro-
array chemistries and real-time PCR quantifications)
together with the plethora of different biological samples
that are being profiled, it is not surprising that there is
often little correlation between data sets coming from differ-
ent laboratories. Here, we have addressed this question by
comparing miRNA expression patterns in well-characterized
melanoma cell lines with patient-derived samples of different
melanoma stages by applying microarray and qPCR profiling
techniques.
A key issue for comparability or lack thereof of different
expression data sets is the selected reference line or tissue,
whose basal miRNA expression levels will determine the cal-
culated fold expressions in the tested samples. We have ob-
served that primary human melanocytes (NHEM), which are
commonly used as calibrators for melanoma studies, consid-
erably change their absolute levels of several important miR-
NAs with increased passage number (data not shown).
Therefore, great care should be taken in choosing negative
controls for comparative and consecutive studies. In this
context, we noted very little agreement between our miRNA
expression patterns of NHEM melanocytes and melanoma
cell lines with a recent study by Mueller and colleagues
(17), who have used Agilent miRNA microarrays. Of the 76
listed miRNAs associated with melanoma development and
progression, we only identified six to be correspondingly reg-
ulated in our data set (miR-27b, miR-92b, miR-10a, miR-182,
miR-26b, and miR-379), with the latter four being only weakly
expressed. This indicates that the use of different profiling
platforms together with the negative control cells and likely
even their passage number may result in strikingly different
conclusions drawn from the data. On the other hand, our
miRNA expression profiles of FFPE-extracted nevi was in
good agreement with results recently reported by Glud and
colleagues, who used Invitrogen arrays to profile miRNA
expression in 15 nevi (18). Taking into account the different
array platforms and miRBase versions that were used, we
found a remarkable 81% (68 of 84) of miRNAs to be similarly
expressed in both studies. Although FFPE samples represent
useful sources for miRNA profiling, it is important to keep in
mind that variable handling conditions as well as lengths and
conditions of storage may directly influence the degree ofwww.aacrjournals.org
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of some miRNAs.
Another source for intrinsic data variability stems from
the various biological sources that are used in miRNA pro-
filing studies. Several miRNAs, such as miR-155, miR-146a,
miR-23b, and miR-205, showed divergent expression pat-
terns in cell lines and patient samples, indicating tissue
culture–induced adaption processes that likely lead to
the loss or upregulation of certain miRNAs, which are
not present in patient material. Nonetheless, we identified
miR-25 to be upregulated in our samples, and this was in
line with a recent observation made in melanoma (30).
miR-200c was reproducibly downregulated in patients rela-
tive to nevi and was absent in normal human melanocytes
and cell lines. The loss or reduced expression of miR-200c
in melanoma cell lines has also been reported previously
(15). The miR-200 family (miR-200a, miR-200b, miR-200c,
miR-141, and miR-429) is clearly emerging as a key regula-
tor of differentiation in various cell types, and a marked
downregulation with tumor progression has been noted
for several cancers (31–33). The loss of E-cadherin expres-
sion in our melanoma cell lines is consistent with absent
miR-200c expression, which releases repression of the tran-
scription factor ZEB1, which in turn suppresses E-cadherin
gene transcription (34). In doing so, the miR-200 family be-
comes an important regulator of epithelial-to-mesenchymal
transition (EMT), a key process for initializing metastasis,
and might therefore represent one of the most promising
miRNA candidates for therapeutic intervention (35). Inter-
estingly, downregulation of miR-205 has also been impli-
cated in the EMT processes (33). Reduced amounts of
miR-205 with tumor progression were detected in all of
our melanoma patients, although melanoma cell lines
showed slightly increased expression of this miRNA.
Olson and colleagues showed that miR-25 was upregulated
2.6-fold in hyperproliferative stages of pancreatic tumors
whereas miR-146a was downregulated 8.4-fold in metastatic
lesions, a pattern that we have also observed in melanoma
patient samples (36). It is noteworthy that miRNA-15b has
recently been suggested to be a prognostic marker for mela-
noma progression (37). Although melanomas have indeed
high levels of miR-15b, we also detected these elevated levels
in nevi, questioning the usefulness of this miRNA as a bio-
marker for melanoma.
Taken together, miRNA-205, miRNA-200, and let-7 family
(-125b, -146a, -155, -21, -25, -23a, -29b) have repeatedly been
shown to become deregulated with tumor progression in
general and in melanomas in particular (this study and refs.
12, 38). Although this is by no means an exclusive list, it cer-
tainly contains some of the most promising miRNAs for ther-
apeutic intervention or to be further evaluated for their
biomarker potential in larger patient cohorts.
Having identified several miRNAs that could be of value
for the understanding of melanoma development, we set
out to find potential target genes by analyzing mRNA expres-
sion patterns in primary melanocytes (NHEM) and two mel-
anoma cell lines. As expected, many genes previously linked
to melanoma development were found to be deregulated,Cancer Res; 70(10) May 15, 2010 4171
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IGR39 cells (primarymelanoma) with the cell line derived from
a metastatic tumor of the same patient (IGR37; Fig. 3). For
example, cKIT was slightly downregulated in IGR39 whereas
its levels were augmented with disease progression in IGR37.
It has been shown that miR-221/miR-222 downregulates cKIT
and p27 in melanomas, thus favoring a malignant phenotype
(30), and another study suggested that melanoma subgroups
exist, which overexpress mutated and active cKIT (39). qPCR
for miR-221 and cKIT confirmed this by a perfect inversely
correlated expression pattern on all our melanoma cell lines
(Supplementary Fig. S1).
Inverse correlation of miRNA expression with their ten-
tative target genes is a useful approach to reduce the gen-
erally extensive number of computationally predicted
target genes for further analysis. In combination with ex-
amination of biological pathways targeted by the deregu-
lated miRNAs, Ingenuity analysis indicated that the
regulatory network around MITF was most prominent in
melanoma cell lines (Fig. 4A). MITF is critically involved
in regulation of melanocyte growth, maturation, apoptosis,
and pigmentation (40, 41). Over 20% of metastatic melano-
mas have been found to carry genetic alterations in the
MITF pathway (MITF or SOX10 mutations; ref. 42), and
amplification of MITF has been linked to poor patient sur-
vival (26). By nucleosome mapping and chromatin struc-
ture analysis, Ozsolak and colleagues have identified
several miRNA promoters that were occupied by MITF
(28). Of those, miR-146a, miR-221, and miR-363 were exper-
imentally confirmed to be regulated by MITF. qPCR anal-
ysis of candidate miRNA-23a and miRNA-23b levels
predicted to target MITF, as well as of cKIT and miRNAs,Cancer Res; 70(10) May 15, 2010
American Asso Copyright © 2010 
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the central part of the predicted pathway (Fig. 4B).
Although altered expression of the miRNome has been well
documented in many cancers, it remains to be shown how
single and/or groups of miRNAs or the whole of the miR-
Nome drives or allows for neoplastic transformation. A key
prerequisite to these analyses is, however, an accurate and
standardized quantification of the miRNA expression levels
in a sufficient number of clinical samples and matching cell
lines, as effects seen in one cell line or patient might be quite
different from those found in another, in which other poten-
tial target genes and also other modulators of miRNA activity
may be present. This is even more so as minute changes in
miRNA levels may have profound consequences for the cell
(2). Accurate and extensive measurements of miRNA levels
together with improved computational target gene predic-
tions and pathway analyses will surely be necessary before
miRNAs make their way into the clinic as robust biomarkers
and/or as therapeutic targets.
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Introduction
MicroRNAs (miRNAs), a class of small non-coding RNAs (~22 
nt), were initially discovered in Caenorhabditis elegans almost 
two decades ago1 and have attracted much attention as major 
regulators of gene expression since.2 The biogenesis of miRNAs 
from miRNA genes has been extensively studied in recent years 
and is reviewed in references 2 and 3. Most miRNAs are encoded 
in intergenic regions, but some are also hosted within introns 
of pre-mRNAs.4,5 Approximately 50% of mammalian miRNA 
loci are located in close proximity to those of other miRNAs. 
So-called miRNA clusters are usually composed of two or three 
miRNAs, which may share similarity in sequence but which are 
not necessarily identical.6 Accumulating evidence suggests that 
most clustered miRNAs are transcribed from single but complex 
transcription units, even though there might be exceptional 
cases in which clustered miRNAs are transcribed individually 
from separate gene promoters.7 Although the precise localization 
of promoter regions of the majority of autonomously expressed 
miRNAs has not been fully mapped, it has been shown that these 
regions are highly similar to those of protein-coding genes.8 In 
general, intergenic miRNAs are believed to be transcribed by 
their own promoters, whereas intronic miRNAs are coordinately 
transcribed with their host gene.9
MicroRNAs are major players in post-transcriptional gene regulation. even small changes in miRNA levels may have 
profound consequences for the expression levels of target genes. hence, miRNAs themselves need to be tightly, albeit 
dynamically, regulated. here, we investigated the dynamic behavior of miRNAs over a wide time range following 
stimulation of melanoma cells with interferonγ (IFNγ), which activates the transcription factor sTAT1. By applying 
several bioinformatic and statistical software tools for visualization and identification of differentially expressed miRNAs 
derived from time-series microarray experiments, 8.9% of 1105 miRNAs appeared to be directly or indirectly regulated 
by sTAT1. Focusing on distinct dynamic expression patterns, we found that the majority of robust miRNA expression 
changes occurred in the intermediate time range (24–48 h). Three miRNAs (miR-27a, miR-30a and miR-34a) had a delayed 
regulation occurring at 72 h while none showed significant expression changes at early time points between 30 min 
and 6 h. expression patterns of individual miRNAs were altered gradually over time or abruptly increased or decreased 
between two time points. Furthermore, we observed coordinated dynamic transcription of most miRNA clusters while 
few were found to be regulated independently of their genetic cluster. Most interestingly, several “star” or passenger 
strand sequences were specifically regulated over time while their “guide” strands were not.
Dynamic regulation of microRNA expression 
following interferonγ-induced gene transcription
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In recent years, miRNAs have emerged as key post-
transcriptional regulators of gene expression as they are predicted 
to directly control the expression of at least 50% of all protein-
coding genes in mammals.2 A single miRNA may control the 
expression levels of several hundred mRNA targets and on 
the other hand, a given mRNA can be regulated by several 
miRNAs.10,11 Due to the fact that deregulation of miRNAs is 
often implicated in human diseases, precise control of miRNA 
amounts is crucial in order to maintain normal cellular 
functions. An initial point of regulation in miRNA biogenesis 
is transcription of miRNA genes, which is a tightly controlled 
multi-step process. Levels of gene expression are often controlled 
by auto-regulatory feedback loops in which miRNAs participate 
together with transcription factors (TFs).2,3,12 However, only few 
examples of TF-mediated miRNA expression have been described 
so far: the oncogenic TF c-myc and the hypoxia-induced factor 
(HIF) have been shown to regulate the expression of individual 
or clustered miRNAs positively or negatively in a tissue-specific 
manner.13-15 Also, STATs (signal transducer and activator of 
transcription) do not only induce protein-encoding target genes 
(like SOCS1, IRF1 and many others) but also appear to drive 
transcription of miRNA genes.16-18 The few known interactions 
include a positive feedback loop between STAT1 and miR-155, 
where STAT1 upregulates miR-155, which in turn downregulates 
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for 12 h while P-STAT1 signals began to gradually wane after 
18 h. Functional activity of the TF was assured by analyzing 
two target genes of STAT1. In line with previous reports in 
reference 36, STAT1 itself and IRF-1 were both upregulated 
by STAT1, albeit with different kinetics. Furthermore, differ-
ent concentrations of the JAK-specific kinase inhibitor JII were 
tested in order to define a minimum concentration to prevent 
activation of STAT1 (Fig. 1B). Lower concentrations (200 nM 
and 1 μM) were not sufficient to fully suppress STAT1 acti-
vation. Pre-incubation with 5 μM JII was adequate to almost 
completely inhibit STAT phosphorylation (right) and this con-
centration was used in the time-course experiments. Figure 1C 
shows STAT1 activation status of samples that were subjected to 
microarray and/or RT-qPCR analyses.
Analysis of time-series microarrays. In total, 20 microarrays 
(two samples for every time point including the untreated and 
the JII pre-treated samples at 72 h) were included in the study. 
Quality control scatter plots illustrated good reproducibility 
of the expression data (Fig. S3A and S3B). Reproducibility of 
array experiments was evaluated by calculating coefficients of 
determinations (r2) between expression data (Fig. S4). Overall, 
the coefficient of determination between duplicate RNA samples 
was high (mean r2 ~ 0.967) and was enhanced even more (mean 
r2 ~ 0.989) after filtering out lowly expressed miRNAs. This 
indicates that most variability between arrays was detected in the 
very low expression range close to the detection limit. Mean r2 
values for biological replicates were significantly higher than r2 
for non-replicate samples: 0.989 vs. 0.890, respectively (p-value 
is 9.45 × 10-8), indicating a good reproducibility for the biological 
replicate samples considered in the study.
To obtain a global view of the time evolution of the miR-
Nome, all miRNAs were analyzed by GEDI (Fig. 2). Each 
sample exhibits a characteristic color pattern, reflecting the tran-
scriptional behavior over time. Although IFNγ treatment has 
shifted global miRNA expression patterns already after 30 min, 
overall expression changes were small (note the color bar: maxi-
mum change range 0.7, with all values normalized to the mean 
of the untreated control). Candidates that were upregulated 
between 0.5 h and 12 h (upper right corners of self organizing 
maps (SOMs)-based mosaics) included miRNAs present in the 
complete data set only, which were removed after threshold filter-
ing for downstream analyses (see below). The majority of robust 
expression changes were scored after 24 h of IFNγ treatment 
and after 48 h a clear separation between up and downregulated 
miRNAs became evident.
After filtering out miRNAs whose maximum log
2
 expression 
values never exceeded 7.0 in all of the 9 different time points, 158 
miRNAs remained, which were then analyzed by unsupervised 
hierarchical clustering (Fig. 3A). The filtering threshold was 
chosen because we had previously established that miRNAs 
associated with hybridization signal intensities below log
2
 of 
7.0 using Affymetrix technology were not reliably detectable 
by RT-PCR (data not shown). The heatmap illustrates that 
the majority of differentially expressed miRNAs were either 
upregulated (~50 miRNAs) or downregulated (~80 miRNAs) at 
around 24 h of IFNγ treatment. Several miRNAs appeared to 
SOCS1, a negative inhibitor of JAK/STAT signaling.19 Further, 
STAT3-mediated regulation of miR-21, miR-181b, miR-17–92 
and miR-199a-5p has also been described in references 16 and 
20–22. Inactive STATs become activated by extracellular 
signals, mainly through cytokines and growth factors that bind 
to cell surface receptors.23,24 STAT1 responds to type I and 
type II interferons and has been implicated in host anti-tumor 
responses.25,26 In this context, Yang and colleagues have recently 
shown that type I interferon-induced upregulation of miR-21 was 
STAT3-dependent and resulted in inhibition of IFN-induced 
apoptosis.27 Here, we used IFNγ-induced activation of STAT1 to 
trigger miRNA transcription in a melanoma cell model. Although 
some TF-mediated miRNA activations have been documented, 
the dynamic nature of this transcriptional regulation has, to our 
knowledge, not been investigated much so far.
Microarray assays have become a widely used technology to 
study gene regulations by measuring global expression patterns of 
genes or miRNAs. The comparison of steady-state expression lev-
els of healthy vs. diseased states or treated vs. untreated samples 
has become a routine tool in many laboratories in recent years.28 
In a static experiment, the samples are obtained irrespective of 
time, providing only a “snapshot” of gene expression. However, 
gene expression is generally not considered a static process result-
ing in a steady-state level of transcripts, but is highly variable over 
time depending on cell types, environmental influences, cellular 
physiology, phenotypes and circadian rhythms and can as such be 
considered a “dynamic information processing system.”29-31 The 
aim of this study was the investigation of dynamic and global 
miRNA expression patterns following activation of miRNA gene 
transcription in a detailed time-course experiment. In the experi-
mental setup, the transcription factor STAT1 was activated by 
IFNγ stimulation of melanoma cells in order to identify STAT1-
regulated miRNAs over time. We chose the melanoma cell sys-
tem and the JAK/STAT signaling cascade as these experimental 
systems are well characterized in our laboratory32-34 and have pre-
viously been established to be suitable for specific activation of 
subsets of miRNAs.18,35 For analysis (clustering, visualization and 
identification of differentially expressed miRNAs) of time-series 
microarray data sets, we used and compared different biostatisti-
cal approaches in order to gain insights into global regulation of 
the miRNome as well as into the behavior of individual miRNAs 
after transcriptional activation.
Results
In a detailed time-course, A375 cells were stimulated with IFNγ 
and, in parallel, pre-treatment with JAK Inhibitor I (JII) was 
performed. Selected RNA samples were subjected to microar-
ray analysis, followed by identification of differentially expressed 
miRNAs using different statistical methods. Temporal expres-
sion changes of selected miRNAs were verified by RT-qPCR 
(Fig. S1).
Stimulation of A375 cells resulting in subsequent activation 
of STAT1 was confirmed by western blot analysis of protein 
lysates (Fig. 1). Strong STAT1 phosphorylation was already 
detectable after 15 min of IFNγ treatment and remained elevated 
980 RNA Biology Volume 9 Issue 7
first cluster had no significant regulation, the sharp increase in 
between the two untreated control samples was likely due to the 
slightly higher variation of those duplicate data sets. Similarly, 
the larger positive and negative peaks for the 6 h time point also 
reflect higher variability among those duplicate samples.
Taken together, different clustering approaches revealed that 
during the analyzed time course reproducible dynamic changes 
in miRNA expression levels occurred. In samples from short 
periods of IFNγ stimulations (less than 12 h), small expression 
changes were detected for five individual miRNAs (Fig. 3A). 
However, after 24 h, levels of most of the expressed miRNAs 
were profoundly altered indicating that IFNγ-induced JAK/
STAT signaling takes approximately one day to result in measur-
able transcriptional expression changes of the miRNome.
Identification of groups of differentially expressed miRNAs 
over time. In order to elucidate the transcriptional responses 
to IFNγ-treatment in more detail, three statistical programs 
were used that were specifically designed to analyze replicated, 
be upregulated very rapidly after IFNγ stimulation (30 min–6 
h) however, these changes were not significant, rather small with 
maximum fold changes up to 1.5 relative to the untreated control 
and could also be unspecific fluctuations in expression changes. 
On the other hand, a clearly delayed upregulation, which only 
occurred after 48 h was detected for miR-34a, miR-30a and miR-
27a (Fig. 4).
Next, we subjected the filtered miRNA data set to soft 
clustering by Mfuzz (Fig. 3B). The upper part represents time 
evolution of individual miRNA expressions that were altered upon 
treatment, and in the lower panel the averaged expression profiles 
of all miRNAs in the respective cluster are displayed. Cluster 2 
and 3 were comprised of miRNAs with high membership values 
(colored in red) representing very similar expression profiles. 
Three major expression profiles were found with either very small 
randomly fluctuating changes (cluster 1) or pronounced up or 
downregulated miRNAs after 24 h of IFNγ treatment (cluster 
2 and 3, respectively). Although the averaged profile in the 
Figure 1. sTAT1 activation by IFNγ. (A) A375 cells were treated with human IFNγ (50 ng/mL) up to 96 h. proteins were detected with antibodies against 
psTAT1, sTAT1 and IRF1. Tubulin or actin served as loading controls. (B) Titration of JAK-Inhibitor I (JII). A375 cells were pre-treated with different JII con-
centrations followed by IFNγ (50 ng/mL) to monitor the inhibition of the Janus kinases. (c) All samples selected for microarray and/or RT-qpcR analysis 
were monitored for sTAT1 phosphorylation and the lack thereof following JII treatment.
www.landesbioscience.com RNA Biology 981
expression evolution for 158 filtered miRNAs, we identified four 
distinct dynamic patterns: (1) gradual upregulations, the most 
frequent type of activation model; (2) abrupt upregulations, where 
expression was sharply amplified between two time points; (3) 
delayed upregulations at around 72 h, which are possibly due to 
secondary effects and (4) gradual downregulations, which might 
be caused by indirect effects following STAT1 activation that 
result in suppression of these miRNAs. In addition, we observed 
very isolated events with an expression peak at one time point 
followed by a rapid return to baseline levels (miR-146b and miR-
367). Parallel duplicate treatments with JII (at 72 h) abrogated 
JAK/STAT signaling and therefore counteracted IFNγ-specific 
transcriptional regulation of all selected miRNAs (depicted by 
crosses, Fig. 4). This modeling approach documents the different 
dynamic courses of individual miRNA regulations, highlighting 
the importance to consider the parameters “time” and “dynamics 
of expression” when analyzing miRNA expression patterns.
Validation of individual miRNA expression patterns. For 
the validation of microarray results by RT-qPCR, 14 miRNAs, 
some of which had already been described to play a role in cancer, 
were chosen to represent up, down and non-regulated miRNAs 
as well as “star”-sequences and genetically clustered miRNAs. 
The majority of clustered miRNAs share a genome location in 
a region smaller than 10 kb, together with two or more other 
miRNAs. Table S3 lists those miRNAs and the correspond-
ing program(s) by which they were identified, their direction of 
regulation as well as information derived from miRBase (version 
17).38 Figure 6A illustrates that microarray-measured expression 
levels over time were confirmed for both strands of the selected 
miRNAs and irrespective of type, direction or time of regulation. 
In qPCRs, JII-treated control samples were analyzed for all time 
points (hatched bars), clearly demonstrating that regulations of 
miRNAs were averted when JAK signaling was interrupted, indi-
cating that observed modulations of miRNA levels were indeed 
caused by cytokine-induced activation of the JAK/STAT path-
way. Individual miRNAs differed considerably with regard to 
their temporal induction patterns. For example miR-21, a known 
target of STAT3,16 was upregulated 48 h after IFNγ stimulation 
and expression remained high up to 96 h. The same expression 
pattern, however, with a stronger upregulation (fold change of 
8.7 in microarray analysis and up to 4 fold change in RT-qPCR) 
was found for miR-424* while miR-149 was downregulated after 
24 h in response to IFNγ. MiR-25 remained unaffected by IFNγ 
time-series microarray data. The individual programs are 
described in more detail in Material and Methods and in the 
Supplements. In the current study, these programs were applied 
in order to generate a robust set of differentially expressed 
miRNAs over time, which were jointly identified by the different 
algorithms. For all calculations only expressed miRNAs (after 
the filtering step) served as input. The resulting 158 miRNAs 
(14.3% of all human and mature miRNAs on the chip) were 
used for further statistical analysis. Figure 5A summarizes the 
results of all three programs in a Venn diagram with a total of 
98 miRNAs being differentially expressed. EDGE returned 
a list of 95 differentially expressed miRNAs (60%), while the 
betr function identified 69 out of 158 miRNAs (~43%) with a 
probability of 1 to be differentially expressed. The timecourse 
package ranked all 158 miRNAs according to the Hotelling 
T2 statistics (see Sup. Materials and Methods). By setting the 
cut-off threshold to a FDR of 0.05, we identified 23 miRNAs 
(~15% of expressed miRNAs), which had also been detected by 
the other two programs (listed in Table S2). The heatmap (Fig. 
5B) visualizes expression levels of those 23 commonly identified 
miRNAs over time.
Bioinformatic analysis revealed distinct dynamic activation 
patterns for groups of seemingly co-regulated miRNAs. In 
contrast to a recent study where several miRNAs were found to 
be strongly upregulated after 30 min of IFNβ treatment,37 we 
found several miRNAs reacting slightly to our transcriptional 
stimulus in the early time periods, albeit none of these expression 
changes were significant (Figs. 3A and 4). The majority of strong 
miRNA alterations occurred in the intermediate (around 24 h) 
time ranges. In total, we identified 98 differentially expressed 
miRNAs, whose levels were either increased or attenuated in 
response to IFNγ (Fig. 5A). The three statistical programs used 
here commonly identified 23 differentially and significantly 
regulated miRNAs (all amplitudes of regulations > 2.3-fold). Of 
those, seven were downregulated at around 24 h while 16 were 
upregulated following STAT1 activation (Fig. 5B). The heatmap 
visualizes expression changes over time and further illustrates 
that the 24 h time point appears to be a transitional phase where 
most regulatory events are beginning to manifest.
Dynamic expression changes of individual miRNAs. In order 
to visualize time evolution of expression changes, we built smooth 
regression models (Fig. 4) by the logistic function described in 
Supplemental Materials and Methods. Analyzing the models of 
Figure 2. GeDI maps (mosaics) representing progression of expression profiles after IFNγ stimulation of A375 cells for the indicated time periods. Log2-
transformed expression levels were used for analysis of each miRNA relative to the untreated sample (ctrl), which served as a control. On the right, 
a sOM map color bar indicates log2 values: highest expression levels (red) and lowest expression levels (blue). GeDI maps are displayed for all 1,105 
miRNAs simultaneously for each treatment time point. The expression profiles of 18 arrays (duplicates) corresponding to 9 time points were visualized 
as 9 GeDI maps, each consisting of a 13-by-12 mosaic, representing 156 mini clusters.
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stimulation (Table S1) and therefore served as a non-regulated 
control miRNA in qPCR validations (Fig. 6A).
To examine whether clustered miRNAs are co-regulated, 
we compared profiles of members of several genetic clusters. 
For example, the miR-23 and miR-27 families are coordinately 
regulated with miR-23a~27a of the first cluster being upregulated 
while members of the second cluster (miR-23b- and -27b) were 
downregulated (Fig. 6B). Other clusters like miR-29a~29b1 and 
miR-29b2~29c also showed a very obvious co-regulation (data not 
shown), which was to be expected given that clustered miRNAs 
are generally (but not always) transcribed together. Adversely, 
some genetically clustered miRNAs like miR-92a~18a and miR-
93~25 appeared to be regulated independently showing completely 
divergent expression patterns over time (data not shown).
Apart from the different dynamic regulation patterns, biosta-
tistical analysis revealed another interesting and rather unexpected 
finding: passenger strands (so called “star” sequences, labeled 
with “*”) were often and specifically regulated. Surprisingly, four 
“star” sequences (miR-424*, miR-29b-1*, miR-27a* and miR-
23a*) were among the top 10 miRNAs displaying maximum fold 
changes > 4 in qPCR analyses and even higher values in micro-
array results. Examples of “star” strand regulations are given in 
Figure 6B with miR-23a* and miR-27a* being clearly increased 
between 12–24 h of IFNγ stimulation, while expression levels of 
the respective guide strands were largely unaffected. In contrast, 
both strands of miR-27b and miR-23a were similarly downregu-
lated over time.
In summary, detailed data analyses of this miRNA time 
course revealed several new findings: (1) in the melanoma cell 
model used here, 14.3% (158 of 1105 human and mature miR-
NAs) were detected to be expressed and of those 62% (98 of 158) 
were differentially expressed following IFNγ stimulation, which 
activated the STAT1 TF; (2) 23 differentially expressed miRNAs 
were commonly identified by three different statistical programs, 
which included gradual as well as abrupt up and downregulation 
events over time. (3) Most regulatory events occurred around 
24 h after IFNγ stimulation with only three miRNAs showing 
a delayed reaction at 72 h. (4) Inhibition of JAK/STAT signal-
ing (by JII treatment) abrogated most responses implying a spe-
cific JAK-dependent and likely STAT-mediated transcriptional 
induction. (5) Most genetically clustered miRNAs were tran-
scriptionally co-regulated. (6) Finally, several “star” strands were 
dynamically and strongly regulated while their guide strands 
remained unaffected.
Discussion
MicroRNAs are known to influence fundamental cellular activities 
in health and disease through their ability to post-transcriptionally 
Figure 3. (A) expression evolution of 158 miRNAs presented as a heat-
map. expression values were standardized (transformed to z-scores) 
and miRNAs were re-ordered by unsupervised hierarchical clustering 
using euclidean distance. colors for each miRNA represent z-scores and 
derive from “inter-miRNA-standardisations” with red corresponding to 
high standardised expression levels and blue representing low expres-
sion levels.
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of melanoma cells.42 Here, we asked if and which miRNA genes 
could be specifically targeted by IFNγ-induced STAT activation 
and which dynamic patterns these potential activation processes 
would follow.
Thus far, only a small number of studies have addressed inter-
actions between miRNAs and STAT factors and even fewer have 
investigated dynamic issues of miRNA regulation. Very recently, 
IFNα-induced upregulation of miR-21 has been demonstrated 
to be an early event (after 2 h of IFNα treatment), which was 
directly co-mediated by STAT3 and NFκB.27 Löffler and col-
leagues investigated the role of STAT3 in the regulation of miR-
21 by quantifying primary and mature miR-21 by RT-qPCRs. 
They showed that the induction of miR-21 was controlled by 
IL-6 and required STAT3 in myeloma cells. However, in contrast 
to the rapid induction of the primary miR-21 already after 1 h, 
the mature miR-21 levels increased slowly (up to 5 d),16 which is 
in line with our findings of miR-21 remaining upregulated for up 
to 96 h. At the same time, Pedersen et al. analyzed kinetic induc-
tion of miRNAs following IFNβ stimulation. They performed a 
short time-series experiment with 5 time points after stimulation 
of a human hepatoma cell line and primary hepatocytes for 0.5 h, 
2 h, 8 h, 24 h and 48 h. IFNβ rapidly and strongly modulated the 
expression of few miRNAs (among them miR-1 and miR-196) 
regulate gene expression of most genes. However, not much is 
known about the transcriptional activation and regulation 
of miRNA genes themselves. Transcription is a dynamic and 
well controlled process allowing the cell to respond flexibly to 
environmental stimuli and internal signals. Transcription factors 
(TFs), among other gene transcriptional regulators, mediate such 
responses in order to quickly adapt to changes by influencing the 
expression of relevant genes including those encoding miRNAs. 
In order to better understand the principles of these complex 
interactions and to investigate the dynamics of TF-mediated 
miRNA regulation, we chose the JAK/STAT pathway as a model 
system in A375 malignant melanoma cells, both well-established 
experimental systems in our laboratory, which furthermore, can 
be controlled at several steps.32,34,39 Cytokine signaling in general 
is of major importance for the mammalian immune system as it 
mediates cellular response to infections, inflammatory processes 
and transformation of normal into malignant cells.40 Almost all 
cell types can come into contact with surrounding cytokines, 
e.g., interferonγ, which is mainly secreted by activated T and 
NK cells.41 Interferons predominantly signal through the JAK/
STAT pathway culminating in STAT-mediated transcriptional 
activation of target genes. Interestingly, IFNγ-mediated STAT1 
activation has previously been shown to induce growth inhibition 
Figure 3. (B) soft clusters of miRNA expression data using Mfuzz. Temporal expression patterns obtained during the time-course experiment of A375 
cells treated with IFNγ for the indicated time points. Overall expression patterns (upper part) and average expression patterns (lower part) were dis-
played. profiles of three major clusters were found: small irregular regulations (cluster 1), up and downregulation of miRNAs over time (cluster 2 and 3, 
respectively). Light and dark blue colored lines correspond to miRNAs with low membership; red colored lines represent miRNAs with high member-
ship values. On the x-axis arrays for the replicated time points were placed next to each other, the y-axis represents standardised expression values.
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but also activated by IFNγ (e.g., via the MAPK pathway) could 
participate in the direct or indirect regulatory events we have 
observed here. Repressors of miRNA transcription, which are 
regulated by STAT1 or other IFNγ-regulated TFs could explain 
the delayed responses and downregulation events we have scored 
and might indicate that most of the late regulatory events are 
rather indirect effects of STAT1 activation (Figs. 5 and 6). Even 
though we and others have previously shown that JII specifically 
inhibits JAK/STAT signaling in melanoma cells and human 
retinal pigment epithelial cells,19,34,44 it cannot be entirely ruled 
out that JAK-independent factors also play a role in IFNγ-
induced miRNA transcription.
To investigate the presence of potential STAT binding sites, 
we performed an overlay of a publicly available ChIP-Seq data set 
of IFNγ-stimulated HeLa cells45 with Jaspar-generated profiles 
of promoter regions of the 23 commonly identified miRNAs. 
All 23 miRNAs turned out to have 2 to 14 STAT binding sites 
within 50 kb upstream of their genomic location, while 15 miR-
NAs had 1–3 STAT binding sites within 10 kb (data not shown). 
Taken together, the presence of STAT binding sites in their pro-
moter regions, the dynamic regulation of these miRNAs as well 
as the abrogation of their transcriptional activation by JII are 
highly suggestive of a direct regulation of a subset of miRNAs by 
STAT TFs. The importance of these complex, but so far scarcely 
within 30 min.37 In the melanoma cell line used here, we did 
not observe any statistically significant regulations during early 
time periods (30 min–6 h). Expression level alterations for those 
few “early responders” were weak and not sufficiently reproduc-
ible between duplicate samples. Therefore, in our experimental 
setup, earliest and robust expression changes started to emerge 
well after 12 h.
Another interesting interaction between a miRNA (miR-155) 
and STAT factors (STAT1) in form of a positive feedback loop 
has recently been described by Kutty et al.19 who demonstrated 
that miR-155 expression levels in human retinal pigment 
epithelial (HRPE) cells gradually increased over a period of 24 h 
after exposure to inflammatory signals (cytokine mixture TNFα, 
IL-1β and IFNγ). Recently, Wang and colleagues identified 83 
active promoter regions of miRNA genes in IFNγ-treated HeLa 
cells, 41 of which contained STAT1 binding sites.43 In their in 
silico study, they used a bioinformatic approach to analyze high-
throughput functional genomic data. ChIP-Seq experiments 
provided TF as well as RNA Pol II binding sites, which were 
used to construct potential feedback loops containing regulatory 
cascades of TFs and miRNAs. They found that 51.4% of STAT1-
targeted miRNAs contained AP-1 binding sites suggesting that 
such interactions could also be involved in the regulation of 
miRNA transcription. In this context, TFs other than STAT1, 
Figure 4. Time evolution of log2 expression values for selected miRNAs exemplifying the four different dynamic expression patterns. Individual 
microarray-based expression results are illustrated by black dots in a natural timescale (hours). A smooth model was built using regression with a 
parameterised logistic function as detailed in Supplemental Materials and Methods. crosses represent JII-control experiments at 72 h. expression 
profiles of miRNAs highlighted with gray boxes have been validated by RT-qpcR.
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have been classified into two types: homo-clusters (composed 
of miRNAs from a single family) and hetero-clusters (miRNAs 
from multiple families).46 Usually members of the same miRNA 
family target a similar set of mRNAs because they share the same 
seed region,47 which predominantly determines the targets of 
miRNAs.48 Accordingly, we have identified a co-regulated homo-
cluster (miR-29a~29b1*, data not shown) and two hetero-clusters 
(miR-23a~27a and miR-23b~27b), which had reverse expression 
patterns: miR-23a~27a was upregulated, while miR-23b~27b 
was downregulated (Figs. 5 and 6) suggesting overlapping 
regulatory roles of these important miRNA clusters, which are 
often augmented in multiple types of cancers.49
Surprisingly, almost 10% of the 98 differentially expressed 
miRNAs were passenger strands (*). The co-accumulation of 
both “sister” strands of miRNA pairs does not necessarily imply 
that both are functional, however, functional roles of miRs* 
are being increasingly recognized and described. Tsang and 
Kwok showed that miR-18* may function as a potential tumor 
suppressive miRNA by targeting K-Ras.50 In contrast to let-
7, which targets both K-Ras and H-Ras, miR-18* only targets 
K-Ras mRNA. This specificity might be important for targeting 
the specific isoforms of Ras and therefore it was suggested that 
miR-18* could serve as therapeutic agent in future cancer therapy. 
Recently, it was demonstrated that well-conserved vertebrate 
miR* species such as miR-19* have an impact on regulatory 
networks and should be taken into account when studying 
functional roles of miRNAs and their contribution to disease.51 
In this context, “*”-designations have been removed in the latest 
version of miRBase (v18) and only 5'- and 3'-designations are 
used to describe the two opposite miRNA strands indicating 
equally important roles the two strands may have. Remarkably, 
among the 10 most upregulated miRNAs we noted four passenger 
strands (miR-424*, miR-29b1*, miR-27a* and miR-23a*). A 
possible tissue-specificity of passenger vs. guide strand sequences 
as well as the regulatory function of the miRs*-sequences will 
have to be investigated further in order to establish differential, 
similar or possibly synergistic roles of both miRNA strands.
Another aspect of this study was the grouping of miRNAs 
according to their temporal expression patterns. We applied 
several unsupervised learning techniques (GEDI, Mfuzz, 
heatmaps) and a modeling approach to reveal hidden structures 
in large expression data sets. Using only miRNAs which were 
detectable in our melanoma cells (filtered data set), most robust 
expression changes (either gradual or abruptly between two time 
points) became evident at around 24 h after stimulation with 
IFNγ. Later time intervals (48 h and later) produced a distinct 
separation in either up or downregulated miRNAs with only 
three examples showing a delayed activation type (72 h). Early 
expression changes (30 min–6 h) detectable in our melanoma 
cell line were few and negligible. Whether some of these rather 
small increases in miRNA levels may still have functional 
consequences for their respective target genes and as such for 
the cellular responses to IFN-induced signaling, remains to be 
investigated. In this context, Perry and colleagues52 have shown 
that two miRNAs (miR-146a and miR-146b) were induced 3 h 
after IL-1β treatment in A549 human alveolar lung epithelial 
described interactions between STAT factors and miRNAs has 
been highlighted in a recent review in reference 18.
It is generally assumed that genetically clustered miRNAs 
are coordinately transcribed.7 In this context, the TF c-Myc 
has been shown to directly regulate the miR-17 cluster, which 
comprises a region encoding six miRNAs.15 Here, we have found 
genetically clustered miRNAs to be regulated together as well as 
independently of one another. For instance, miR-23b and miR-
27b were both downregulated during the time-course experiment 
while miR-24-1, the third member of this cluster (Fig. 6B; Table 
S3), was not detected in A375 cells. Recently, miRNA clusters 
Figure 5. (A) Venn diagram displaying the overlay of results from three 
biostatistical programs. MiRNAs from each program are listed in Table 
S2. (B) heatmap displaying the expression of 23 miRNAs identified by all 
three statistical tools.
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Figure 6. For figure legend, see page 987.
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at the end of the course for further experimental analyses. Prior to 
this, optimal concentrations of JII, a potent JAK inhibitor, which 
prevents activation/phosphorylation of STAT1, were determined 
(Fig. 1).
RNA extraction and quality control. Two methods for RNA 
extraction were used according to the manufacturer’s instruc-
tions for different downstream applications: (1) miRNeasy 
Mini kit (Qiagen) with an additional on-column DNase I diges-
tion for microarrays and (2) TRIsure (Bioline) for downstream 
RT-qPCR validations. All RNA extractions were performed on 
three biological replicates each consisting of three technical rep-
licates for each of the stimulation time points. RNA quality and 
purity were assessed by a Nanodrop 2000 Spectrophotometer 
(Thermo Scientific) and with an Agilent 2100 Bioanalyser 
(Agilent Technologies).
Real-time qPCR. A total of 14 miRNAs were selected for 
real-time quantitative PCR (RT-qPCR, Bio-Rad CFX96 system, 
Bio-Rad Laboratories) in order to validate the microarray results. 
Reverse transcription (RT) of triplicate RNAs from IFNγ and 
JII-treated cells was performed for all time points using the miS-
cript Reverse Transcription kit and miScript Primer assays (both 
from Qiagen) as described in reference 32. For miRNA expres-
sion analysis, three endogenous reference controls were included: 
RNU1A, RNU5A and SCARNA17, which are small non-coding 
RNA species expressed in the A375 cell line and which had pre-
viously been tested not to be differentially regulated by IFNγ 
stimulation or JII pre-treatment (data not shown). Based on the 
geometric mean of the three reference genes, a normalization fac-
tor was calculated for each sample using geNorm, a VBA applet 
for Microsoft Excel.53 The relative amount of each miRNA in 
each sample was then corrected by dividing its amount with the 
corresponding normalization factor. Finally, the fold change of 
each miRNA for each time point after IFNγ stimulation with 
or without JII pre-treatment, was calculated by dividing its 
normalized relative amount by the normalized relative amount 
of the untreated sample that served as control. All RT-qPCRs 
were performed in technical triplicates on each of the biological 
replicates.
Western blot. Western blots were performed as described 
before in reference 34, to detect phosphorylation of STAT1 and 
upregulation of STAT1 target genes using the following pri-
mary antibodies: anti-(pY701)-STAT1 (dilution 1:1,000, BD 
Transduction Laboratories), anti-STAT1 (dilution 1:1,000, BD 
Transduction Laboratories), anti-IRF1 (dilution 1:1,000, Santa 
Cruz), anti-α-tubulin (dilution 1:4,000, Santa Cruz) and anti-
actin (dilution 1:4,000, Millipore).
miRNA microarray expression profiling. The global 
expression patterns of miRNAs after IFNγ stimulation were 
cells with their expression levels remaining elevated until the end 
of the time-course at 24 h. In contrast, we found miR-146b to 
have a strong expression peak at 24 h but then it immediately 
returned to baseline levels (data not shown). Although the 
regulation of miRNA stability may play an important role in the 
control of gene expression, very little is known about the decay 
and the half-lives of individual miRNAs. Further, it remains to 
be shown whether distinct dynamic miRNA expression behaviors 
are specific to certain cell types and transcriptional stimuli.
The current study aimed at investigating dynamic expression 
changes of miRNAs following transcriptional activation. Detailed 
microarray time-course experiments were performed to globally 
analyze miRNA expression patterns. A computational analysis 
pipeline consisting of several tools for efficient biostatistical inves-
tigation of dynamic data sets has been generated. Examination of 
the microarray-based results revealed distinct temporal groups of 
miRNA activation with most expression changes taking place at 
around 24 h. Individual miRNAs were found to follow highly 
diverse dynamic expression profiles emphasizing the importance 
of the parameter “time” when studying miRNAs. Furthermore, 
we observed that several miRNA passenger strands (miR*) were 
also specifically regulated and that genetically clustered miR-
NAs were often but not always co-regulated. Future elucidation 
of transcriptional regulation of miRNAs over time following 
diverse cellular or environmental stimuli will be necessary to 
obtain a more complete systems-biological view of complex regu-
latory networks in cells.
Materials and Methods
Cell culture. The human malignant melanoma cell line, 
A375 (ATCC, CRL-1619TM), was maintained in RPMI 1640 
medium supplemented with 10% fetal bovine serum (FCS, PAA 
Laboratories), 50 μg/mL penicillin, 100 μg/mL streptomycin 
and 0.5 mmol/L L-glutamine (all from Lonza) at 37°C in a 
humidified atmosphere with 5% CO
2
. Cells were tested routinely 
to be Mycoplasma negative. For all experiments described below, 
50,000 cells/well were seeded in 6-well plates.
Time-course experiments. To investigate a possible dynamic 
regulation of miRNAs, time-series experiments were performed 
as summarized in Figure S1. During the course of the experiment, 
biological triplicates of A375 cells were stimulated with human 
interferon gamma (IFNγ, PeproTech Inc., final concentration 
of 50 ng/mL) for the indicated periods of time or were left 
untreated (ctrl). In parallel, a second time-course experiment was 
performed including a pre-treatment step with 5 μM of Janus 
kinase inhibitor I (JII; Calbiochem), added one hour before 
commencing IFNγ stimulation. Cells were collected all together 
Figure 6. (See opposite page) Quantitative RT-pcR validation of selected miRNAs. Fold changes were calculated for each miRNA relative to the 
untreated control. Results are depicted as mean of biological triplicates plus standard deviation. Grey bars and lines illustrate “*” sequences while 
black bars and lines show guide strands. (A) Microarray-measured expression levels of miRNAs exemplifying no regulation over time (miR-25), 
upregulation of “star” strands only (miR-424*), of both strands (miR-21) and gradual downregulation (miR-149) are shown in the top graphs. Duplicate 
microarrays are plotted by two circles for each time point. expression values for the JII-control measurements at 72 h (72J) are shown on the far right 
of the graphs. In the graphs below, qpcR validations are depicted with hatched bars showing JII-treated controls. (B) co-regulations of genetically 
clustered miRNAs. All RT-qpcR expression levels were normalized to reference genes RNU1A, RNU5A and scarna17. statistical significance was 
determined by one-way ANOVA followed by a Dunnett’s Multi comparison test with ***p < 0.001, **p: 0.001–0.01, *p: 0.01–0.05.
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of heatmaps were performed using the heatmap.2 function of the 
R package gplots.
(C) To identify differentially expressed miRNAs statistical 
analyses were performed using three different approaches. The 
Extraction of Differential Gene Expression (EDGE) measures 
statistical significance of genome-wide studies based on the con-
cept of false discovery rate (FDR).57 The Bayesian Estimator of 
Temporal Regulation (BETR) algorithm58 calculates the prob-
ability of differential expression for each miRNA in the microar-
ray time-course data set. Finally, the timecourse package59 uses 
a multivariate empirical Bayes (MB) approach to rank differen-
tially expressed miRNAs according to the Hotelling T2 statistics. 
Additional and more detailed information on bioinformatics and 
statistical analyses is provided in the Supplemental Materials 
and Methods.
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analyzed using the Affymetrix GeneChip miRNA 2.0 Arrays and 
the FlashTag Biotin HSR RNA labeling kit (Genisphere, USA) 
according to the manufacturer’s instructions. The Affymetrix 
chip was designed based on the miRBase version 15 to target 
1,105 human precursor and mature RNAs as well as 32 scaRNAs 
and 2302 snoRNAs (Affymetrix Datasheet P/N EXP00180). 
Duplicate RNAs of samples were analyzed, which were selected 
to represent different periods of IFNγ stimulations and the 72 
h time point samples that were pre-treated with JII. Microarray 
data are available at ArrayExpress (ebi.ac.uk/arrayexpress) under 
accession number E-MEXP-3544.
Analysis of time-series-derived data. The workflow of biosta-
tistical analyses is outlined in Figure S2.
(A) Data pre-processing: Microarray data were pre-processed, 
quality was controlled and a filtering step was performed. Pre-
processing of microarray data was performed with Partek 
Genomics Suite (version 6.5) using the robust multi-chip analy-
sis (RMA) algorithm, which performs background adjustment, 
quantile normalization and probe summarization as described 
before in reference 54. Since low expression estimates are unre-
liable, a filtering step was included to remove all miRNAs, for 
which maximum expression over all arrays did not reach a thresh-
old of 7.0 in a log
2
 scale. We have previously established that 
microarray-measured log
2
 values < 7.0 are generally not detect-
able by RT-qPCR (data not shown).
(B) Visualization and clustering: Microarray data were 
visualized before and after the filtering step. Gene Expression 
Dynamics Inspector (GEDI) analysis was performed to obtain 
an overall picture of all miRNAs before filtering55 whereas the 
Mfuzz package56 was applied to cluster and visualize dynamic 
expression patterns of the remaining miRNAs after filtering. 
Hierarchical cluster analysis and expression visualization in form 
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